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Abstract
Mucosal transmission accounts for the majority of new human immunodeficiency virus type 1 (HIV-1)
infections and results in a genetically and phenotypically homogenous founder virus population in 60-80
percent of cases. Biological properties common to these transmitted and founder (T/F) viruses but not
chronic control (CC) viruses would define key targets for microbicides and vaccines. To identify such
properties, we tested 45 T/F and 52 CC envelope glycoproteins (Envs) from the best studied and most
prevalent HIV-1 subtypes (B and C, respectively) in various pseudotype assays to determine their receptor
and coreceptor interaction, tropism for primary CD4+ T cell subsets, and sensitivity to neutralizing
antibodies. T/F Envs were unable to mediate entry into cells expressing low amounts of CD4, thus
macrophages and other CD4low cells likely do not support their replication during mucosal transmission. In
contrast, T/F Env pseudoviruses efficiently infected primary memory CD4+ T cells with a preference for the
effector rather than central memory subset, as did CC pseudoviruses. There was a trend towards increased
sensitivity of T/F viruses to neutralization by antibodies targeting the CD4 binding site. All T/F Envs were
able to use the coreceptor CCR5 for cell entry, whereas some CC Envs used CXCR4 alone. However, one
bona fide T/F virus entered and replicated very poorly in CCR5+ cells in vitro, so efficient use of CCR5 as
tested is not absolutely required for transmission. To extend these studies beyond intrinsic Env functions, we
characterized the Env content, infectivity, dendritic cell interaction, and interferon alpha (IFN-α) sensitivity
of 27 T/F and 14 CC infectious molecular clones from subtypes B and C. T/F viruses contained more Env
and were more infectious than CC viruses. T/F viruses also readily attached to DCs and were effectively
transferred to CD4+ T cells. T/F viruses were more resistant to the inhibitory effect of IFN-α on virus spread
than CC viruses, suggesting that selective pressure imposed by the innate immune response may in part
mediate the bottleneck associated with mucosal transmission. Future work is needed to define the
mechanistic basis of these phenomena in order to target them to prevent HIV-1 transmission.
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ABSTRACT 
 
PHENOTYPIC CHARACTERISTICS OF MUCOSALLY TRANSMITTED HIV-1 
Nicholas F. Parrish 
Beatrice H. Hahn 
 
Mucosal transmission accounts for the majority of new human immunodeficiency virus 
type 1 (HIV-1) infections and results in a genetically and phenotypically homogenous founder 
virus population in 60-80 percent of cases.  Biological properties common to these transmitted 
and founder (T/F) viruses but not chronic control (CC) viruses would define key targets for 
microbicides and vaccines.  To identify such properties, we tested 45 T/F and 52 CC envelope 
glycoproteins (Envs) from the best studied and most prevalent HIV-1 subtypes (B and C, 
respectively) in various pseudotype assays to determine their receptor and coreceptor interaction, 
tropism for primary CD4+ T cell subsets, and sensitivity to neutralizing antibodies.  T/F Envs were 
unable to mediate entry into cells expressing low amounts of CD4, thus macrophages and other 
CD4low cells likely do not support their replication during mucosal transmission. In contrast, T/F 
Env pseudoviruses efficiently infected primary memory CD4+ T cells with a preference for the 
effector rather than central memory subset, as did CC pseudoviruses.  There was a trend towards 
increased sensitivity of T/F viruses to neutralization by antibodies targeting the CD4 binding site.  
All T/F Envs were able to use the coreceptor CCR5 for cell entry, whereas some CC Envs used 
CXCR4 alone.  However, one bona fide T/F virus entered and replicated very poorly in CCR5+ 
cells in vitro, so efficient use of CCR5 as tested is not absolutely required for transmission.  To 
extend these studies beyond intrinsic Env functions, we characterized the Env content, infectivity, 
dendritic cell interaction, and interferon alpha (IFN-α) sensitivity of 27 T/F and 14 CC infectious 
molecular clones from subtypes B and C.  T/F viruses contained more Env and were more 
infectious than CC viruses.  T/F viruses also readily attached to DCs and were effectively 
transferred to CD4+ T cells.  T/F viruses were more resistant to the inhibitory effect of IFN-α on 
virus spread than CC viruses, suggesting that selective pressure imposed by the innate immune 
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response may in part mediate the bottleneck associated with mucosal transmission.  Future work 
is needed to define the mechanistic basis of these phenomena in order to target them to prevent 
HIV-1 transmission. 
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CHAPTER 1 
Introduction to Mucosal HIV-1 Transmission 
Nicholas F. Parrish 
Department of Medicine and Microbiology, Perlman School of Medicine at the University of 
Pennsylvania 
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Abstract 
	  
The majority of new human immunodeficiency virus type 1 (HIV-1) infections result from 
mucosal virus exposure.  Vaccines or microbicides must interfere with the processes that occur 
after a mucosal surface is exposed to virus but before life-long clinical HIV-1 infection is 
established.  Here I review current models of these events, developed through a combination of 
simian immunodeficiency virus (SIV) and human explant challenge experiments, as well as the 
earliest immune responses to infection.  These responses, which may guide immunization 
attempts, have been demonstrated to be effective based on the selective pressure they place on 
the transmitted virus population.  By extension, I argue that characterizing the biological function 
of transmitted viruses prior to the onset of immune pressures is a complementary approach to 
refine current models of mucosal HIV-1 transmission and define vaccine targets.  Previously 
defined genotypic traits of transmitted viruses have led to a number of hypotheses about 
phenotypic differences between transmitted viruses and their chronic counterparts.  Technical 
and conceptual advances now allow us to define the exact nucleotide sequence of 
transmitted/founder genes and entire viruses, biologically characterize the encoded gene 
product(s), and thereby test these hypotheses.	  
	  
	  
 
 
 
	  
	  
 
  
	  3 
Mucosal Transmission and Early Immune Responses 
Human immunodeficiency virus is a lentivirus that causes Acquired Immunodeficiency 
Syndrome (AIDS) in humans.  Since entering the human population via chimpanzees infected 
with simian immunodeficiency virus (SIV) (121), the main group of human immunodeficiency virus 
type 1 (HIV-1) has become a global pandemic, leading to over 25 million deaths.  The pandemic 
main group (M) of HIV-1 is one of four HIV-1 groups (M, N, O and P), each representing 
independent SIV zoonoses (329), and is further divided into subtypes A-K along with circulating 
recombinant forms (122).  Subtype C accounts for about half of all HIV-1 infections, and is 
prevalent in Southern Africa and India (154).  Subtype B is prevalent in Western Europe and 
North America and is the most thoroughly studied of the subtypes.  HIV-1 is transmitted 
predominantly by mucosal contact, especially in sub-Saharan Africa where most infected 
individuals reside (2) (82).  While several types of interventions have recently been shown to 
reduce transmission through this route (265), a broadly effective vaccine holds promise as a cost-
effective and cross-validated means to stop the epidemic (155, 244).  Developing such a vaccine 
is thought to require a more detailed understanding of the biology of HIV-1 transmission (1).  
At the most basic level, HIV-1 transmission requires virus entry into human target cells 
(reviewed in (373)).  HIV-1 enters target cells following the interaction of viral envelope 
glycoprotein (Env) spikes, formed by three gp120/gp41 heterodimers, with the cellular receptor 
CD4 and a coreceptor.  Gp120 and gp41 are translated as a single polypeptide, gp160, which is 
subsequently cleaved by cellular proteases (149).  The surface subunit of Env, gp120, contains a 
signal peptide, five relatively conserved core domains, and five variable regions (V1-V5) with 
extraordinary diversity across different strains.  The transmembrane subunit, gp41, contains 
external helical domains involved in membrane fusion, a transmembrane region, and a 
cytoplasmic domain. The CD4 binding site (CD4bs) of gp120 is formed predominantly via core 
domains (193), while both core region domains and the third variable region form the coreceptor-
binding sites (301).  HIV primarily uses chemokine receptors CCR5 (R5) and CXCR4 (X4) as 
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coreceptors.  Use of X4 evolves during chronic infection in some individuals (318), but during 
acute infection most viruses use R5 (75). 
A molecular perspective on viral entry is foundational but incomplete because HIV-1 
transmission occurs in the context of tissues and organ systems.  Our current understanding of 
HIV-1 transmission at this level of analysis is built largely by extension from SIV transmission, 
which can be studied directly and experimentally.  For example, thoroughly rinsing the vaginal 
vault with a virus-inactivating solution prevents transmission if performed 15 minutes after 
exposure, but not if delayed for 60 minutes (163).  Therefore it can be inferred that virus(es) 
sufficient to confer productive infection traverse the vaginal lumen within 60 minutes.  Several 
mechanisms have been proposed to account for this movement, including diffusion between cells 
forming an otherwise intact barrier (159), active transcytosis through epithelial cells (37), or 
movement through breaks in the epithelial barrier due to microabrasions (254).  Both cell-free and 
cell-associated (174) forms of SIV are capable of initiating infection after mucosal exposure, but 
most experiments are performed using a cell-free challenge.  The endocervix, the transitional 
zone from the endocervix to the ectocervix, the ectocervix, and the vaginal epithelium have all 
been proposed as sites through which virus can be transmitted (reviewed in (158). Radically 
hysterectomized macaques are fully susceptible to intravaginal challenge (237), thus the vaginal 
epithelium is sufficient for transmission.  SIV RNA derived from infected cells can be detected as 
soon as 2 hours after infection (238), yet the identity of these initial target cells in SIV and HIV-1 
infection is controversial.   
Early studies implicated macrophages and dendritic cells as the initial cellular targets of 
SIV and HIV.  For SIV, histological data has been presented to suggest that macrophages (153, 
236), intraepithelial dendritic cells (DCs) (163, 341) and Langerhan’s cells (240) are productively 
infected days to weeks after exposure.  Several studies have reported that HIV isolated from 
acutely infected subjects did not induce syncytia formation in MT2 cells (326) (303) or was 
macrophage tropic (399), (359).  Notably, these reports pre-date the discovery of R5 as a 
coreceptor (95).  Since the discovery of R5, the phenotypic dichotomies previously defined as 
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macrophage vs. T cell tropism or non-syncytia-inducing vs. syncytia-inducing has often been 
shown to correspond to R5 tropism vs. X4 or R5/X4 dual-tropism (197).  Indeed, challenge 
experiments with a number of phenotypically characterized SIV strains suggested that 
macrophage tropism per se may not be required for mucosal transmission (239).  
Correspondingly, more recent studies of HIV isolated from acutely infected individuals have 
shown predominant use of R5 as a coreceptor but not necessarily robust virus production in 
macrophages (75).  Nonetheless, this has been interpreted as indirect support for the hypothesis 
that myeloid lineage cells are initial targets cells: mucosal DCs express R5 but not much X4, thus 
implicating them as a potential “gatekeeper” for R5-using viruses (389).  On the other hand, 
almost all CD4+ T cells express X4 while only a subset express R5 (35).  A key aspect of models 
in which DCs or macrophages represent the initial productively-infected cells is that these cells, 
whether they stay in the mucosa or migrate to regional lymph nodes, eventually disseminate virus 
to CD4+ T cells. 
A second model of mucosal transmission envisions CD4+ T cells as the critical first target 
cell.  Evidence for this comes from similar histological methods as support the DC-first model.  
Ashley Haase and collaborators have been the major contributors to this work (209, 238, 395), 
which shows clusters of SIV RNA+ cells that express T cell receptors and CD4, but not 
conventional markers of cellular activation.  Studies using human vaginal explants have shown 
that CD4+ T cells are more readily infected than DCs in these tissues (160). A concern in 
interpreting these studies is the super-physiologically high virus challenge used.  Resting CD4+ T 
cells are proposed to be the initial target cells not solely due to ease of infection but by nature of 
their abundance relative to other susceptible cells (396).  Because resting CD4+ T cells express 
more X4 than R5 (35), and generally less of both than activated cells (377),  this model does not 
readily account for the predominance of R5-tropic viruses in acute HIV-1 infection.  Moreover, 
resting CD4+ T cells are poorly infected by HIV-1 in vitro (340, 345).  Unlike HIV-1, SIV encodes 
a Vpx protein capable of degrading SAMHD-1 (196), which is a restriction factor known to limit 
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HIV-1 infection of resting CD4+ T cells (17).  Thus it is unclear if the tropism of SIV is 
representative of HIV-1 in this context. 
Still another model of mucosal transmission proposes that viruses interact with both DCs 
and CD4+ T cells shortly after entering the mucosa.  Specifically, it has been proposed that DCs 
can interact with HIV-1 and transfer infectious virus to CD4+ T-cells without being productively 
infecting themselves (123).  This concept is supported by in vitro and ex vivo work.  Early studies 
from Ralph Steinman and colleagues showed that DCs from skin pulsed with virus can interact 
with CD4+ T cells to facilitate infection and high-titer replication (283, 284).  Virus replication 
within DC/CD4+ T-cell conjugates is extremely efficient, and the phenomenon of trans-infection, 
whereby a DC-associated virus infects a CD4+ T cell but not the original DC, is well described 
(376).  The identity of the first infected cell has important practical implications.  For example, it 
has been suggested that antibody-neutralized HIV is capable of being transmitted by DCs to 
CD4+ T cells (119, 358).   If DCs are critically involved in the transmission event, inhibiting their 
glycan-dependent binding to HIV could be pursued (39, 249).  On the other hand, if CD4+ T cells 
are the initial target, inhibiting their recruitment by chemokine-secreting cells may be an option 
(209). 
Cells not directly targeted by SIV and HIV-1 are also involved in mucosal transmission.  
After exposure to an SIV inoculum, epithelial cells in the endocervix produce CCL20 (29), which 
leads to the recruitment of of plasmacytoid DCs (pDCs) (209).  The specific triggers involved in 
these signaling events have not been explained, and pDC recruitment has also been reported in 
response to mild, non-specific tissue damage (120).  It remains to be determined if pDC 
recruitment follows physiological HIV-1 exposure.  However, pDCs are capable of secreting 
significant amounts of various cytokines; in the case of type I interferons, they produce 100-1000 
times more than any other cell type (337).  Thus even small numbers of pDCs may play a 
disproportionately important role in downstream events relevant to transmission.  For example, by 
secreting beta-chemokines such as CCL4 they have been proposed to promote trafficking of 
additional CCR5+ CD4+ T cells to sites of exposure (209).  Indeed, clusters of 40-50 infected 
	  7 
resting and activated CD4+ T cells are detectable in mucosal tissues three to four days after 
infection, whereas similar groupings of cells are not present in these tissues prior to exposure 
(209, 238).  CCL4 can also occupy CCR5 and prevent its use as a viral coreceptor (69).  
However, the net effect of this and other innate immune responses by pDCs, including interferon 
alpha (IFN-α) and beta (IFN-β) secretion, has been interpreted as negative, because interfering 
with pDC recruitment and cytokine release prevents transmission after high-dose exposure (209). 
Furthermore, pre-treating animals with toll-like receptor agonists (CpG oligonucleotides and 
imiquimod) that induce IFN-α and other antiviral cytokines did protect from infection after high-
dose challenge (364), leading authors to conclude “induction of mucosal innate immunity 
including an IFN-α  response is not sufficient to prevent sexual transmission of human 
immunodeficiency virus.” 
After establishment of initial clusters of infection in mucosal tissues, virus spreads to 
regional lymph nodes (147).  Around this time, as early as five to seven days prior to detectable 
plasma viral RNA, evidence of the first systemic antiviral immune response is detectable in the 
form of elevated acute phase serum amyloid A and a fragment of alpha-1-antitrypsin (190).  Virus 
is detectable in the plasma seven days after SIV exposure (238) and approximately 10 days 
following HIV-1 exposure (225).  In both cases the predominant site of viral replication is the gut-
associated lymphoid tissues (139, 208, 360), which harbor the majority of activated CD4+ T cells 
under normal conditions (282).  By the time virus is detectable in the plasma, many soluble innate 
immune factors are also detectable in both SIV and HIV-1 infection (118).  To characterize this 
response for HIV-1, Borrow and colleagues measured levels of 30 cytokines in serial plasma 
samples from seroconverting plasma donors (343).   They describe a storm of cytokine and 
chemokine production including rapid elevations of IFN-α and interleukin 15 (IL-15) and delayed 
production of the more anti-inflammatory IL-10.  These investigators interpreted that “the intense 
early cytokine storm in acute HIV-1 infection may have immunopathological consequences, 
promoting immune activation, viral replication, and CD4+ T-cell loss.” 
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 In contrast to the seemingly ineffective innate immune responses to acute HIV-
1infection, the first documented adaptive responses to HIV-1 are associated with decline of 
viremia and resolution of acute infection.  HIV-1-specific major histocompatibility complex (MHC) 
class I-restricted cytotoxic lymphocytes (CTLs) become detectable a few days prior to peak 
viremia, some two to three weeks after exposure (114).  The effectiveness of this response is 
evidenced by the strong selective pressure it places on the virus; as virus load begins to 
decrease towards set-point, mutations that mediate escape from CTLs become fixed in the viral 
population, completely replacing the wild-type strain (129).  Mathematical modeling of the kinetics 
of this replacement suggests that CTLs contribute directly to decline of viral load (129).  The 
specificity of these CTLs for transmitted viruses has been confirmed in vitro using ELISPOT (129) 
and replication inhibition assays (116); on the other hand, “escaped” peptides and viruses are not 
targeted.  Thus by indirect, retrospective analysis the in vivo effectiveness of this immune 
response has been definitively shown for HIV-1.  In accordance with this observation, depleting 
CD8+ cells in acutely simian/human immunodeficiency virus (SHIV)-infected macaques leads to a 
sustained peak of viral replication and rapid disease progression (222).  CTLs also have a role in 
chronic infection, since depletion is associated with increased viral replication at these time points 
as well (321).  Additionally, the genetic loci most closely associated with HIV disease progression 
encode MHC class I (273), thus determining the range of viral proteins that may be targeted in 
this response (187).  
 The humoral response to HIV-1 begins slightly after the CTL response and is initially 
comprised by antibodies (Abs) that bind to gp41 but are incapable of neutralization (353).  
Because these Abs also frequently bind to host proteins or bacteria in the normal gut flora, it is 
thought they arise from B cells that were activated prior to infection but cross-react with HIV, thus 
explaining their rapid ontogeny (210).  While these and gp120-binding Abs are capable of 
mediating Ab dependent cell-mediated cytotoxicity (ADCC), their importance in vivo is uncertain 
because there are conflicting reports regarding whether or not mutations that prevent binding of 
such antibodies arise in vivo (11, 61).  However, if Env-binding Abs exert selective pressure on 
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HIV-1, one mechanism of escape may be to avoid these Abs (for example, by limiting Env 
expression at the cell surface (317)) rather than mutate the epitopes involved.   
Neutralizing antibodies (nAbs) develop as early as two weeks after the first binding 
antibodies and, like CTLs, are known to be effective because they drive replacement of the 
infecting strain with escape mutants (22).  Notably, they impose this selective pressure at titers at 
which neutralization cannot be readily detected in vitro (22).  As with CTLs, the specificity of these 
responses for the transmitted but not escape variants can be demonstrated through in vitro 
neutralization and adsorption studies.   These Abs are focused on variable regions of gp120 (22, 
247), and Therefore they are effective only against the autologous or very closely related strains, 
and only later in infection do nAbs target more conserved viral epitopes (135, 216).  Abs can also 
limit viral replication in chronic HIV-1 infection, as has been directly demonstrated by therapeutic 
B cell depletion (165).  
 Despite the range of known immune responses during chronic HIV-1 infection, there are 
no known cases in which natural immunity has lead to sterile cure.  Indeed, some contend that 
established infection with one strain of HIV-1 provides little or no protection from subsequent 
infection with another strain of HIV-1 (189, 275, 293).  Some reasons for this may be disruption of 
normal CD4+ T cell helper functions needed to develop functional adaptive immunity (175, 245), 
a large viral effective population size and rapid mutation rate that ensures pre-existence of 
immune escape (and similarly, drug resistance variants) at any single loci (368), or the large 
reservoir of latently infected cells that is established during acute infection (113).  Thus the virus 
may be most susceptible to interventions at the earliest stages of infection when the viral 
population is small and less genetically diverse, prior to massive CD4+ T cell depletion and 
establishment of the reservoir. 
However, all experimental systems currently available to study the earliest events in HIV-
1 transmission have key deficiencies.  Direct SIV challenge experiments can provide information 
about the first hours and days after exposure, but the cell tropism of these viruses may not be 
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representative and high inoculums must be used to ensure infection in a reasonable timeframe.  
This is in contrast to HIV-1, to which individuals may be exposed hundreds or thousands of times 
prior to productive infection (166, 287).  Human tissue explant experiments can be informative 
about the tropism and initial target cells of HIV-1, but not about cells recruited after exposure, 
such as pDCs or activated CCR5+ CD4+ T cells.  In contrast, indirect yet definitive evidence 
regarding the effectiveness of early immune responses to HIV-1 has been gained by studying the 
record they leave in sequences of the evolving viral population (22, 129).  These studies have 
been enabled by very early samples that are difficult to acquire.  In the earliest of these samples, 
the virus population is unchanged by selective pressure from immune responses, and thus is 
representative of the virus(es) that are transmitted (176, 201).  These samples therefore provide 
the basis for an additional strategy to study mucosal HIV-1 transmission: characterizing the 
biological functions of the virus proteins or complete viruses directly responsible for HIV-1 
transmission.  By inference, the biological functions of these viruses are sufficient for 
transmission.  For example, if these viruses are unable to replicate in epithelial cells in vitro it is 
highly unlikely that viruses must do so in vivo in order to be transmitted.  Some of these functions 
are likely to be strictly necessary while others may be accessory, so studying large groups of 
these viruses may allow us to define the functions required for transmission.  Finally, some 
properties may be more common in transmitted viruses than representative chronic control 
viruses, and such properties would be good vaccine targets.  For example, if all transmitted 
viruses are able to use a certain coreceptor while only half of viruses from chronic infection use 
this coreceptor, the role of this coreceptor in transmission should be investigated and viruses that 
use this coreceptor should preferentially be evaluated as vaccine immunogens. 
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Genotypic and Phenotypic Characterization of Transmitted Viruses 
The initial step in characterizing transmitted viruses to gain insights into HIV-1 
transmission is identifying transmitted variants in comparison to non-transmitted control viruses 
by sequencing.  The first report of genotypic differences between such viruses came from cases 
of vertical transmission.  A potential N-linked glycosylation site (PNLG) was absent in sequences 
from three infants, yet was present in sequences from each of their mothers (375).  Next, it was 
reported that sequences of the third variable region of gp120 were strikingly homogenous across 
six acutely infected individuals despite no epidemiological linkage between these individuals 
(393).  Env sequences from individuals acutely infected with subtype C have been shown to have 
significantly shorter variable loops and fewer N-linked glycosylation sites than those from their 
partners (88) or envs from randomly chosen chronically infected individuals (207).   Shorter V1 
and V2 variable regions and fewer PNLGs were also observed in individuals acutely infected with 
subtype A compared to all subtype A sequences in the Los Alamos National Laboratory HIV 
sequence database; however, this same analysis did not result in significance for sequences from 
individuals infected with subtype B viruses (59).  Longer V2 regions of have been reported for 
transmitted subtype B viruses in Trinidad (72).  Subtype A and recombinant Envs transmitted 
from mother-to-child have also been reported to have fewer PNLGs than average Envs in the 
mother (378).  Comparing recipient to donor sequences in 10 subtype A and three subtype D 
transmission pairs detected several signature amino acids, mostly following the V3 loop (309).  A 
shorter V1-V5 region and lower V3 charge were also observed in the transmitted viruses.  
Several genetic signatures of acute viruses were found by analyzing thousands of subtype B env 
sequences, including a number in the cytoplasmic tail of gp41 and the signal peptide (126).  
Recent work has shown that T/F viruses often come from a minor population of the donor’s 
plasma virus (36).  Moreover, it has been concluded that this minor transmitted population is 
genetically closer to strains from earlier time points than those circulating in the plasma at the 
time of transmission (292).  
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Several mechanisms might explain the observed sequence differences between acute 
and chronic viral sequences or sequence differences between donors and recipients in 
epidemiologically linked pairs.  The most trivial is that these differences reflect population-level 
sampling bias.  It has been estimated that acutely infected individuals contribute to as many as 
40-50% of new HIV-1 transmissions (42, 286, 365).  Thus genetic changes that develop after 
years of chronic infection, as has been suggested for increased PNLGs or variable region length 
(79, 310), may be underrepresented in acute samples.  Another potential interpretation is that the 
virus population in the genital track is compartmentalized and thus individuals are exposed to 
viruses that differ from those sampled from the plasma.  Machine learning algorithms have been 
trained to predict with 90% accuracy whether a given sequence was derived from the semen or 
plasma, suggesting that some compartmentalization may exist (277).  Other groups have shown 
that depending on the subject there may be almost complete compartmentalization or no 
evidence of compartmentalization (6, 76, 178, 400).  Thus compartmentalization may play some 
role in the genetic differences observed between acute and chronic plasma sequences.   
Another hypothesis is that these sequence differences correspond to phenotypic 
characteristics that confer an increased likelihood of transmission.  A number of phenotypic 
characteristics of transmitted viruses have been proposed (143).  The most robust is the 
observation that viruses from acute infection frequently use R5 (75), whereas X4-using strains 
are often found during chronic infection.  Additionally, those who lack functional R5 are highly 
resistant to infection (212).  However, this resistance is not absolute as 12 case reports of such 
individuals being infected with X4-using strains (260, 334).  Several reviews have been dedicated 
to hypothesizing “gatekeepers” responsible for selective transmission of R5-using variants (137, 
220).  However, others have recently contended that transmission is stochastic with respect to 
coreceptor tropism, arguing that when dual-tropic or X4-using variants are present in the 
transmitting partner, they are found in virus recipients based on their proportion in the donor (51, 
83, 152).  Thus it is of ongoing interest to determine if the preponderance of R5-using virus in 
acute infection is due to a selective bottleneck requiring or favoring R5 use at transmission. 
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One hypothesis about the phenotype of transmitted viruses pertains to their sensitivity or 
resistance to nAbs.  The transmitted virus population replicates during acute infection for at least 
one month , and more routinely ~80 days (71), prior to development of autologous neutralizing 
antibodies.  Does this allow for reversion of mutations that mediated escape from the previous 
host’s nAb? Are neutralization-sensitive Envs inherently more fit for transmission?  Acute Envs 
from transmission pairs were shown to be more sensitive to neutralization by donor plasma than 
randomly chosen donor Envs taken at time points close to transmission (88).  However, it is 
unclear if this is a generalizable phenomenon because subsequent studies have observed a 
similar difference (307, 390), no difference (182, 308), or a difference in the opposite direction 
(90, 290, 378) in sensitivity of viruses from acute infection to nAb.  
Another hypothesized property of transmitted viruses pertains to their efficiency of 
receptor or coreceptor use.  Since macrophages, proposed to be an initial target cell (359, 399) 
have little CD4 on their plasma membrane, successfully transmitted viruses might use CD4 very 
efficiently.  Additionally, increased CCR5-use efficiency might allow some viruses to gain a 
foothold in early infection (104, 167).  Transmitted viruses might interact better than chronic 
viruses with the integrin pair α4β7, which is present on CD4+ T cells homing to the gut (250).  
The most statistically robust genotypic signature found after analyzing the largest set of acute env 
sequences to date was shown to increase steady-state Env expression, which may have a 
number of biological effects that could promote transmission (11). Cheng-Mayer and colleagues 
found mutations in SHIV gp120 that increased dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) binding as well as mucosal transmissibility (162, 
215), suggesting that attachment to dendritic cells could be important for transmission.  Finally, 
while innate immune responses may be harmful once foci of infection are established, viruses 
better able to overcome these responses may have an advantage in establishing productive 
clinical infection. 
The approach taken here to test these hypotheses was enabled by a single-genome 
amplification technique that allows proportional sampling and sequencing of viral variants without 
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PCR recombination or other in vitro artifacts (312).  Using this technique, Keele and colleagues 
analyzed the plasma of patients early in acute HIV infection and discovered that the sequences 
were often homogenous (176).  In fact, mathematical modeling of random evolution of HIV 
sequences showed that the consensus of these homogenous sequences likely represented the 
very virus or infected cell that crossed the mucosa and gave rise to infection (201). Experimental 
SIV challenges with genetically defined stocks showed that sequence of the virus inferred to be 
transmitted was often identical to a sequence from the challenge stock (177).  When the 
sequences inferred in this manner were cloned or synthesized, they invariably encoded Envs 
functional for entry (176) or replication-competent viruses (313).  Thus it is possible to define the 
exact nucleotide identity of the virus or viruses that are transmitted and found clinical infection.  
These have been termed transmitted/founder (T/F) viruses; the properties of T/F viruses are 
precisely those relevant for mucosal HIV-1 transmission.  
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Phenotypic and Immunologic Comparison of Subtype B Transmitted/Founder and Chronic 
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Abstract 
 Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal 
barriers is responsible for the vast majority of new infections.  This relatively inefficient process 
results in the transmission of a single transmitted/founder (T/F) virus - from a diverse viral swarm 
in the donor - in approximately 80% of cases.  Here we compared the biological activity of 24 
subtype B T/F envelopes (Envs) with that of 17 chronic controls (CC) to determine whether the 
genetic bottleneck that occurs during transmission is linked to a particular Env phenotype. To 
maximize the likelihood of an intact mucosal barrier in the recipients and to enhance the 
sensitivity of detecting phenotypic differences, only T/F Envs from individuals infected with a 
single T/F variant were selected. Using pseudotyping to assess Env function in single round 
infectivity assays, we compared coreceptor tropism, CCR5 utilization efficiency, primary CD4+ T 
cell subset tropism, dendritic cell trans-infection, fusion kinetics, and neutralization sensitivity. T/F 
and CC Envs were phenotypically equivalent in most assays; however, T/F Envs were modestly 
more sensitive to CD4 binding site antibodies b12 and VRC01, as well as pooled immunoglobulin 
from HIV-1-infected subjects (HIVIG). This finding was independently validated with a panel of 14 
additional CC HIV-1 Envs controls.  Moreover, the enhanced neutralization sensitivity was 
associated with more efficient binding of b12 and VRC01 to T/F Env trimers. These data suggest 
that there are subtle but significant structural differences between T/F and CC subtype B Envs 
that may have implications for HIV-1 transmission and the design of effective vaccines. 
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Introduction 
Sexual transmission of HIV-1 across mucosal barriers is a relatively inefficient process 
and is most often due to the transmission of a single transmitted/founder (T/F) virus from the 
swarm of viral variants present in the donor, resulting in a profound genetic bottleneck (88, 176, 
267, 285, 374, 375, 393, 399).  A question of central importance is whether T/F viruses have 
particular phenotypic properties, which favor their transmission. If so, viruses with these 
properties should logically be targets of vaccination and microbicide efforts.  The viral envelope 
(Env) protein is a likely candidate for transmission-related signatures. For example, viruses 
expressing Envs that utilize the CCR5 coreceptor (R5-tropic) are transmitted far more frequently 
than those expressing Envs that utilize CXCR4 (X4-tropic) (176, 303, 326, 399). Variations in Env 
have also been linked to differences in the utilization of CD4 and coreceptor, the rate and 
efficiency of membrane fusion, as well as binding to C-type lectins such as DC-SIGN that are 
expressed on dendritic cells (DCs) and can function as virus attachment factors (123, 288, 294, 
351). 
Studies to characterize the properties of transmitted HIV-1 strains face several 
challenges. First, it is difficult to identify individuals during the acute phase of HIV-1 infection, 
particularly before the onset of immune responses (that is, at early Fiebig stages (112)), thus 
limiting sample sizes. Second, individual viruses cloned from the peripheral blood or plasma of 
acutely infected individuals within weeks of transmission may have already evolved away from 
the actual T/F virus and may thus have acquired phenotypic changes (40). Third, in the absence 
of extensive sampling of the early viral quasispecies by single genome amplification (SGA), it is 
impossible to know if one or more virus strains established the clinical infection, making it difficult 
to assess the integrity of the mucosal barrier (176). Infection with multiple T/F viruses may reflect 
a different mechanism of transmission, with these T/F Envs likely facing different or reduced 
transmission selection pressure (145, 204). Nonetheless, small numbers of Envs cloned from 
acutely infected individuals have been obtained and compared to Envs cloned from 
corresponding donors or from other chronically infected individuals. Derdeyn et al. examined 
subtype C Envs from eight heterosexual transmission pairs and concluded that transmitted Envs 
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have fewer putative N-linked glycosylation sites (PNGs), more compact variable loops, and 
enhanced neutralization sensitivity to donor plasma (88), although subsequent phenotypic studies 
of a subset of viruses bearing these Envs did not reveal functional differences (5, 167). Analysis 
of subtype A and D transmission pairs also identified shorter recipient Envs with a lower V3 
charge, although no differences in the number of PNGs were noted (309).  For subtype B Envs, 
initial studies suggested that transmission was independent of variable loop length and PNGs 
(59, 79, 117); however, more recent comparisons of thousands of subtype B T/F and chronic env 
sequences confirmed significantly fewer total PNGs and a trend towards fewer in the V1/V2 loops 
of transmitted Envs (126).  Finally, several studies have investigated neutralization sensitivities of 
acute or T/F Envs compared to CC Envs, but reported conflicting results (117, 176, 307, 327). 
These discrepancies may have resulted from differences in sample size, demographics of acutely 
infected individuals and CCs, cloning strategy, and whether the Envs under investigation 
represented true T/F viruses. 
The use of SGA of plasma viral RNA during the earliest stages of infection has allowed 
the inference of the nucleotide sequence of T/F viruses from an increasingly large number of 
individuals (3, 176, 312, 313).  Recent analyses of a large number of subtype B T/F Env 
sequences led to the identification of transmission signatures in the CCR5 binding site, certain 
PNGs, and sites in the signal peptide and gp41 cytoplasmic domain that could affect Env 
processing and localization (126).  These results suggested that T/F Envs might differ in some 
phenotypic properties from chronic Envs.  To examine this, we conducted a comprehensive 
phenotypic analysis of T/F and CC subtype B HIV-1 Envs in the context of viral pseudotypes.  
Specifically, we assessed coreceptor tropism, CCR5 utilization efficiency, CD4+ T cell subset 
tropism, DC-mediated trans-infection efficiency of T cells, and membrane fusion kinetics. In 
addition, we examined the sensitivity T/F and CC Envs to neutralization by purified 
immunoglobulin from infected subjects (HIVIG) and a panel of broadly neutralizing monoclonal 
antibodies (MAbs) and assessed the binding efficiencies of these MAbs to trimeric Env on the cell 
surface.  Our results failed to identify a major transmission phenotype, but uncovered subtle 
functional differences between T/F and CC Envs that may be of biological significance.  
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Materials and Methods 
Pseudovirus production.  Pseudotyped virus was produced by calcium phosphate co-
transfection of 6 µg of pcDNA3.1+ containing env with 10 µg of HIV-1 core (pNL43-ΔEnv-vpr+-
luc+ or pNL43- ΔEnv -vpr+-eGFP) into 293T17 cells.  Virus was harvested 72 hours post-
transfection, filtered through a 0.45 µm filter, aliquoted, and stored at -80°C.  For the primary 
CD4+ T cell infection, pseudovius was concentrated by ultracentrifugation through a 20% sucrose 
cushion.  Pelleted pseudovirus was then resuspended in PBS.  All luciferase-encoding 
pseudoviral stocks were serial diluted and used to infect NP2 cells to define the linear range of 
the assay. A viral dilution was chosen in the middle of the five-fold linear range of the assay to 
maximize sensitivity. 
Env cloning and sequence analysis.  The derivation of most T/F Env clones used in 
this study has been described (176). THRO.F4.2026, SUMAd5.B2.1713, 9010-09.A1.4924, and 
PRB959-02.A7.4345 were cloned from SGA amplicons known to contain the nucleotide sequence 
of the corresponding T/F env sequence into pcDNA3.1 according to manufacturer’s instructions 
(Invitrogen). The AD17.1 env gene was subcloned from a full-length infectious molecular T/F 
clone described elsewhere (204). Chronic Envs HEMA.A4.2125 and HEMA.A23.2143 were also 
cloned in pcDNA3.1; briefly, viral RNA was extracted from plasma of chronically infected patients 
and amplified using SGA methods. Individual env genes were then either cloned at random, or 
selected, to maximize within-patient env sequence diversity. Env clones were sequenced to 
confirm that they did not contain Taq polymerase errors, but represented env genes of viruses 
circulating in the patient. The nucleotide sequences of all T/F and CC Envs have previously been 
reported (105). PNGs were determined with N-glycosite (hiv.lanl.org) (394). To assess lengths of 
the V1/2, V3, V4, V5, and V1-4 regions, sequences were aligned to HXB2, then boundaries were 
identified for each region and non-gap residues were counted. 
Coreceptor tropism testing and cell line infections. NP2 cells stably expressing CD4 
and either CCR5 (NP2/CD4/CCR5) or CXCR4 (NP2/CD4/CXCR4) were infected with HIV-1 
pseudoviruses expressing luciferase by spinoculating in 96-well plates at 450 g for 90 minutes at 
25°C.  Cells were lysed with Brite-Glo (Promega) 72 hours post-infection and analyzed on a 
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Luminoskan Ascent luminometer.  Coreceptor tropism was arbitrarily defined by mean relative 
light units (RLUs) greater than 1 (approximately 100-fold over background). To assess sensitivity 
to coreceptor inhibitors, NP2/CD4/CCR5 or NP2/CD4/CXCR4 cells were pre-incubated for 30 
minutes with saturating concentrations of the CCR5 inhibitor maraviroc (1 µM), the CXCR4 
inhibitor AMD3100 (2 µM), or the fusion inhibitor enfuvirtide (10 µ/ml) prior to infection. To assess 
sensitivity to broadly neutralizing MAbs, viral pseudotypes were pre-incubated with 10 µg/ml of 
antibody for 30 minutes at 37°C.  Virus and antibody mixes were then used to infect 
NP2/CD4/CCR5 or NP2/CD4/CXCR4 cells. All NP2 cell line infections were done in at least 
triplicate in at least three independent experiments using R5-tropic JRFL as a positive control and 
Env-deficient pseudotypes as a negative control. 
The following reagents were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3-deltaE-eGFP (Cat# 11100) from Drs. 
Haili Zhang, Yan Zhou, and Robert Siliciano (391), bicyclam JM-2987 (hydrobromide salt of AMD-
3100; Cat# 8128) (43, 81, 156), maraviroc (Cat #11580) (34, 103, 344), and HIV-1 gp120 MAb 
IgG1 b12 (Cat# 2640) from Dr. Dennis Burton and Carlos Barbas (23, 46, 47, 302). 
Primary human CD4+ T cell tropism assay. Primary human CD4+ T cells, purified by 
negative selection, were obtained from the University of Pennsylvania’s Human Immunology 
Core.  2x106 cells per virus were stimulated with plate-bound anti-CD3 (clone OKT3) 
(eBiosciences) and anti-CD28 (clone 28.2, BD biosciences) and 20 units (U)/ml recombinant IL-2 
in RPMI containing 10% FBS.  Three days post-stimulation cells were transferred to 96-well V-
bottom plates prior to infection. Five µl/well of concentrated HIV-GFP was used to infect cells in 
triplicate.  Plates were then spinoculated at 1200 g for 2 hrs.  Cells were then transferred to new 
24-well plates and new media containing 20 U/ml IL-2 was added.  Three days post-infection, 
cells were stained for flow cytometry. 
Determination of alternative coreceptor use.  Primary human CD4+ T cells from two 
different ccr5Δ32 homozygous donors were obtained and purified as previously described.  Prior 
to infection, cells were pre-incubated with 50 µM AMD3100 for 30 min.  Cells were infected as 
previously described.  Two hours after spinfection, enfuvirtide (1 µg/ml final concentration) was 
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added to all samples to prevent additional fusion prior to transferring cells to a 24-well plate for 
further incubation.  Samples were stained and analyzed as previously described. 
Flow cytometry. 1-2x106 cells were stained per tube for flow cytometry.  All incubations 
were done at RT and in Facs Wash Buffer (PBS, 2.5% FBS, 2mM EDTA), and all antibodies were 
from BD Biosciences, unless otherwise noted.  To stain CD4+ T cells, cells were first washed in 
PBS.  Then, live/dead Aqua (Invitrogen) was added and incubated for 10 min.  Next, anti-CCR7 
IgM in Facs Wash Buffer was added and incubated for 30 min. Cells were then washed in Facs 
Wash Buffer before staining with anti-CD3 Qdot 655 (Invitrogen), anti-CD4 Alexa Fluor 700, anti-
CD45RO PE-Texas Red (Beckman Coulter), and anti-IgM PE (Invitrogen) for 30 min. Cells were 
then washed in Facs Wash Buffer and resuspended in 1% PFA.  Samples were run on a LSRII 
(BD) and analyzed with FlowJo 8.8.6 (Treestar).  Cells were gated as follows: singlets (FSC-A by 
FSC-H), then live cells (SSC-A by live/dead), then lymphocytes (SSC-A by FSC-A), then CD3+ 
cells (SSC-A by CD3), then by memory markers (CCR7 by CD45RO). 
DC trans-infection assay. To differentiate DCs, freshly isolated monocytes from the 
University of Pennsylvania’s Human Immunology core were treated with 50 ng/ml GM-CSF (R&D 
systems) and 100 ng/ml IL-4 (R&D systems) in AIM V serum free media (Invitrogen). New media 
containing GM-CSF and IL-4 was added on day 3.  Six days post-stimulation DCs were washed 
and plated at 3x104 cells per well in a V-bottom 96 well plate. 3x104 CD4+ T cells alone, three 
days post-stimulation with plate-bound anti-CD3/anti-CD28 were used as a negative control.  
Viral stocks were first titered by RLUs on NP2/CD4/CCR5 or CXCR4 cells. Virus sufficient to 
generate 80 RLUs was added to DCs or a CD4+ T cell control and allowed to bind for two hours 
at 37°C.  Cells were washed three times with fresh media to remove cell-free virus.  Then, 3x105 
stimulated heterologous CD4+ T cells were added to each well containing 3x104 HIV-bound DCs 
or CD4+ T cells.  As an additional control, and equal amount of virus was added to 3x105 
stimulated CD4+ T cells to ensure there was no differential infection of CD4+ T cells.  For CD4+ T 
cell luciferase infection, cells were spinoculated at 450 g for 90 minutes and then incubated 
without washing off virus.  Cells were then transferred to a flat bottom 96-well plate for three days 
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prior to take down with Brite Glo.  Each condition was done in triplicate and each viral pseudotype 
was used in at least three independent experiments with cells from different healthy donors. 
Enfuvirtide time-of-addition assay. To assess entry kinetics of T/F and CC Envs, 
NL43vpr+luc+ pseudotypes were chilled to 4°C and added to NP2/CD4/CCR5 (or 
NP2/CD4/CXCR4 for the one X4-tropic Env) cells on metal blocks embedded in ice covered by a 
moist towel.  Cells were then spinoculated at 1300 rpm for 90 minutes at 4°C to enhance viral 
binding.  Immediately post-spinoculation, cold supernatant was aspirated off and all wells were 
flooded with 270 µl of pre-warmed 37°C media and transferred to a 37°C incubator.  30 µl of 10 
µg/ml enfuvirtide (final concentration of 1µg/ml) was then added at 0, 5, 10, 20, 40, 80, or 160 
minutes post-warming. A no drug control was also included to normalize percent infection.  Cells 
were then incubated for 72 hours and assessed for RLUs.  At least three wells per virus per time 
point were included in each experiment, and all Envs were examined in at least three 
independent experiments.  Data was analyzed with Prism 4.0 (GraphPad Software, Inc.) by fitting 
a best-fit sigmoidal line to each independent experiment prior to averaging the Hill slopes and 
time to half-max fusion. 
Neutralization sensitivity.  Neutralization assays were performed using both NP2 and 
TZM-bl cells in two independent laboratories. To assess sensitivity to MAbs b12, VRC01, PG9, 
and PG16, viral pseudotypes were pre-incubated with 10 µg/ml of antibody for one hour prior to 
infection of NP2 cells.  To assess sensitivity to HIVIG, pseudotypes were pre-incubated with two-
fold serial dilutions of subtype B HIVIG from 1500-23 µg/ml. This mix was then added to NP2 
cells and spinoculated as described previously.  For MAbs, neutralization was assessed by 
determining the maximum percent inhibition (MPI) compared to a no antibody control. Subtype B 
HIVIG (lot 12 100158) was obtained from the AIDS Repository.  
Neutralization sensitivity was assessed on TZM-bl cells as previously described (84, 
367). Briefly, 8 x 103 TZM-bl cells were plated overnight.  Five-fold dilutions of MAbs (b12, 
VRC01, PG9, PG16, and subtype B HIVIG) were incubated in the presence of 40 µg/ml DEAE-
Dextran and 2000 infectious units (as measured on TZM-bl cells) of pseudovirius for one hour at 
37°C.  After media was removed from TZM-bl cells, the virus/MAb dilutions were added to the 
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cells and incubated for 48 hours before being analyzed for luciferase expression (Promega).  The 
highest concentration tested for b12, VRC01, PG19 and P16 was 10 µg/ml.  The highest 
concentraion of subtype B HIVIG was 1500 µg/ml.  Samples were tested in duplicate with all 
experiments repeated at least two times. IC50 values were calculated as described previously 
(84). 
Cell-Based Enzyme-Linked Immunosorbent Assay (CELISA).  The binding of MAbs to 
HIV-1 Env trimers expressed on cells was measured using a cell-based ELISA system, as 
previously described (148).  Briefly, COS-1 cells were seeded in 96-well plates (1.8 × 104 
cells/well) and transfected the next day with 0.1 µg of a plasmid expressing Env and 0.02 µg of a 
Rev-expressing plasmid per well using Effectene transfection reagent.  Three days later, cells 
were incubated with the indicated MAb suspended in blocking buffer (35 mg/ml BSA, 10 mg/ml 
non-fat dry milk, 1.8 mM CaCl2, 1 mM MgCl2, 25 mM Tris, pH 7.5 and 140 mM NaCl) for one hour 
at room temperature. Cells were then washed four times with blocking buffer and four times with 
washing buffer (140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and 20 mM Tris, pH 7.5).  A 
horseradish peroxidase-conjugated antibody specific for the Fc region of human IgG was then 
incubated with the samples for 45 minutes at room temperature.  Cells were washed five times 
with blocking buffer and five times with washing buffer.  HRP enzyme activity was determined 
after the addition of 33 µl per well of a 1:1 mix of Western Lightning oxidizing and luminol 
reagents (Perkin Elmer Life Sciences) supplemented with 150 mM NaCl.  Light emission was 
measured with a Mithras LB 940 luminometer (Berthold Technologies). To correct for the level of 
cell surface expression of each envelope glycoprotein, binding of the antibodies is expressed as 
percent binding of the CD4-Ig probe at saturating concentrations (5 mg/ml). We decided a priori 
to exclude all envelope glycoproteins that bound CD4-Ig at less than 20% of the binding 
measured for the SC05.8H2.3243 control isolate. Five of the 57 Envs were thus not analyzed, 
including three T/F and two CC Envs. Measurements of antibody binding and neutralization were 
performed under code to prevent potential bias.  
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Statistical analyses. T/F and CC Envs were compared with Mann-Whitney tests and 
correlations were assessed by Spearman tests.  P-values less than 0.05 were considered 
significant.  Data was analyzed with Prism 4.0 software. 
Ethics Statement.  All human cells used in this study were from normal healthy donors 
who provided written informed consent after approval by the University of Pennsylvania’s 
institutional review board. 
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Results 
Panels of T/F and CC Envs. To determine if there are functional differences between 
T/F Envs and those that predominate during chronic infection, we assembled a panel of 24 
subtype B T/F Envs previously inferred and cloned from plasma viral RNA of 24 individuals with 
acute HIV-1 infection as defined by the Fiebig staging system, in which patients are classified 
from Stage I (viral RNA positive, antibody and antigen negative) to Stage VI (ELISA and western 
blot positive with multiple bands) (21, 176, 204) (Table 1).  Twelve individuals were sampled 
during Fiebig stage II, five during Fiebig stage III, two during in Fiebig stage IV, and five during 
Fiebig stage V.  Acutely infected individuals were predominantly males (22 of 24) from the 
southeastern United States (18 of 24) with a variety of sexual risk factors, all denying intravenous 
drug use (IDU). All T/F Envs were inferred from SGA-derived sequences, which are devoid of 
PCR-induced errors and cloning bias (176). Env clones identical to this inferred T/F sequence 
were then chosen for phenotypic analysis. Importantly, all T/F Envs were selected from subjects 
with single variant transmissions. This was done to increase the likelihood that the viruses 
encoding these Envs were transmitted across an intact mucosal barrier, thereby maximizing our 
chances of observing properties required for this process (145, 204).  
To generate chronic subtype B control Envs, we used SGA to amplify env genes from 
plasma viral RNA of two groups of anti-retroviral therapy naïve individuals. The first group 
consisted of 11 individuals sampled 14-83 months post-infection (mean 42 months). A test set of 
CC 17 Env clones was derived from this group consisting predominantly of males (8 of 11) from 
the southeastern United States (10 of 11) all denying IDU (Table 2-1). An additional 14 subtype B 
control Envs were SGA amplified and cloned from six chronically infected individuals residing in 
the northwestern United States. This second group of CC Envs served as a validation set to 
confirm differences in neutralization sensitivity observed with the first test set. A phylogenetic tree 
of the 31 CC Envs is depicted in Figure 2-1 along with the 24 T/F Envs.  None of the Envs were 
from epidemiologically linked infections. 
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Table 1. Description of T/F and CC Envs 
Env 
type Subject env Clone name 
Fiebig 
Stage, or 
minimal 
time since 
infection 
Viral load 
(copies/ml) Gender 
Risk 
behaviorc 
Geographic 
location 
Sampling 
date CoR
d 
 
T/F 
REJO4541 REJO.D12.1972 V 722,349 M HSX Alabama 9/28/01 R5 
RHPA4259 RHPA.A19.2000 V 1,458,354 F HSX Alabama 12/5/00 R5 
SUMA0874 SUMAd5.82.1713 II 939,260 M MSM Alabama 5/13/91 R5 
THRO4156 THRO.F4.2026 V 5,413,140 M MSM Alabama 8/1/00 R5 
WEAU0575 WEAUd15.410.5017 II 216,415 M MSM Alabama 5/30/90 R5X4 
WITO4160 WITO.B10.2062 II 325,064 M HSX Alabama 8/4/00 R5 
700010040 CH40.C9.4520 V 298,026 M MSM North Carolina 7/27/06 R5 
700010058 CH58.A4.4375 III 394,649 M Unknown North Carolina 9/8/06 R5 
700010077 CH77.SA2.6559 V 144,145 M Unknown North Carolina 9/31/06 R5X4 
1006-11 1006-11.C3.1601 III 1,600,000 M SPD North Carolina 6/5/97 R5 
1018-10 1018-10.A5.1732 III 270,000 M SPD South Carolina 6/20/97 R5 
1053-07 1053-07.B15.1648 III 1,400,000 M SPD South Carolina 12/3/97 R5 
1056-10 1056-10.TA11.1826 II 140,000 M SPD South Carolina 1/14/98 R5 
1058-11 1058-11.B11.1550 IV 550,000 M SPD South Carolina 3/18/98 R5X4 
9010-09 9010-09.A1.4924 II 146,954 F SPD South Carolina 11/25/97 R5 
9015-07 9015-07.A1.4729 II 500,000 M SPD South Carolina 12/27/97 R5 
9021-14 9021-14.B2.4571 II 143,379 M SPD California 6/10/98 R5 
9032-08 9032-08.A1.4685 III 40,815 M SPD Alabama 7/30/98 R5 
PRB956-04 PRB956-04.B22.4267 II 600,000 
 
SPD Virginia 8/19/97 R5 
AD17 AD17.1 II 47,600,000 M MSM New York 6/14/99 R5 
PRB959-02 PRB959-02.A7.4345 II >2,000,000 
 
SPD South Carolina 11/17/99 R5 
TT35P TT35P.11H8.2874 II 1,849,301 M HSX Trinidad 1/26/99 R5 
SC20 SC20.8A8.2437 IV 2,789,313 M HSX Trinidad 2/18/98 R5 
SC05 
SC05.8C11.2344 II 9,980,952 
M HSX Trinidad 
6/28/93 R5 
 
CC 1a 
SC05.A10.2362 
5 y 5 m 19,514 12/9/98 
R5 
SC05.8H2.3243 R5 
SC05.8A11.2363 R5 
SHKE4761 
SHKE.A26.4112 
1 y 2 m 544,000 M MSM Alabama 8/2/06 
R5 
SHKE.A7.2118 R5 
SHKE.A4.2116 R5 
HEMA4284 HEMA.A4.2125 1 y 10 m 49,755 M MSM Alabama 10/2/02 R5 
HEMA.A23.2143 R5 
WICU4248 WICU.B4.2973 5 y 11 m 8,424 M MSM Alabama 10/6/05 R5 
WICU.C1.2992 R5 
CRPE4571 CRPE.B28.4072 2 y 21,917 F HSX Alabama 11/30/01 R5X4 
JOTO5278 JOTO.TA1.2247 1 y 6 m 404,180 M HSX Alabama 2/13/04 X4 
OLLA4645 OLLA.A14.1923 2 y 1 m 382,000 F HSX Alabama 2/22/02 R5 
SAMI4303 SAMI.A8.1863 3 y 11 m 116,000 M MSM Alabama 8/5/04 R5 
SMRE4166 SMRE.A13.4127 1 y 4 m 135,858 F HSX Alabama 11/16/01 R5 
TALA4022 TALA.A2.1780 6 y 11 m 228,200 M MSM Alabama 12/9/03 R5 
YOMI4024 YOMI.F2.4137 6 y 1 m 14,178 M MSM Alabama 2/15/06 R5 
 
CC 2b 1632 
1632.TA9 
2 y 5 m 97,800 M MSM Washington 9/14/05 
R5 
1632.A17 R5 
1632.A6 R5 
1632.TA1 R5 
1632.A7 R5 
1632.A23 R5 
1451 
1451.D17 
20 y 3 m 532,000 M MSM Washington 3/1/05 
R5 
1451.C16 R5 
1451.D1 R5 
1451.C8 R5 
1588 1588.TA7 7 y 2 m 99,600 M MSM/ID
U 
Washington 7/6/05 R5 
1470 1470.D27 4 y 3 m 492,200 M MSM/ID
U 
Washington 3/15/05 R5 
1599 1599.B11 6 y 7 m 112,000 M-F IDU Washington 7/26/05 R5 
1444 1444.A21 7 y 86,300 M MSM Washington 2/22/05 R5 
aOriginal panel of chronic control Envs 
bChronic control Envs from Washington state assessed only in neutralization assays 
cHeterosexual (HSX); Men who have sex with men (MSM); Serial plasma donor (SPD); 
Intravenous drug user (IDU) 
dCoreceptor tropism was assessed on NP2 cells for T/F and CC 1 Envs; tropism of CC 2 Envs 
was assessed on TZM-bl cells. 
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Figure 2-1. Phylogenetic relationships of T/F and chronic Envs selected for phenotypic 
analyses. The tree was constructed from Env amino acid sequences of T/F (dark red), original 
CC (red), and Washington state CC (pink) viruses. Subtype B reference sequences from the 
database are shown in black). All sequences were derived by SGA methods; Env sequences 
from the same individuals form discrete subclusters.  A bracket indicates epidemiologically linked 
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infections from Trinidad and Tobago (68).  The tree was inferred using maximum likelihood 
methods (141); Numbers on nodes indicate posterior probabilities (only values above 0.95 are 
shown). The scale bar represents 0.05 amino acid substitutions per site. 
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Previous studies noticed fewer PNGs in the gp120 region of T/F compared to CC Envs 
(207) (105).  To determine whether our selected subset of T/F and CC Envs differed from this 
much larger group, we compared variable loop length as well as the number and distribution of 
putative PNGs. There were no differences in V1/2, V3, V4, V1-4 lengths between T/F and chronic 
subtype B Envs. Further, the median gp120 PNGs in T/F Envs was 26.0 compared to 27.0 for the 
CCs (p=0.16) and 26.0 for subtype B Envs in general (391). Thus, the panel of T/F Envs selected 
for our functional analyses exhibited no statistically significant differences in patient 
demographics, virus phylogeny, variable loop length, or PNGs relative to the panel of chronic 
Envs we assembled or to subtype B Envs in general. 
Determination of coreceptor tropism. R5-tropic viruses represent the vast majority of 
transmitted viruses, with dual (R5X4)-tropic viruses being transmitted less frequently (176, 303, 
326, 399). On rare occasions, X4-tropic viruses can be transmitted (20, 255, 348). To determine 
the coreceptor usage in our panel, we characterized the CCR5 and CXCR4 utilization of the 24 
T/F and 17 CC Envs by producing viral pseudotypes and using these to infect NP2 cell lines 
expressing CD4 and either CCR5 (NP2/CD4/CCR5) or CXCR4 (NP2/CD4/CXCR4), as well as 
primary human CD4+ T cells.  NP2 cells were selected because they provide a 5-6 log linear 
range of infection, approximately 2-3 logs greater than that of the TZM-bl assay. We found that of 
the 24 T/F Envs, 21 were R5-tropic and three were R5X4-tropic, while of the 17 CC Envs, 15 
were R5-tropic, one was R5X4-tropic, and one was X4-tropic (Table 2-1). This is consistent with 
previous results with the exception of T/F Envs 1058-11.B11.1550 and CH77.SA2.6559, which 
were R5X4-tropic on NP2 cells and R5-tropic on TZM-bl cells (176) (105). This discrepancy is 
likely due to differences in CXCR4 expression, as the NP2 cells used stably express high levels 
of CXCR4 compared to the HeLa-derived TZM-bl cells, which express lower endogenous CXCR4 
levels. All four R5X4-tropic Envs utilized CCR5 and CXCR4 with approximately equivalent 
efficiency as assessed by a less than two-fold difference in RLUs between the NP2/CD4/CCR5 
and NP2/CD4/CXCR4 cells. To assess coreceptor use on human CD4+ T cells, we infected 
ccr5Δ32 or ccr5wt CD4+ T cells in the presence or absence of saturating concentrations of the 
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CXCR4 inhibitor AMD3100.  The results paralleled those obtained with the NP2 cell lines.  R5-
tropic Envs mediated infection of ccr5wt but not ccr5∆32 CD4+ T cells, while R5X4 Envs 
mediated infection of both cell types. Infection of ccr5∆32 CD4+ T cells by three of the R5X4 
Envs was completely inhibited by AMD3100, while Env CRPE.B28.4072 could infect ccr5Δ32 
cells in the presence of AMD3100, though with reduced efficiency (data not shown). However, we 
found that AMD3100 inhibited infection of NP2/CD4/CXCR4 cells by viruses bearing the 
CRPE.B28.4072 Env by only 50%. In addition, this Env was unable to infect NP2 cells expressing 
CD4 alone or in combination with any of 17 different putative alternative coreceptors, indicating 
that this Env can utilize the drug-bound conformation of CXCR4 (data not shown).  Several other 
HIV-1 Env proteins have been shown to exhibit this property (151). In summary, all T/F Envs 
utilized CCR5, while three were R5X4-tropic. Thus, there were no differences in coreceptor 
tropism between the T/F and CC Envs with the exception of the one X4-tropic CC Env, and there 
was no evidence for utilization of coreceptors other than CCR5 or CXCR4 to infect human CD4+ 
T cells. 
Sensitivity to coreceptor antagonists and CCR5 utilization efficiency. Mucosal 
transmission of HIV-1 is dependent upon CCR5. Hypothesizing that the ability to use low levels of 
CCR5 may confer selective advantage to viruses at the moment of transmission, we determined 
the sensitivity of each Env to the CCR5 inhibitor maraviroc (MVC) as a surrogate for CCR5 
utilization efficiency.  High MVC IC50 values indicate that an Env can mediate infection at low 
levels of CCR5, while low IC50 values suggest an Env requires high CCR5 expression for viral 
entry.  We found no significant difference in median MVC IC50 values between the T/F (2.4 nM) 
and CC Envs (2.3 nM) (p=0.79; Mann-Whitney) (Figure 2-2A). In addition, we determined the 
maximal percent inhibition (MPI) of infection by MVC.  While uncommon, several in vivo derived 
MVC-resistant R5-tropic viruses have been identified that can utilize the drug-bound form of 
CCR5 (352, 371).  Such viruses engage the coreceptor differently, relying predominantly upon 
the N-terminus for entry whereas most viruses require the N-terminus as well as the extracellular 
loops of CCR5.  Furthermore, determining the MVC sensitivity of T/F viruses has implications for 
microbicides and pre-exposure prophylaxis.  All 41 Envs examined had MPIs greater than 85%, 
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with the vast majority greater than 95%.  There were no significant differences (p=0.17 Mann-
Whitney) between the T/F (median=99.1%) and CC Envs (median=98.3; Figure 2B).  Together, 
these data indicate that the HIV-1 transmission bottleneck does not impose a selection pressure 
for viruses capable of using low concentrations of CCR5. 
Primary CD4+ T cell tropism. CD4+ T cells, the major target and source of HIV-1 in vivo 
(183, 395), can be broadly divided into four subsets: naïve (CCR7+CD45RO-), central memory 
(TCM) (CCR7+CD45RO+), effector memory (TEM) (CCR7-CD45RO+), and CD45RA+ effector 
memory (TEMRA) (CCR7-CD45RO-) (316). These subsets are differentially infected due in part to 
variation in coreceptor expression (274), cellular activation (124), and tissue localization (130). 
TEM and TEMRA cells are found predominantly in effector sites including the rectal and 
cervicovaginal mucosa, while naïve and TCM cells are most abundant in the lymph nodes. TEM 
cells, the most abundant subset in mucosal effector sites, are preferentially infected and 
massively depleted during acute infection (reviewed in (228)). Since potential target cells in the 
mucosa may be limiting during transmission, we hypothesized that T/F Envs may infect TEM and 
TEMRA cells preferentially relative to the matched CC controls.  
Peripheral blood CD4+ T cells from three normal uninfected donors were purified by 
negative selection and stimulated with anti-CD3/anti-CD28 and IL-2 for three days prior to 
infection with HIV-1 pseudotypes expressing a GFP reporter. Three days post-infection, viability 
and expression of CD3, CD4, CCR7, CD45RO, and GFP was assessed by FACS analysis. 
Productively infected cells were defined as CD3+ GFP+ since CD4 was down-regulated in the 
majority of infected cells (80). The gating strategy is shown in Figure 3A. In all three donors, 
infected cells were predominantly TEM  (~65%), followed by TCM (~30%), TEMRA (~3%), and naïve 
(~2%) cells (Figure 2-3B). As X4-tropic viruses have been previously reported to readily infect 
naïve CD4+ T cells compared to R5-tropic viruses (99, 253, 263), this assay contains an 
important internal validation: the five viruses that could utilize CXCR4 for entry (one X4-tropic Env 
shown in  
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Figure 2-2. CCR5 utilization efficiency.  (A) Viral pseudotypes were used to infect 
NP2/CD4/CCR5 cells in the presence of serial dilutions of the CCR5 antagonist maraviroc (MVC). 
Higher IC50 values correspond to Envs that can utilize CCR5 more efficiently, and vice versa. T/F 
and CC subtype B Envs have similar MVC IC50 values (p=0.79) suggesting they engage CCR5 
comparably. (B) Since some Envs can utilize the MVC-bound conformation of CCR5 and since 
MVC is a candidate microbicide, we assessed the maximal percent inhibition (MPI) of MVC for 
each Env. All Envs were sensitive to MVC and there was no difference in MPI between the T/F 
and CC Envs (p=0.17). All infections were done in at least triplicate in each of at least three 
independent experiments. Data was analyzed by a Mann-Whitney test.  
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cyan; four R5X4-tropic Envs shown in red) preferentially infected naïve cells.  With the exception 
of these five Envs, no other pseudotypes were reproducibly outliers in their ability to mediate 
entry into any of the subsets, and there were no statistically significant differences or trends 
between the T/F and CC Envs for any of the four cell subsets in any of the three donors 
examined (Figure 2-3B).  In addition, there was no statistically significant difference in overall 
infectivity between the T/F and CC Env pseudotypes in any of the three donors examined 
suggesting comparable Env fitness in peripheral CD4+ T cells (Figure 2-3C). Together, this 
suggests that transmission and early expansion is not due to differential infection of CD4+T cells 
or their subsets between T/F and chronic Envs. 
DC-mediated trans-infection. DCs can enhance HIV-1 infection in trans by efficiently 
capturing virus particles and presenting them to CD4+ T cells. In vitro, co-culture of monocyte-
derived DCs with CD4+ T cells results in enhanced virus infection, particularly at low virus inocula 
(reviewed in (276)). To assess whether DCs preferentially bind and transfer T/F compared to 
chronic Env pseudoviruses, we performed DC:CD4+ T cell co-culture experiments. Viral 
pseudotype stocks were normalized for infectivity on NP2 cells to control for differences in viral 
titer. A relatively limiting amount of virus (80 RLUs on NP2 cells) was bound to DCs, which were 
then washed to remove cell-free virus and co-cultured with CD4+ T cells.  All Envs were 
assessed in at least three independent experiments, each time using DCs and CD4+ T cells from 
different normal donors.  Adding this amount of virus to 3x104 CD4+ T cells, then washing as with 
the DCs, resulted in infection at background levels.  However, adding virus associated with DCs 
markedly increased infection.  Nonetheless, the magnitude of DC:CD4+ T cell trans-infection was 
not different between T/F and CC Envs (Figure 2-4; p=0.44 Mann-Whitney). In addition, there 
was no difference in CD4+ T cell infectivity in the absence of DCs and there was no detectable 
infection of DC control cultures in the absence of CD4+ T cells (data not shown). The absence of 
any difference between T/F and CC pseudoviruses in this trans-infection assay suggests that, at 
least when presented with an equal amount of infectious pseudovirus, DCs bind and transfer T/F 
and CC Env pseudotypes similarly. 
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Figure 2-3. CD4+ T cell subset tropism. To assess human CD4+ T subset tropism of the T/F 
and CC Envs, cells were infected with Env pseudotypes expressing GFP and then stained and 
analyzed by flow cytometry. (A) Cells were gated as shown. Infected cells (GFP+) were then 
back-gated on the memory markers CCR7 and CD45RO to evaluate differential subset infection. 
Naïve (CCR7+CD45RO-); central memory (TCM) (CCR7+CD45RO+); effector memory (TEM) 
(CCR7-CD45RO+), effector memory RA (TEMRA) (CCR7-CD45RO-). (B) T/F and chronic Envs 
infected all four CD4+ T cell subsets comparably. TEM and TCM cells were infected most readily 
followed by naïve and TEMRA cells. As expected, Envs that could utilize CXCR4 preferentially 
infected naïve cells compared to Envs that used exclusively CCR5. (C) T/F and CC Env 
pseudotypes have comparable overall CD4+ T cell infection frequency in each of the three 
donors examined.  R5X4-tropic Envs are shown in red and the one X4-tropic Env is shown in 
cyan.  R5X4-tropic Envs are shown in red and the one X4-tropic Env is shown in cyan.  Tropism 
was assessed in cells obtained from three different, uninfected normal donors as indicated 
(ND218, ND335, and ND337). The horizontal lines indicate the mean value for each group of 
Envs. 
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Figure 2-4. Dendritic cell (DC) trans-infection. To assess differential DC-binding and CD4+ T 
cell trans-infection of T/F and CC Envs, we pulsed DCs with luciferase expressing Env 
pseudotypes and then washed off unbound virus and added CD4+ T cells. Relative light units 
(RLUs) were then measured as a surrogate for infection. DC trans-infection efficiency was 
comparable between the T/F and CC Envs (p=0.44). Viral input was normalized based upon 
infectivity on NP2 cell lines. Data shown is from one of at least three independent experiments 
with cells from different donors, each done in at least triplicate. Data was analyzed by a Mann-
Whitney test. 
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Entry kinetics and enfuvirtide sensitivity. Productive entry of HIV-1 into cells may 
occur following internalization and delivery to endosomes, albeit in a pH-independent manner 
(241). If so, then the rate at which a virus is internalized, fuses, and enters cells could impact viral 
tropism. In addition, the rate at which a virus fuses is a measure of how well it productively 
engages CD4 and coreceptor. Hypothesizing that faster-fusing viruses may preferentially 
overcome mucosal barriers to transmission, we indirectly assessed the entry kinetics of the T/F 
and CC pseudoviruses using a time-of-addition experiment with the fusion inhibitor enfuvirtide. As 
enfuvirtide is not membrane permeable, time to enfuvirtide escape may reflect the rate of viral 
endocytosis, fusion, or some combination thereof. HIV-1 pseudotypes were added to NP2 cells 
on ice.  Cells were spinoculated at 4°C to facilitate HIV-1 binding and then cold media was 
removed and replaced immediately with pre-warmed media.  Saturating concentrations of 
enfuvirtide were then added at 0, 5, 10, 20, 40, 80, and 160 minutes post-warming, and then 
infectivity was normalized to a no-drug control. To control for experimental variation, the 
prototypic R5-tropic virus JRFL was included in all experiments. There was no significant 
difference or trend in the rate at which T/F and CC Env pseudotypes productively entered NP2 
cells, thus becoming resistant to enfuvirtide addition.  The median time to half maximal resistance 
(t ½ max) post-warming was 32.5 minutes for the T/F and 31.4 minutes for the CC Envs (p=0.55 
Mann-Whitney). Interestingly, JRFL became resistant to enfuvirtide significantly faster (t ½ max= 
15.9 minutes) than all 41 T/F and chronic Envs (Figure 2-5A).  In addition, we assessed 
enfuvirtide potency, a measure of pre-hairpin bundle exposure that also reflects kinetics of 
CD4/coreceptor engagement and endocytosis (242).  There was no difference between T/F and 
CC Env sensitivity to enfuvirtide (mean IC50 0.10 vs 0.13 µg/ml; p=0.53; Figure 2-5B).  Together 
this suggests that the kinetics of viral entry/endocytosis are comparable between T/F and chronic 
Envs. 
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Figure 2-5. Entry kinetics and enfuvirtide sensitivity. (A) To examine differences in T/F and 
chronic Env endocytosis/fusion kinetics, we employed an indirect assay in which viral 
pseudotypes were bound to NP2 cells in the cold prior to the addition of pre-warmed media. A 
saturating concentration of enfuvirtide was added at various times post-warming.  The time to 
half-maximal resistance to enfuvirtide (t ½ max) was then calculated.  The T/F and CC Envs 
became resistant to enfuvirtide at equal rates (p=0.55), with all of the Envs acquiring resistance to 
enfuvirtide more slowly than a prototypic R5-tropic HIV-1 control, JRFL. (B) Enfuvirtide potency, a 
compound measure of fusion kinetics and affinity, was assessed for all T/F and CC Envs.  There 
was no difference in enfuvirtide IC50 between the T/F and CC Envs (p=0.53) further suggesting 
there is no difference in endocytosis/fusion rates between T/F and chronic Envs. Each infection 
condition was done in triplicate (A) or duplicate (B) for each Env in each of at least three 
independent experiments. Data was analyzed by a Mann-Whitney test. 
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Sensitivity to broadly neutralizing antibodies and HIVIG. It has previously been 
reported that Envs derived from acutely infected individuals may exhibit enhanced sensitivity to 
antibody-mediated neutralization because of changes in glycosylation and/or variable loop length 
(88). This finding raised the possibility that such Envs might be able to bind to CD4 and 
coreceptor more efficiently. To examine this, we measured the sensitivity of the T/F and CC Envs 
to four broadly neutralizing MAbs. MAbs b12 (47) and VRC01 (397) neutralize Env by engaging 
the CD4 binding site (CD4bs), while the epitopes for PG9 and PG16 (363), distinct germ-line 
variants from the same individual, are glycosylation-dependent and include parts of the V1/2 and 
V3 loops (93). To assess neutralization sensitivity, pseudoviruses were pre-incubated with a 
single concentration (10 µg/ml) of each MAb for 60 minutes prior to infection of NP2 cells. 
Maximal percent inhibition was then determined by normalizing to a control without antibody. 
Interestingly, T/F Envs were more sensitive than CC Envs to both b12 (mean MPI 66% vs. 17%; 
p=0.0003; Figure 2-6A) and VRC01 (mean MPI 89% vs. 50%; p=0.0077; Figure 2-6B compare 
T/F to CC 1).  There was also a trend towards enhanced sensitivity to neutralization by PG9 
(Figure 2-6C) and PG16 (Figure 2-6D). To confirm these differences, the neutralization sensitivity 
of T/F Envs was independently examined using a different backbone (SG3) and HIV-1 reporter 
cell line (TZM-bl), with both MPI and IC50 values being determined. The results confirmed the 
NP2 cell data in that the T/F Envs were more sensitive to neutralization by b12 (Figure 6E) and 
VRC01 (Figure 6F). In addition, the T/F Envs exhibited a trend towards increased neutralization 
sensitivity to both PG9 (Figure 2-6G) and PG16 (Figure 2-6H).  While this did not reach statistical 
significance, it is consistent with a more neutralization sensitive phenotype of T/F compared to 
chronic Envs. 
To assess whether the neutralization sensitive phenotype of our T/F Envs depended on 
the particular panel of CC Envs used, we examined the neutralization sensitivity of 14 subtype B 
control Envs derived from six additional chronically infected individuals (Chronic 2 in Figure 2-6A-
D). Similar to the initial test set of CC Envs (Chonic 1 in Figure 2-6A-D), this validation set 
exhibited increased resistance to b12 compared to T/F Envs (p=0.0001 Mann-Whitney). 
However, unlike the initial CC Env panel, the validation Envs were similar to the T/F Envs in their 
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sensitivity to VRC01 (p=0.14 Mann-Whitney).  Finally, there were no differences in PG9 and 
PG16 sensitivity between the T/F and the validation Envs (Figure 2-6C, D).  
While broadly neutralizing MAbs are useful tools in examining neutralization sensitivity, 
they are rare in HIV-1-infected individuals and thus may give a biased view of HIV-1 
neutralization.  Thus, we examined neutralization sensitivity of the T/F and CC Envs to pooled 
sera from patients infected with subtype B HIV-1 strains (subtype B HIVIG). The T/F Envs 
(median IC50 741 µg/ml) were approximately two-fold more neutralization sensitive than the CC 
test panel (median IC50= 1179 µg/ml p=0.062), the CC validation panel (median IC50 =1500 µg/ml 
p=0.0095), and the combined subtype B CC panel (median IC50 1324 µg/ml p=0.0078; Figure 6I).   
To examine the basis for the enhanced b12 and VRC01 neutralization sensitivity of T/F 
Envs, we measured the binding of the two MAbs to both T/F and CC Envs.  Binding to the trimeric 
form of the Env expressed on the surface of cells was measured using a cell-based ELISA 
system (148). To obtain an accurate measure of antibody binding affinity, we corrected binding 
measurements for the level of cell surface expression of the different Envs. For this purpose, the 
binding efficiency of b12 and VRC01 was expressed as a fraction of the binding of a CD4-Ig 
probe added at saturating concentrations. CD4-Ig is a fusion protein that consists of two copies of 
the two N-terminal domains of CD4 that are linked to the Fc region of human IgG1.   
For the entire group of Envs (i.e., T/F and both CC Envs groups combined), a very strong 
correlation was observed between the binding of the MAbs to the trimeric Envs and their 
sensitivity to inhibition. Spearman rank-order correlation coefficients of 0.62 (p<0.0001) and 0.77 
(p<0.0001) were obtained for b12 and VRC01, respectively (Figure 7A and B).  Comparison of 
MAb binding to the T/F and CC Envs showed clear differences between the two groups for both 
b12 and VRC01. Binding of b12 to the T/F Envs was significantly increased relative to both 
groups of CC Envs (Figure 7C). Binding of VRC01 to the T/F Envs was increased relative to 
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Figure 2-6. Neutralization sensitivity. The sensitivity to monoclonal antibodies b12, VRC01, 
PG9, and PG16 was assessed on both NP2 cells (A-D) and TZM-bl cells (E-H). Neutralization 
sensitivity on NP2 cells was assessed by determining the maximal percent inhibition (MPI) to 
10µg/ml of the indicated MAb. IC50 values were determined in the TZM-bl assay. Subtype B T/F 
Envs (dark red) were more sensitive to b12 and VRC01 compared to the geographically-matched 
panel of CC Envs (CC 1, light red).  To confirm this finding, we assessed an independent panel of 
subtype B chronic Envs from Washington state (CC 2, pink). “All chronic” includes subtype B 
chronic panels 1 and 2 and is shown in black. (I) Subtype B T/F Envs are also more sensitive to 
subtype B HIVIG on NP2 cells as measured by IC50. P-values shown are from Mann-Whitney 
tests with the corresponding T/F Envs.  NP2 and TZM-bl experiments were performed in at least 
three and two independent experiments, respectively. 
	  42 
 
the original group of CC Envs (p=0.004; Figure 7D). The differential formation/exposure of these 
epitopes suggests the existence of at least modest structural differences within or near the CD4-
binding site of T/F and chronic Envs. No significant differences were observed between VRC01 
binding to the T/F and the Washington Envs (p= 0.21). 
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Figure 2-7. Correlation between MAb binding and neutralization. Env was expressed on the 
surface of cells and then binding to b12 (A) and VRC01 (B) was assessed relative to a CD4 
control by ELISA.  There is a strong positive correlation between binding and Env pseudotype 
neutralization sensitivity for both b12 and VRC01 for the T/F and both panels of CC Envs serving 
to validate the assay. To assess the mechanism of enhanced neutralization sensitivity, we 
compared b12 (C) and VRC01 (D) binding between T/F (dark red) and CC Envs (light red and 
pink for CC 1 and 2, respectively). This suggests that differences in MAb binding explain 
neutralization differences between T/F and CC Envs.  Data shown is the mean of two 
independent experiments. 
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Discussion 
 The genetic bottleneck that occurs during mucosal transmission of HIV-1 is the result of a 
single founder virus that is successfully transmitted from amongst a diverse swarm of viruses 
present in the donor (176).  It is evident that a significant degree of selection is manifest at this 
step since transmission of R5-tropic virus strains is far more efficient than that of X4-tropic and 
even R5X4-tropic viruses (318, 399). Whether there is selection for additional viral phenotypes 
beyond coreceptor use or whether viral transmission is essentially a stochastic process, in which 
any reasonably fit R5-tropic HIV-1 strain can be transmitted, has not yet been determined. 
Addressing this question is of practical importance since properties associated with preferential 
viral transmission could potentially be exploited by vaccine or other antiviral approaches.  
 Genetic, immunologic, and phenotypic signatures associated with transmitted HIV-1 Envs 
have been sought in a number of previous studies, most entailing Envs obtained from early 
infections (acute Envs) (5, 59, 88, 167, 307, 375, 399) as opposed to true T/F Envs obtained by 
SGA analyses (176, 204, 313). Several studies concluded that T/F and acute Envs have on 
average shorter variable loops and fewer PNGs than Envs derived from chronically infected 
individuals (88, 375). While such differences have been noted for Envs from multiple HIV-1 
subtypes, they are relatively subtle, variable in location and far from predictive, with some being 
evident only when larger numbers of sequences are compared. The 24 T/F Envs examined here, 
for example, exhibited no consistent genetic differences from the CCs.  Nonetheless, a much 
larger sequence comparison that included all but one of the envs examined here identified a 
small number of sequence signatures associated with transmission, including specific sites in the 
signal sequence and gp41 cytoplasmic domain that could affect Env processing, localization, and 
incorporation into virus particles as well as changes in the receptor binding regions in gp120 and 
in N-linked glycosylation sites (126). Thus, existing evidence points to an array of genetic features 
that may be associated with enhanced HIV-1 transmission across mucosal surfaces by unknown 
mechanisms. 
 The identification of genetic motifs in env that are enriched in T/F viruses is consistent 
with the possibility that specific phenotypic properties can be identified that might provide a 
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selective advantage to transmitted viruses. This is clearly the case at a global level, in that T/F 
Envs are almost invariably R5-tropic and replicate well in CD4+ T cells but poorly in monocyte-
derived macrophages (with the exception of subtype D viruses, G.M. Shaw and J. Baalwa, 
unpublished data) (313). More detailed phenotypic studies of recently transmitted viruses are 
generally lacking, although donor and recipient Envs from eight transmission pairs exhibited no 
differences in CD4 or CCR5 utilization, while a second study using some of these same Envs did 
not find consistent differences in primary cell infection or use of receptors other than CCR5 and 
CXCR4 (5, 167). As genetic signatures associated with transmission can be both variable and 
subtle, we employed a more detailed series of functional assays to seek differences between viral 
pseudotypes bearing the T/F Envs and those expressing Envs from CCs. We found no 
phenotypic differences between the T/F and CC Envs examined here in assays designed to 
probe the efficiency and rate of membrane fusion, the efficiency of coreceptor use, the ability to 
infect primary CD4+ T cell subsets from different donors, and the ability of virus to be captured by 
DCs and transferred to adjoining CD4+ T cells. One could ask whether the assays we employed 
are sufficiently sensitive to detect functional differences between viruses bearing different Env 
glycoproteins. We feel that they are, as we and others have used these and similar assays to 
identify significant functional differences between Envs at the level of primary CD4+ T cell 
tropism, membrane fusion kinetics, the efficiency of CD4 and co-receptor utilization, and 
attachment to C-type lectins such as DC-SIGN (123, 288, 294, 351). Even single amino changes 
in Env can impact these properties to extents that can be easily detected. The CD4+ T cell subset 
tropism assay that we have developed, which can determine the efficiency with which a given 
virus infects TCM, TEM, TEMRA and naïve T cells, is a particularly sensitive measure of CD4 and 
coreceptor use, as these receptors are expressed differently on various CD4+ T cell subsets (35, 
138, 199, 243, 274). The fact that that 24 T/F Envs here were functionally equivalent to the 
chronic Env controls in all of the assays employed argues that any phenotypic differences 
between these and chronic Env controls are apt to be slight in magnitude. 
 A second consideration regarding the presence or absence of phenotypic traits 
associated with enhanced virus transmission is whether the assays we employed effectively 
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recapitulate the key events during the earliest stages of HIV-1 transmission (reviewed in (146)). 
Following mucosal transmission of HIV-1, virus is not detected in the circulation for about 10 
days, a period termed the eclipse phase (reviewed in (190)). Detailed studies in the macaque 
model show that after vaginal exposure small clusters of infected cells are found in the 
endocervical region, which is lined by a single layer of epithelial cells (395). The recruitment of 
plasmacytoid DCs, T cells, and macrophages over several days transforms the initial focus of 
infection into a CD4+ T cell-rich environment. Similar studies have not yet been conducted 
assessing penile or rectal transmission in the rhesus model, the likely mode of transmission in the 
predominantly male cohort assessed in this study.  Conceivably, Env properties that promote 
entry into resting and activated CD4+ T cells in the submucosa as well as transmission between 
cells could increase the possibility that an initial focus of infection will successfully propagate and 
eventually lead to dissemination to regional lymph nodes and a systemic infection. The CD4+ T 
cell subset tropism assay we employed, while more detailed and sensitive than bulk CD4+ T cell 
infection assays, may not produce CD4+ T cells with properties identical to those found in the 
rectal or cervicovaginal mucosa. In addition, the DC:CD4+ T cell transmission assay we used is 
but a surrogate for the likely more complex cell-cell interactions found in the initial foci of infection. 
It is important to keep in mind that since virus appears to replicate locally for a period of at least a 
few days to a week, even a relatively subtle change in an Env property that might enhance 
infection could result in a significant selective advantage over the course of multiple rounds of 
infection. The single-cycle assays we employed, while sensitive and well-validated, cannot 
capture the impact of more subtle differences in Env fitness over time. Future studies employing 
T/F infectious molecular clones in both primary cell and tissue explant cultures might be better 
suited for the identification of early fitness differences associated with T/F viruses. 
 In addition to genetic signatures, differences at the level of sensitivity to antibody-
mediated neutralization have been found in some studies of recently transmitted viruses (88, 
176). We found that the panel of subtype B T/F Envs was more sensitive to the CD4 binding site 
MAbs b12 and VRC01 as well as subtype B HIVIG, but not to the broadly neutralizing antibodies 
PG9 and PG16. These differences were approximately two-fold in magnitude and partially 
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dependent upon the control group employed. Specifically, when a second panel of CC Envs was 
used as a control, enhanced sensitivity to VRC01 was not observed, though MAb b12 and 
subtype B HIVIG continued to neutralize the T/F Envs more efficiently. The relatively modest 
differences that were observed, along with the fact that enhanced neutralization was not seen 
between all study groups raises several important questions: do T/F Envs exhibit features that 
generally enhance their sensitivity to certain types of neutralizing antibodies, and if so, what is the 
basis for these differences and what are the implications for virus transmission? 
One limitation of this study is the selection of CC Envs. Ideally, CC Envs would be 
selected from longitudinal samples or confirmed transmission pairs; however, such samples are 
difficult to find in sufficient numbers, especially since the great majority of acute subtype B 
infections are treated with anti-retroviral therapy.  It would also be preferable to obtain chronic 
Envs from semen or genital secretions, the likely source of the viral inoculum, but again such 
samples are exceedingly scarce.  In addition, the majority of Envs used in this study were from 
males who likely acquired HIV by penile or rectal transmission.  Thus, further work is needed to 
characterize the transmission bottleneck that occurs during vaginal transmission. Our results 
emphasize the importance of selecting appropriate matched controls since the chronic test and 
validation sets differed in their neutralization profiles to VRC01 (though not to MAb b12 and 
subtype B HIVIG) despite no obvious differences in length of infection, transmission risk factor, 
patient demographics, or phylogenetic relationships to the T/F Envs. Of course, since we are 
unable to reliably predict neutralization sensitivity from sequence information alone, a control 
group could by chance differ immunologically from the T/F Envs despite being otherwise well-
matched. To mitigate this, selecting CC Envs from geographically-matched individuals may be 
important. For example, we previously reported that subtype B T/F Envs are more resistant than 
chronic Envs to b12 and the membrane proximal external region (MPER) antibodies 2F5 and 
4E10 (176), seemingly in contradiction with our current findings.  However, re-examination of the 
data in Keele et al. showed that this was due to the predominance of neutralization-sensitive 
Envs derived from chronically-infected individuals in Trinidad.  These Trinidad Envs form a 
subcluster within the other subtype B Envs used in this study (Figure 2-1), have a Thr deletion in 
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the V3 loop compared to the subtype B consensus, were over-represented in the CCs and were 
more sensitive to neutralization by MAbs b12, 2F5 and 4E10 (68). Thus, the previous 2F5 and 
4E10 neutralization difference between T/F and chronic Envs was due to bias resulting from 
disproportionate representation of Envs from Trinidad in the controls. 
Several other studies that have assessed neutralization sensitivity of subtype B Envs did 
not use geographically-matched CCs, raising the possibility that the results from theses studies 
could be complicated by genotypic differences linked to geographic location (327, 363, 379). In 
addition to the location, it may also be important to match the time of sample collection when 
developing well-matched chronic control groups. For example, Bunnik et al. reported that HIV-1 
has become more neutralization resistant over the course of the epidemic and thus patient 
sampling times may bias comparisons between T/F and chronic Envs (45).  Here, the chronic 
Envs were sampled four calendar years before the T/F Envs on average. However, this difference 
is significantly shorter than the 14-21 year time-span between contemporary and historic Envs 
assessed in Bunnik et al.  In addition, we detected no correlation between sampling time and 
neutralization sensitivity, and thus this cannot account for the neutralization differences between 
the T/F Envs and the chronic controls. It is also of note that multiple chronic Envs from the same 
individual were treated as independent events in this study. Reanalyzing the data to include only 
one CC Env value (mean of the multiple Envs) per individual did not change the magnitude of the 
neutralization difference, though it did decrease the p-values above the level of significance for 
VRC01 and HIVIG, but not b12, likely due to decreased sample size.  In summary, more detailed 
studies involving larger numbers of T/F Envs with appropriately matched CC Envs, including Envs 
derived from the same individuals over time, and a greater number of broadly neutralizing MAbs 
and human sera, will be needed to draw definitive conclusions about the neutralization sensitivity 
of transmitted virus strains. 
When our data are considered along with other published studies on T/F and acute Envs, 
several conclusions can be drawn. First, we believe that HIV-1 transmission is in part stochastic, 
with any reasonably fit R5-tropic virus being capable of initiating an infection (176, 303, 326, 399). 
With a now relatively large number of T/F and acute Envs having been examined, it is evident 
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that no single major genetic, phenotypic or immunologic signature is required for transmission 
beyond the use of CCR5.  Second, an array of genetic traits including but not limited to shorter 
variable loops and reduced numbers of N-linked glycosylation sites are associated with enhanced 
virus transmission. The structural implications of these signatures are not well understood, and it 
is not yet clear if these or as yet unidentified other genetic traits are responsible for the modestly 
enhanced sensitivity to antibody-mediated neutralization that is characteristic of some T/F and 
acute Envs. Third, the presence of genetic signatures linked to transmission implies some impact 
on function that enhances transmission. If so, then the functional impact is apt to be modest given 
the variable nature of the genetic signatures and the fact that neither we, nor others, have 
observed clear differences between T/F and acute Envs with CCs. However, the possibility exists 
that relatively subtle alterations of Env function, perhaps in the context of full-length T/F viral 
genomes, could provide a sufficiently robust selective advantage during the eclipse phase of HIV-
1 transmission to result in preferential transmission of viruses with specific properties. The 
growing application of SGA technology coupled with increasingly sophisticated cell-to-cell and ex 
vivo tissue systems will make it possible to more rigorously identify immunologic and phenotypic 
traits associated with HIV-1 transmission. 
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Abstract 
 Sexual transmission of human immunodeficiency virus type 1 (HIV-1) most often results 
from productive infection by a single transmitted/founder (T/F) virus, indicating a stringent 
mucosal bottleneck.  Understanding the viral traits that overcome this bottleneck could have 
important implications for HIV-1 vaccine design and other prevention strategies.  Most T/F viruses 
use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain 
fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from 
chronic viruses.  Moreover, it has been reported that the gp120 subunits of certain transmitted 
Envs bind to the gut-homing integrin α4β7, possibly enhancing virus entry and cell-to-cell spread.  
Here we sought to determine whether subtype C T/F viruses, which are responsible for the 
majority of new HIV-1 infections worldwide, share biological properties that increase their 
transmission fitness, including preferential α4β7 engagement.  Using single genome 
amplification, we generated panels of both T/F (n=20) and chronic control (CC, n=20) Env 
constructs as well as full-length T/F (n=6) and CC (n=4) infectious molecular clones (IMCs).  We 
found that T/F and chronic control Envs were indistinguishable in the efficiency with which they 
used CD4 and CCR5.  Both groups of Envs also exhibited the same CD4+ T cell subset tropism 
and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies.  Finally, 
saturating concentrations of anti-α4β7 antibodies failed to inhibit infection and replication of T/F 
as well as CC viruses, although the growth of the tissue culture-adapted strain SF162 was 
modestly impaired.  These results indicate that the population bottleneck associated with mucosal 
HIV-1 acquisition is not due to the selection of T/F viruses that use α4β7, CD4 or CCR5 more 
efficiently. 
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Introduction 
Mucosal transmission of HIV-1 is most often caused by a single variant from amongst the 
complex viral quasispecies in the infected donor (36, 64, 85, 226, 267, 374, 375, 399).  After an 
eclipse phase of approximately two weeks during which virus is generally not detected in the 
blood, the progeny of this transmitted/founder (T/F) virus give rise to a productive systemic 
infection (3, 21, 145, 176, 204, 312, 332).  At a minimum, this significant population bottleneck 
selects for replication competent viruses, most of which use CCR5 as a coreceptor, since viruses 
that exclusively use CXCR4 are rarely transmitted (51, 176).  Whether other phenotypic traits are 
associated with enhanced mucosal transmission remains uncertain, though addressing this 
question is of importance because T/F viruses are the targets of vaccines, microbicides, and pre- 
and post-exposure prophylaxis. 
Characterization of T/F virus properties is complicated by the challenges inherent in 
identifying acutely infected individuals, generating bona fide T/F molecular clones, procuring 
appropriate CC viruses, obtaining sufficient numbers of samples to perform meaningful 
comparisons, and developing sufficiently sensitive in vitro assays to detect phenotypic differences 
that could impact transmission fitness in vivo.  Almost all studies examining viral properties 
associated with mucosal transmission have focused on the viral envelope (Env) glycoprotein, 
most often in the context of viral pseudotypes (5, 10, 167, 176, 372).  In addition, most initial 
studies examined viruses obtained weeks to months after infection from relatively few 
transmission events (88, 104, 207).  Given the rapidity with which HIV evolves in the face of 
immune pressures (129), “early” isolates could differ in important ways from true T/F viruses.  
Nonetheless, analyses of single genome amplification (SGA) derived T/F Env proteins and 
viruses have shown that mucosal transmission is associated with CD4+ T cell tropism and CCR5 
use (176, 257, 313, 372) as well as a variety of signatures in the viral env gene (59, 79, 88, 117, 
126, 309, 310).  These include shorter variable loops, fewer potential N-linked glycosylation sites 
(PNGs) and, in some cases, enhanced sensitivity to neutralization by CD4 binding site (CD4bs) 
monoclonal antibodies (mAbs) (372).  More recently, it has been shown that the gp120 subunit of 
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some Env glycoproteins can bind to, and signal through, the integrin α4β7 that is expressed on 
activated CD4+ T cells in the gut mucosa (9, 63, 250).  These findings have been taken to 
suggest that these interactions play an important role early in sexual transmission of HIV-1 (62, 
250).  Specifically, it has been hypothesized that genetic signatures associated with transmission 
of certain subtype A and C viruses, including the absence of some PNGs in V1/V2 and C3/V4 
regions, reflect selection for Envs that exhibit strong α4β7 binding and thus increased 
transmission fitness (250). 
To explore the role of α4β7 interactions and other Env properties that might impact 
mucosal transmission, we employed SGA to generate a panel of T/F (n=20) and CC (n=20) Env 
constructs from geographically-matched individuals infected with subtype C viruses, the most 
prevalent HIV-1 lineage worldwide.  To examine Env phenotypes in the context of replication 
competent viruses, we also produced full-length infectious molecular clones (IMCs) for six T/F 
and four CC subtype C strains.  Testing their biological activity in a variety of functional assays, 
we found no differences in the efficiency with which T/F and CC Envs utilized CD4 or CCR5, 
mediated infection of primary CD4+ T cell subsets, or were neutralized by mAbs targeting the 
CD4bs.  We confirmed that infection of α4β7-expressing CD4+ T cells by the prototypic subtype 
B strain HIV-1/SF162 could be partially inhibited by antibodies to α4β7 under some conditions as 
previously described (9, 63).  However, saturating concentrations of α4β7 antibodies had no 
inhibitory effect on infection of all-trans retinoic acid (atRA) stimulated CD4+ T cells from multiple 
donors by any of the T/F or CC viruses, even though most of their gp120 subunits are predicted 
to bind this integrin pair based on previously identified genetic signatures (250).  These findings 
indicate that the ability of some gp120 proteins to engage α4β7 may not be recapitulated by their 
native Env trimers on the surface of infectious particles, and thus suggests that interaction with 
this integrin pair is not critical for mucosal HIV-1 transmission. 
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Results 
Generation of subtype C T/F and chronic Envs. Previous studies of T/F phenotypes 
focused almost exclusively on HIV-1 subtype B (171, 176, 258, 372).  To examine the extent to 
which these results are applicable to other subtypes, we focused in this study on the transmission 
properties of HIV-1 subtype C.  To assess viral entry, we assembled a panel of 20 T/F Env 
clones, six of which have previously been described (191). The remaining 14 clones were derived 
from 13 acutely infected individuals from South Africa and Zambia (8 males, 5 females) - nine of 
whom were sampled during the earliest stages of viral infection (Fiebig stages I and II (112); 
Table 3-1).  Plasma viral RNA was extracted, subjected to SGA and direct amplicon sequencing, 
and used to infer the T/F env sequences as previously described (3).  Consistent with earlier 
findings, infection was established by one or a limited number of viral variants.  Of the 18 acutely 
infected individuals included in this panel, 14 acquired a single variant, while three others were 
infected with two variants and one was infected by four variants (Table 3-1 and Figure 3-1). 
To generate an appropriate control group, we obtained 20 Env clones from individuals 
chronically infected with subtype C viruses (Table 3-1).  Seven of these have previously been 
described (115, 180).  The remaining 13 were generated from chronically infected individuals (11 
females, 2 males) enrolled in the CHAVI 001 cohort (70).  While T/F Envs were derived from 
individuals of both sexes (10 males; 10 females), chronic Envs were predominantly derived from 
female subjects (2 males; 18 females).  To increase the probability of identifying functional env 
genes, we used SGA to generate up to 42 env gene sequences for each chronically infected 
individual (Figures 3-2 and 3-3).  We then constructed phylogenetic trees to identify viruses that 
had undergone a recent clonal expansion as evidenced by clusters or “rakes” of closely related 
sequences (Figures 1, 3-2 and 3-3).  We reasoned that the common ancestor of such clonally 
expanded “rakes” would be more likely to encode a fully functional env gene than a sequence 
chosen at random from the quasispecies.  To approximate this ancestor, we cloned env 
amplicons whose sequences were either identical to the consensus sequence of the 
corresponding rake (n=5) or encoded an Env that differed in a single amino acid residue (n=2).  
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Table 3-1.  Origin of T/F and CC HIV-1 env clones 
 
aSPD = source plasma donors who denied having sex for money or with multiple partners, 
homosexual activity, injection drug use, or receiving a blood transfusion or a tattoo in the 
preceding six months; HSX = heterosexual exposure.        
bdefined in (112); n/a = not applicable for subjects enrolled in chronic cohorts.      
cIMC from subject also tested, see Table 2. 
dmultiple Env clones from single subject.   
eEnv differs from “rake” consensus by a single amino acid. 
fKappes et al., manuscript in preparation. 
gSANBS = South African National Blood Service; ZEHRP = Zambia-Emory HIV Research Project; 
CHAVI = Center for HIV/AIDS Vaccine Immunology; TDRC = Tropical Diseases Research Centre 
 
Env type Subject Env clone designation Country Risk 
factora 
Sex Viral load (RNA 
copies/ml) 
Fiebig 
stageb 
Number of 
SGA 
sequences 
Number 
of T/F 
variants 
Reference Cohortg 
T/F 20258279 20258279-V2_3A5
d S. Africa SPD F 281,838 IV 41 4 this study SANBS 
 20258279-V4_3D10 d 
 2833264 2833264_3G11 S. Africa SPD M 234,423 I/II 13 1 this study SANBS 
 21197826 21197826-V1_3A1 S. Africa SPD F 343,923 I/II 13 2 this study SANBS 
 21283649 21283649_3E8 S. Africa SPD M 3,180 I/II 27 1 this study SANBS 
 20927783 20927783_3E2 S. Africa SPD F 1,886 I/II 11 1 this study SANBS 
 1245045 1245045_3C7 S. Africa SPD M 234,068 I/II 10 1 this study SANBS 
 19157834 19157834-V1_3C3 S. Africa SPD M 275,423 I/II 36 2 this study SANBS 
 2935054 2935054_3A3 S. Africa SPD M >10,000,000 I/II 18 1 this study SANBS 
 ZM246Fc ZM246F_C1G c Zambia HSX F 10,013,800 II 41 1 312 ZEHRP 
 ZM247F ZM247Fv1.Rev-
 d Zambia HSX F 10,823,500 II 44 2 312 ZEHRP 
 ZM247Fv2.fs d 
 ZM249Mc ZM249M-B10 c Zambia HSX M >2,000,000 IV 49 1 312 ZEHRP 
 704809221 704809221.1B3 S. Africa HSX M >750,000 I/II 28 1 3 CHAVI 
 703010054 703010054.2A2 Malawi HSX M 13,936 V 27 1 3 CHAVI 
 703010217 703010217.B6 Malawi HSX F 102,602 V/VI 25 1 3 CHAVI 
 706010018 706010018.2E3 S. Africa HSX F 93,700 VI 23 1 3 CHAVI 
 704010042c 704010042.2E5 S. Africa HSX M 181,000 IV 42 1 3 CHAVI 
 705010198 705010198.tf S. Africa HSX M 14,950,000 I/II 10 1 in prep f CHAVI 
 705010185 705010185.tf S. Africa HSX F 14,800 I/II 10 1 in prep f CHAVI 
Chronic 704010330 704010330.G5h S. Africa HSX M 46,100 n/a 26 n/a this study CHAVI 
 704010207 704010207.D11 S. Africa HSX F 15,400 n/a 26 n/a this study CHAVI 
 702010141 702010141.synR1 Malawi HSX F 151,282 n/a 39 n/a this study CHAVI 
 703010180 703010180.A3 e Malawi HSX F 105,430 n/a 15 n/a this study CHAVI 
 702010432 c 702010432.synR1 c Malawi HSX M 40,570 n/a 30 n/a this study CHAVI 
 703010167 703010167.synR1 Malawi HSX F 73,505 n/a 30 n/a this study CHAVI 
 ZM414 ZM414.1
 d Zambia HSX F 213,600 n/a 41 n/a 180 TDRC 
 ZM414.20 d 
 707010457c 707010457.synR1 c Tanzania HSX F 234,671 n/a 20 n/a this study CHAVI 
 705010534c 705010534.synR1 c S. Africa HSX F 63,300 n/a 36 n/a this study CHAVI 
 704010499 704010499.H1 S. Africa HSX F 15,200 n/a 21 n/a this study CHAVI 
 704010461 704010461.A7h S. Africa HSX F 22,900 n/a 7 n/a this study CHAVI 
 704010028 704010028.F6 S. Africa HSX F 9,220 n/a 20 n/a this study CHAVI 
 703010269 703010269.synR1 Malawi HSX F 30,434 n/a 30 n/a this study CHAVI 
 704010273 704010273.E5 e S. Africa HSX F 25,700 n/a 24 n/a this study CHAVI 
 709013902 3902.bmG14 Malawi HSX F 19,900 n/a 20 n/a 115 CHAVI 
 709014707 4707.E1 Malawi HSX F 83,400 n/a 22 n/a 115 CHAVI 
 
709014403 
4403.A18 d 
Malawi HSX F 100,892 n/a 38 n/a 115 CHAVI  4403.D1
 d 
 4403.bmB6 d 
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Figure 3-1.  Inference of T/F env sequences.  Maximum likelihood trees of SGA-derived env 
sequences (left) and corresponding Highlighter plots (right) are shown for eight subjects acutely 
infected with HIV-1 subtype C viruses.  Highlighter plots depict sequence alignments (Highlighter 
v2.1.1; hiv.lanl.gov); tick marks indicate differences compared to the top sequence (red, T; green, 
A; blue, C; orange, G; grey, gap).  The trees were constructed using PhyML (245).  Except for in 
panel A (bar = 0.005 substitutions per site), the scale bar represents a single nucleotide 
substitution.  Sequences chosen for cloning are marked with an arrow.  In most subjects, a single 
low diversity lineage was observed (B, D, E, F, H), indicating infection with a single T/F virus.  
Subjects 20258279 (A) and 21197826 (C) were infected with four and two T/F viruses, 
respectively.  The tree from subject 19157834 (G) shows a lineage with at least four shared 
mutations, which likely represents a second closely related T/F virus (a single sequence 
highlighted in green exhibits G->A hypermutation).  In all cases, the cloned envs represent 
unambiguously determined T/F viruses. GenBank accession numbers for the env sequences are 
listed in Table 3-3. 
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Figure 3-2. Clonal virus expansion in a chronically infected subject.  The phylogenetic 
relationships of SGA-derived 3’ half genome sequences depicting the quasispecies complexity in 
a chronically infected subject are shown.  Sequences highlighted in light blue are members of a 
recently expanded lineage, the consensus sequence of which approximates their most recent 
common ancestor.  The tree was constructed using maximum likelihood methods (140).  Nodes 
with bootstrap support of greater than 80% are labeled (the scale bar represents 0.02 nucleotide 
substitutions per site). 
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Figure 3-3.  Identification of clonally expanded viral lineages in chronically infected 
individuals.  The phylogenetic relationships of SGA-derived env sequences depicting the 
quasispecies complexity in chronically infected subjects are shown (A-J).  Trees were 
constructed using maximum likelihood methods (245).  Asterisks indicate bootstrap support of 
greater than 80% (the scale bar represents 0.02 substitutions per site).  Sequences highlighted in 
blue indicate a recently expanded viral lineage, the consensus sequence of which approximates 
their most recent common ancestor.  Red arrows denote env amplicons chosen for cloning (A, B, 
D, F, G, H, J) while red lines indicate “rakes” used to infer consensus sequences for 
chemicalsynthesis (C, E, I).  GenBank accession numbers for the env sequences are listed in 
Table 3-3. 
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Figure 3-4. Construction of CC IMCs from overlapping 5’ and 3’ half genome sequences.  
The phylogenetic relationships of SGA-derived 5’ and 3’ half genome sequences depicting the 
quasispecies complexity in chronically infected subjects are shown.  Trees composed of 5’ (A, C, 
E, G) and 3’ (B, D, F, H) half genome sequences were constructed using maximum likelihood 
methods (245).  Sequences highlighted in blue were used to generate half genome consensus 
sequences for each subject (A and B 703010256, C and D 702010432, E and F 707010457, H 
and G 705010534) that were confirmed to be identical in sequence in the region of overlap then 
chemically synthesized to generate full-length IMCs.  Asterisks indicate bootstrap support of 
greater than 80% (the scale bar represents 0.02 substitutions per site).  GenBank accession 
numbers for the 5’ and 3’ half genome sequences are listed in Table 3-3. 
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For subjects from whom none of the env amplicons met these criteria, the rake consensus 
sequence was inferred and chemically synthesized (n=6).  This same approach had also been 
employed to generate the previously reported CC Env constructs (180, 314).  Thus, all 20 CC 
Envs used in this study were derived from clonally expanded viruses.  
Functional analysis of subtype C T/F and CC Envs. Virus pseudotypes containing a 
luciferase reporter gene and bearing one of the T/F or CC Envs were produced in human 293T 
cells and then diluted serially on NP2/CD4/CCR5 and NP2/CD4/CXCR4 cells to assess 
coreceptor usage and to determine the linear range of the assay.  All viral pseudotypes were 
functional, leading to infection of NP2/CD4/CCR5 cells at least 100-fold above Env-negative 
particles.  In contrast, none of the T/F Envs and only one CC Env (4707.E1) mediated entry into 
NP2/CD4/CXCR4 cells at levels 10-fold above background.  However, this Env did not mediate 
entry of GFP-encoding pseudoviruses into primary CD4+ T cells in the presence of the CCR5 
antagonist maraviroc (data not shown).  Thus, the small amount of CXCR4-dependent infection 
seen in NP2/CD4/CXCR4 cells is likely due to the over-expression of this coreceptor and does 
not reflect CXCR4 use on primary cells.  Importantly, all T/F and CC Env constructs were 
functional, thus validating our methods to correctly infer T/F as well as clonally expanded CC 
viruses.  
 Enhanced utilization of CD4 and CCR5 could influence virus transmission since changes 
in CD4 and CCR5 expression have been shown to impact infection by different HIV-1 strains (74, 
95, 96, 274, 336).  A previous study of subtype B T/F and CC viral Envs did not reveal differences 
in their utilization of CCR5 (372). To determine the efficiency with which the newly derived 
subtype C T/F Envs utilized CD4 relative to the CC Envs, we compared their ability to infect 
affinofile cells, a 293T cell line that expresses CD4 and CCR5 under independently inducible 
promoters (172) (Figure 3-5).  We induced CCR5 to maximal levels and induced CD4 to high or 
low expression levels (relative to primary human CD4+ T cells; Figure 2-5B) prior to infection.  
Infection levels of each pseudovirus in the CD4-low cells were then expressed relative to the 
values obtained in the CD4-high cells (Figure 3-5A).  The macrophage-tropic JR-FL Env, which is 
known to mediate efficient entry into cells expressing low levels of CD4 (44, 188), was used as a 
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control.  Using this system, we found that virus pseudotypes expressing T/F and clonally 
expanded CC Envs utilized CD4 with similar efficiency, while CD4 use by JR-FL was 10-fold 
more efficient than most of the other pseudoviruses (Figure 3-5A).  These results demonstrated 
that the affinofile system is sufficiently sensitive to detect differences in CD4 utilization amongst 
different virus strains.  Additionally, the results confirmed earlier studies of subtype B and C 
viruses, which indicated that the ability to use limiting levels of CD4 is not a major determinant of 
transmission fitness (5, 258). 
 To assess the efficiency of CCR5 use, we infected NP2/CD4/CCR5 cells in the presence 
of increasing concentrations of the CCR5 antagonist maraviroc and measured the IC50 value for 
each virus.  We chose this approach over the use of affinofile cells since we have found that 
CCR5 expression levels cannot be controlled with sufficient precision at intermediate 
concentrations of the inducing reagent.  Moreover, maraviroc titration should impact CCR5 
availability to the same degree on all cells in the population.  Therefore, maraviroc sensitivity is a 
surrogate for the efficiency of CCR5 use, provided that none of the Envs tested can use CCR5 
when it is bound to maraviroc (350, 371).  This was true of our Env panel; all T/F and chronic 
Envs examined were sensitive to saturating concentrations of maraviroc with maximal percent 
inhibitions of >95%.  Additionally, T/F and chronic Envs exhibited similar maraviroc IC50 values 
(median T/F=2.22 nM; chronic=1.67 nM; p=0.45).  Thus, enhanced CCR5 utilization efficiency 
does not account for the profound transmission bottleneck of both subtype B (372) and C (Figure 
3-5C) (5) infections. 
CD4+ T cell subset tropism of subtype C T/F and CC Envs. CD4+ T cell subsets have 
different activation and coreceptor expression levels, and thus may be differentially susceptible to 
infection by T/F versus CC viruses (200, 323, 377). Effector memory (TEM) and effector memory 
RA+ (TEMRA) cells predominate in mucosal effector sites where the transmission bottleneck likely 
occurs, while central memory (TCM) and naïve cells are more common in lymph nodes (315, 316).  
Therefore, an enhanced ability to infect TEM and TEMRA cells  
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Figure 3-5.  T/F and CC Envs utilize CD4 and CCR5 with similar efficiency.   (A) Efficiency of 
CD4 usage by T/F and CC Env pseudoviruses.  Luciferase-encoding pseudoviruses were used to 
infect affinofile cells with maximally-induced CCR5 expression and either low or high CD4 
expression.  Infection of CD4-low cells was measured based on luciferase activity and normalized 
to infection of CD4-high cells (y-axis).  Data shown are the mean value from three independent 
experiments for all T/F and CC Envs, each tested in triplicate; for JR-FL the mean of each of 
three experiments is plotted. Grey circles indicate poorly infectious Envs for which the CD4 use 
efficiency is falsely elevated because infection of CD4-low cells was near background, as 
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described in the methods. The bar represents the median value of each group with these Envs 
excluded.  There was no significant difference in the CD4-use efficiency between T/F and CC 
envelopes (Mann-Whitney; p=0.35).  (B) CD4 expression levels from a representative flow 
cytometry experiment depicting CD4 expression on minimally-induced Affinofile cells (low), fully-
induced Affinofile cells (high), and primary human CD4+ T cells (CD4+ T).  (C) Sensitivity of T/F 
and CC Envs to inhibition by maraviroc (MVC).  Viral pseudotypes were used to infect 
NP2/CD4/CCR5 cells in the presence of serial three-fold dilutions of the CCR5 antagonist 
maraviroc.  The concentration required to reduce infection by 50% relative to no drug control 
(IC50) was calculated for each pseudotype.  Log MVC IC50 values are shown in the y-axis. The 
bar represents the median value of each group.  Higher IC50 values indicate that more drug is 
required to prevent infection corresponding to more efficient CCR5 usage, whereas lower IC50 
values correspond to less efficient CCR5 usage.  No significant difference in IC50 values was 
found between T/F and CC envelope pseudotypes (Mann-Whitney; p=0.46).   
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could be linked to enhanced mucosal transmission.  To explore this, we infected primary CD4+ T 
cells with GFP-expressing pseudoviruses and then stained for CCR7 and CD45RO to define 
naïve (CCR7+CD45RO-), TCM (CCR7+CD45RO+), TEM (CCR7-CD45RO+), and TEMRA (CCR7-
CD45RO-) cells.  As shown in Figure 3-6, we saw no differences in the abilities of subtype C T/F 
and CC Envs to mediate entry into these CD4+ T cell subsets.  Similar to our observations for 
subtype B T/F and control Envs (372), most infected cells were TEM, but T/F Envs showed no 
preference for this cell type relative to CC Envs.   
Neutralization sensitivity of subtype C T/F and CC Envs. We recently reported that 
subtype B T/F Envs were more sensitive than CC Envs to the CD4bs mAbs b12 and VRC01, and 
that this was attributable to increased binding of these antibodies to the native Env trimer (372).  
To determine whether this was also true for subtype C, we performed neutralization assays with 
the same antibodies.  No significant differences in neutralization sensitivity to b12, VRC01, PG9 
or PG16 were observed for T/F and CC Envs (Figure 3-7). As expected, VRC01 generally 
neutralized subtype C Envs more potently than b12 (379).  Using 10 µg/ml of b12, only five Envs 
were inhibited by 50%, and the most sensitive Env was inhibited by 83%. Using the same 
concentration of VRC01, 25 Envs were inhibited by 83%, and 16 Envs were inhibited by 95%.  
Nonetheless, we noted a relationship between the sensitivity to both VRC01 and b12 and the 
efficiency of CD4 use. When Envs were divided into those that used CD4 most efficiently (top 
50% regardless of whether they represented T/F or chronic controls) and those that used CD4 
least efficiently, the Envs that used CD4 efficiently were more sensitive to CD4bs (Figure 3-8). In 
contrast, no relationship between CD4-use efficiency and neutralization sensitivity was observed 
for PG9, PG16, or purified immunoglobulin pooled from five individuals infected with subtype C 
HIV-1 (data not shown).  Thus, subtype C T/F and chronic Envs used CD4 with similar efficiency, 
and there was a correlation between CD4 utilization and sensitivity to neutralization by CD4bs 
mAbs.   
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Figure 3-6.  T/F and CC Env pseudotypes enter primary CD4+ T cell subsets with similar 
efficiency.  Primary CD4+ T cells were infected with GFP encoding Env pseudotypes to assess 
the ability of T/F and CC Envs to mediate entry into different CD4+ T cell subsets.  Three days 
post-infection, cells were stained for viability as well as CD3, CD4, CD45RO and CCR7 
expression (372).  In three independent experiments, cells from different donors cells were 
analyzed by flow cytometry and GFP+ cells were back-gated onto memory markers to evaluate 
differential infection of subsets; the average percent of infected cells falling into each subset for 
each Env is plotted on the y-axis.  Cells were classified as central memory (TCM: 
CCR7+CD45RO+), effector memory (TEM: CCR7-CD45RO+), effector memory RA (TEMRA: CCR7-
CD45RO-), and naïve (CCR7+CD45RO-).  While TEM cells permitted the most efficient infection 
by Env pseudoviruses, there was no significant difference in infection efficiency between T/F and 
CC Envs in any of the subsets.  The bar represents the median percentage of cells of each 
subset infected by T/F or CC pseudoviruses. 
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Figure 3-7. Neutralization of T/F and CC Envs.  The maximal percent inhibition (MPI) of 10 
µg/ml of b12, VRC01, PG9 and PG16 on infection by T/F and CC Env pseudoviruses is shown on 
the y-axis.  The bar represents the median MPI.  Numbers at the top indicate two-sided Mann-
Whitney p-values comparing T/F to CC Envs for each mAb. 
 
 
 
 
 
 
 
	  71 
 
Figure 3-8. CD4-use efficiency correlates with CD4 binding site neutralization sensitivity. 
The y-axis shows sensitivity to CD4bs mAbs b12 (A) and VRC01 (B) as measured by the 
maximal percent inhibition (MPI) using 10 µg/ml of each mAb. Envs were divided according to 
their CD4-use efficiency; those that used CD4 efficiently were more sensitive to CD4bs antibodies 
than Envs that used CD4 inefficiently.  The bar represents the median MPI value and p-values 
are from two-tailed Mann-Whitney tests.  
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Effect of α4β7 blockade on infection by Env pseudotypes. The gut-homing integrin 
α4β7 is expressed on activated CD4+ T cells in the gut (107, 108) and vaginal mucosa (223) and  
has been shown to bind the gp120 proteins from several recently transmitted subtype A and 
subtype C viruses (250).  In contrast, gp120 proteins from chronic viruses appear to bind α4β7 
only rarely, although the subtype B HIV-1/SF162 strain is a notable exception (250).  Only a few 
studies have examined the effect of Env-α4β7 interactions on virus replication (9, 63, 272).  It has 
been shown that mAbs specific for α4β7 partially and transiently inhibit infection of α4β7-positive 
CD4+ T cells by HIV-1/SF162 at low inocula.  Based on these studies, it has been suggested that 
engagement of α4β7 may enhance HIV-1 infection, especially in the context of mucosal 
transmission (62, 250). 
 If the ability of gp120 proteins to bind α4β7 is recapitulated by Env molecules present on 
virus particles, we reasoned that α4β7 engagement should enhance virus entry, especially at low 
multiplicities of infection, since binding to the cell surface is a rate-limiting step of virus infection in 
vitro (256, 278).  If so, then saturating levels of mAbs to α4β7 should suppress virus infection, as 
has been shown for the subtype B virus strain HIV-1/SF162 (9, 63).  To investigate this, we used 
a protocol previously developed by Arthos and colleagues in which human CD4+ T cells were 
stimulated with IL-2 (20 IU/ml), anti-CD3 (1.5 µg/ml) and atRA (10 nM).  Under these growth 
conditions, α4β7 expression was enhanced and detected on 15-65% (median 32%) of CD4+ T 
cells, predominantly on effector memory cells, from six different donors (data not shown).  One 
donor was non-responsive to atRA and expressed α4β7 on only five to six percent of CD4+ T 
cells at day six, so these cells were not used for subsequent experiments.  
 We next titrated two commercially available α4β7 mAbs, Act1 (specific for the α4β7 
heterodimer) and 2B4 (specific for α4), both of which have been shown to inhibit gp120 binding 
and to suppress infection of atRA-treated CD4+ T cells by the laboratory adapted HIV-1/SF162 
strain, using concentrations previously reported to be saturating for Act1 (9).  To determine if our 
infection and inhibition conditions were sufficiently sensitive, we used GFP reporter-expressing 
SF162 Env-containing pseudovirus as the positive control.  Pseudovirus expressing the JR-FL 
Env served as the negative control, since the JR-FL gp120 does not bind α4β7 (250).  We failed 
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to detect any inhibition of infection by either pseudovirus at a broad range of inocula using 
saturating concentrations of Act1 (Figure 3-9).  In fact, Act1 treatment enhanced infection of 
SF162, JR-FL and VSV-G pseudoviruses by approximately 30% in cells from two different 
donors.  However, gp120-α4β7 binding has recently been described to be critically dependent on 
Env glycosylation, with high mannose carbohydrates enhancing and complex glycans reducing 
α4β7 interactions (250).  We therefore reasoned that viruses derived from primary CD4+ T cells 
would be physiologically more relevant, since these cells produce Env proteins with 
predominantly high-mannose carbohydrates that support α4β7 binding (38).  
Effect of α4β7 blockade on replication of subtype C T/F and CC IMCs. To examine the 
impact of α4β7 blockade on the infectivity and growth kinetics of replication competent viruses, 
we generated full-length subtype C IMCs representing T/F (n=6) and CC (n=4) viruses (Table 3-2 
and Figure 3-4).  All but three of these had the LDI/V tripeptide motif in the V2 loop, which has 
been shown to play a key role in gp120-α4β7 binding (Figure 3-10) (9, 63, 250).  Moreover, the 
number of N-linked glycosylation sites in the V1/V2 region of these IMCs (range from 3 to 8) was 
comparable to that in gp120 proteins known to interact with α4β7 (range 3 to 9 for the strains 
SF162, 205F, QA203, and CAP88 (250)).  Finally, all replication competent virus stocks were 
produced in primary human CD4+ T cells to ensure physiologically relevant Env glycosylation, 
processing and virion incorporation.  Using these reagents, we infected atRA-treated primary 
CD4+ T cells with each virus strain, using a wide range (100-fold) of inocula in the presence of 
saturating concentrations of Act1.  In three independent experiments, we found that Act1 
consistently inhibited replication of an SF162 Env-containing molecular clone (NL4-3-SF162, gift 
from J. Arthos) at six days post-infection.  This inhibition was greatest at the lowest multiplicity of 
infection (Figure 3-11 A and D).  We also observed significant Act1-mediated inhibition of an NL4-
3 construct that encoded the subtype B Env R3A (231), but again this was seen only at the two 
lowest virus inputs (Figure 3-11B).  No inhibition of infection and replication was observed for YU-
2 (Figure 3-11C), which expresses a gp120 that does not bind α4β7 (250). 
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Figure 3-9.  Blocking α4β7 enhances pseudovirus infection. Infection of primary CD4+ T cells 
by Env pseudoviruses is depicted in the presence and absence of Act1 to block α4β7. atRA-
treated cells were infected with GFP-expressing pseudotypes containing SF162 and JR-FL Envs 
whose gp120 proteins do and do not bind α4β7, respectively, in the absence (top two panels) or 
presence of saturating amounts of the α4β7 specific mAb Act1 (bottom two panels). Infected cells 
were detected by GFP expression (red overlay).  The presence of Act1 resulted in slightly 
increased infection levels of both pseudotypes.  To confirm that saturating levels of Act1 were 
used, cells were stained with fluorescently labeled Act1 before analysis.  The near absence of 
cells in the upper quadrants of the lower panels shows that binding of labeled Act1 antibody was 
blocked by unlabeled antibody added before virus infection. 
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Table 3-2. Description of T/F and CC infectious molecular clones (IMCs) 
IMC type Subject IMC name Country Risk 
factora 
Sex Viral load (RNA 
copies/ml) 
Fiebig 
stageb 
Env AA 
179-181c 
V1V2 
PNGs d 
Reference 
T/F 704010042e CH042 South Africa HSX M 181,000 IV LDI 5 in prepf 
 705010067 CH067 South Africa HSX F 639,000 I/II PDI 5 in prepf 
 705010162 CH162 South Africa HSX M 13,100,000 III LDI 6 in prepf 
 703010131 CH131s Malawi HSX/MSM M 411,873 I/II LDL 5 in prepf 
 ZM246Fe ZM246F-10 e Zambia HSX F 10,013,800 II LDI 3 312 
 ZM249Me ZM249M-1 e Zambia HSX M >2,000,000 IV LDI 6 312 
Chronic 703010256 CH256 Malawi HSX F 28,066 n/a LDV 7 this study 
 702010432e CH432 e Malawi HSX M 40,570 n/a LDI 8 this study 
 707010457e CH457 e Tanzania HSX F 234,671 n/a VDI 6 this study 
 705010534e CH534 e South Africa HSX F 63,300 n/a LDI 5 this study 
aHSX = heterosexual exposure; MSM = Men who have sex with men. 
bdefined in (112); n/a = not applicable for subjects enrolled in chronic cohorts. 
camino acid sequence of α4β7-binding tripeptide in V2 (positions 179-181 in HXB2). 
dpotential N-linked glycosylation sites in the V1V2 region (also see Figure 3-10). 
eEnv from subject also tested, see Table 3-1. 
fKappes et al., manuscript in preparation 
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Figure 3-10. Alignment of V1V2 Env protein sequences.  An alignment of the first and second 
variable regions of the HIV-1 Env glycoprotein (HXB2 gp120 residues 131-196) is shown for 
previously described α4β7-reactive gp120s as well as T/F (dark blue) and CC (light blue) IMCs. 
Asparagine residues predicted to be glycosylated are shown in red. The α4β7 binding-site 
(consensus LDV/I; HxB2 residues 179-181) is highlighted in grey. Gaps, shown as dashes, were 
introduced to optimize the alignment. 
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Figure 3-11.  Blocking α4β7 inhibits replication of NL4-3-SF162 and NL4-3-R3A but not YU-
2.   CD4+ T cells with or without Act1 pre-treatment were infected at three different multiplicities 
using CD4+ T cell derived virus stock (1 µl, 10 µl and 100 µl) to initiate a spreading infection. 
Infections were performed in six replicate wells, each of which was sampled at days three, six 
and nine.  (A-C)  Virus production at day six as measured by p24 content in culture supernatants 
is shown on the y-axis for each of six replicate wells from one of three independent experiments; 
uncorrected Mann-Whitney p values are shown for comparisons of no antibody (solid symbols) 
versus Act1-treated (open symbols) replicate wells (bar = mean).  (D) Replication kinetics are 
shown for NL4-3-SF162 (mean of replicates ± SEM is presented) at three different multiplicities of 
infection. Inhibition of infection was transient and greatest at six days post infection at the lowest 
viral input; uncorrected Mann-Whitney p-values less than 0.05 comparing no mAb to Act1 are 
marked by asterisks.  
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If mucosal transmission selects for viruses that interact with α4β7, we reasoned that the 
replication of T/F IMCs would be inhibited when the Env-α4β7 interaction was blocked.  Our 
subtype C IMC infection assays were powered to detect a 30% or higher decrease in virus (p24 
antigen) production on day six, a time point when the largest effect on virus growth following α4β7 
blockade was observed in previous experiments (63).  Two to four ELISA measurements were 
performed to monitor virus production in each of six replicate wells infected at different 
multiplicities using CD4+ T cells from three different donors.  At the lowest virus inoculum, 
replication was undetectable in one to four of the six replicate wells from each of the ten subtype 
C viruses, indicating that virus was added at limiting dilution.  Using Act1 at saturating 
concentrations, we observed no significant inhibition of replication of any subtype C virus (T/F or 
CC) at any viral inoculum or time point post-infection (Figure 3-12), while replication of the 
positive control SF162 was reduced.  In addition to Act1, we tested the α4 integrin-specific mAb 
2B4 using SF162 and three of the subtype C viruses in CD4+ T cells from two donors and 
obtained similar results: a modest and transient inhibition of SF162, but no inhibition of the other 
viruses (data not shown).  Finally, we tested seven subtype B T/F IMCs (258) using cells from a 
single donor and again observed no inhibition using the anti-α4β7 mAb Act1 (data not shown).  
Taken together, these results indicate that blocking the integrin α4β7 does not reduce the 
replication of T/F and CC subtype C viruses in atRA-stimulated primary CD4+ T cells. 
 While Act1 failed to inhibit infection and/or replication by any of 13 T/F and four CC 
viruses, it significantly increased p24 production of five of the ten subtype C viruses (two of six 
T/F and three of four CC viruses; Figure 3-12).  This was observed at multiple time points and 
with multiple viral inputs.  To determine whether antibody binding to α4β7 could lead to enhanced 
cellular activation (26) and a resulting increase in virus production, we examined the expression 
of cellular activation markers.  We found that neither Act1 nor 2B4 increased the expression of 
CD25, HLA-DR, Ki67, and CD69 at 1 hour, 2 days, and 5 days post-treatment, nor did these 
antibodies lead to an increase in CCR5 or α4β7 expression levels (Figure 3-13).  However, we 
noted increased clumping of cells in both Act1 and 2B4 treated cultures (25),  
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Figure 3-12.  Blocking α4β7 does not inhibit replication of subtype C T/F and CC IMCs.  
CD4+ T cells were infected at three different multiplicities using CD4+ T cell derived virus stock (1 
µl, 10 µl and 100 µl).  Virus replication was monitored by measuring p24 content in culture 
supernatants; each p24 measurement was repeated two to four times.  The average p24 value in 
each of six independent wells at six days post-infection is plotted on the y-axis, with the bar 
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representing the mean p24 value.  Uncorrected Mann-Whitney p-values comparing no mAb to 
Act1 pre-treatment are shown for each viral input.  Blocking α4β7 with Act1 increased p24 
production for some viruses (colored p-values), but had no reproducible inhibitory effect on any 
T/F (A) or CC (B) molecular clones tested, under conditions where reproducible inhibition of NL4-
3-SF162 was achieved, as previously described (250). 
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Figure 3-13.  Act1 and 2B4 do not affect the activation profile of cells compared to a 
murine isotype control.  Cells from three different donors were treated with Act1 (red) or 2B4 
(blue) as well as a murine IgG1 control (open) for one hour (A), two days (B), or five days (C), 
and analyzed for markers of cellular activation, including CD25, HLA-DR, Ki67, and CD69.  The 
expression of CCR5 and α4β7 was also measured.  The percent of live CD4+ T cells expressing 
each marker is shown on the y-axis.  No significant differences were observed comparing Act1 or 
2B4 treated cells to IgG1, except for decreased α4β7 expression at day five, which reflects 
decreased detection due to blocking with unlabeled Act1.  
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which raised the possibility that the enhanced virus production seen in some Act1-treated cultures 
could be due to increased cell-to-cell viral spread.  We thus used high-speed cell imaging to 
examine cell-cell conjugates in CD4+ T cell cultures from a single donor that were infected with 
SF162 as well as three subtype C viruses (2 T/F and 1 CC control) after treatment with Act1, 2B4 
or a murine IgG1 isotype-control.  Neither Act1 nor 2B4 increased expression of the high-affinity 
form of LFA-1, which is known to be upregulated by α4β7 engagement of gp120 (9). However, we 
noted a significant increase in the expression of the cell-cell adhesion molecule ICAM-1 in cells 
exposed to 2B4 or Act1 compared to murine IgG1 (Figure 3-14A).  Consistent with increased cell-
cell spread, more cell-cell conjugates were virus-positive than predicted, with doublets being 
more than twice as frequently infected as singlets (p=0.04) and triplets being more than three 
times as frequently infected as singlets (p=0.06) (Figure 3-14B).  Overall, these results suggest 
that Act1- and 2B4-mediated increases in cell-cell conjugates could facilitate more efficient 
spread and replication of some viruses in the absence of increased cellular activation. 
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Figure 3-14.  Cell-to-cell adhesion and infection analysis.  High-speed imaging of single cells 
and cell aggregates was performed using an ImageStream IS100 cytometer.  (A) Treatment with 
Act1 (red) or 2B4 (blue) increased the percent of singlet cells expressing the cell adhesion 
molecule ICAM-1 (y-axis) relative to a murine isotype (IgG, open) control (p=0.04; Mann-
Whitney).  Each point represents cells from the same donor infected with a different virus, or 
mock infected; the bar indicates the group median. (B) Cells were gated based on DNA content 
and size into individual cells (singlets), two cells in contact (doublets) and three cells in contact 
(triplets).  The percent of singlets, doublets, and triplets infected after exposure to different 
viruses is shown on the y-axis.  Cell infection was determined based on Gag (p24) antigen 
expression compared to mock-infected control.  Cell conjugates contained more infected cells 
than expected by chance, suggesting enhanced cell-to-cell spread (doublets, p=0.04; triplets, 
p=0.06; two-sided paired T-test). 
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Discussion 
The identification of viral traits that might enhance mucosal transmission is an important 
goal for vaccine development and other prevention strategies.  A first step in characterizing such 
traits is the identification of T/F viruses, while a second step is the selection of appropriate 
controls. Virological traits that are strongly associated with transmission, such as CCR5 use, 
should be readily identifiable when comparing T/F viruses to virtually any CC group, while 
identifying more subtle phenotypes will greatly depend on the choice of CC viruses, perhaps 
explaining discrepancies in genetic and phenotypic transmission signatures identified by different 
groups (5, 59, 88, 104, 117, 126, 167, 309, 310).  Finally, the use of in vitro assays that 
recapitulate key steps in mucosal transmission are needed to identify properties unique to T/F 
viruses.  Here, we have compiled a relatively large panel of both Envs and IMCs representing 
subtype C T/F and CC viruses, and developed a series of infection assays using virus 
pseudotypes, replication competent viruses, cell lines and primary human CD4+ T cells to 
improve our ability to identify viral phenotypes associated with transmission. 
 Env glycoproteins of HIV-1 can differ significantly in the efficiencies with which they utilize 
CD4 and the viral coreceptors, which in turn can impact viral tropism (74, 95, 96, 274, 336).  
Given the variability in expression levels of entry cofactors on different cell subsets as well as 
between individuals (35, 133, 212), it is easy to envision several ways in which Env function could 
impact transmission efficiency at the level of virus entry.  To date, several genetic Env signatures 
have been reported, with more compact variable loop structures and fewer PNGs being the most 
frequent findings (59, 117, 126, 309, 310).  It is possible that these genetic traits impact Env 
function in ways that increase transmission fitness.  However, to date no consistent T/F 
phenotype has been described.  Thus, it is possible that mucosal transmission is a stochastic 
event where any reasonably functional R5 or dual tropic Env can initiate a productive infection 
(152).  However, it is also possible that the in vitro assays employed thus far have failed to reveal 
subtler or more transmission-specific phenotypic differences.  The recent finding that some gp120 
proteins from early HIV-1 infections can bind to the α4β7 integrin is consistent with this, although 
the ability of T/F viruses to productively interact with α4β7 was not explored. 
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 To determine whether subtype C T/F viruses, which account for the great majority of new 
infections worldwide, utilize CD4 or CCR5 with enhanced efficiency, we tested both T/F and CC 
Env constructs in pseudotyping assays.  Consistent with previous results for subtype B (372) and 
subtype C (5), we failed to observe differences in both CCR5 and CD4 utilization. This is in 
contrast to findings by Etemad and colleagues who reported enhanced CCR5 utilization by Envs 
from individuals with chronic subtype A infection, although only V1-V5 fragments were tested in 
the context of chimeric viruses (104).  Similarly, Nawaz and colleagues found that gp120s from 
three subjects acutely infected with subtype A and C viruses bound to dodecameric but not 
monomeric CD4, while gp120s from subsequent time points of two of the same subjects bound to 
CD4 in both forms, suggesting an increase in CD4 affinity in later stages of infection (250).  
These results may be specific to the particular Envs (250) or Env fragments (104) used, or due to 
the fact that gp120 and particle-associated Env trimers bind CD4 differently.  In either case, 
current data utilizing a large number of Env constructs strongly suggests that the mucosal 
bottleneck is not the result of selective transmission of viruses with highly efficient CD4 or CCR5 
use (5, 167, 372), or with increased efficiency of entry into particular CD4+ T cells subsets (372).  
 We also examined whether subtype C T/F and CC Envs differed in their interaction with 
the gut homing integrin α4β7 as recently proposed (250), although previous data are almost 
entirely based on gp120 binding studies.  In many ways, the α4β7 hypothesis is an attractive one.  
This integrin is expressed at high levels on activated CD4+ T cells in the gut (107) and 
cervicovaginal mucosa (223), both representing major sites of HIV replication early in infection 
(41, 158).  Moreover, intravenous administration of an anti-α4β7 mAb in rhesus macaques prior 
to and during acute infection with SIVmac239 resulted in decreased virus loads, perhaps by 
inhibiting trafficking of α4β7-positive T cells to the GI tract (7).  Finally, gp120-induced α4β7 
signaling could promote virus replication through increased cell-to-cell adhesion.  However, the 
ability of HIV-1 gp120 to bind α4β7 is far from universal - the commonly studied subtype B 
gp120s examined to date either do not bind to α4β7 or do so weakly, with the exception of SF162 
(250).  Nonetheless, several gp120 proteins derived from early subtype A or subtype C infections 
have been shown to exhibit α4β7 binding capacity, and there is an obvious link between some 
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α4β7 binding properties (fewer PNGs in the V1-V4 region) and genotypes associated with virus 
transmission in subtype C viruses (59, 88, 250).  While monomeric gp120 binds CD4, viral 
coreceptors and most broadly neutralizing antibodies, it differs from virion-associated Env trimers 
in important ways.  Perhaps the best example is that numerous antibodies that bind to gp120 fail 
to neutralize the cognate Env trimer, consistent with both conformational differences and the fact 
that certain gp120 domains are sequestered in the oligomeric molecule.  Thus, a key question 
that remains relatively unexplored is whether α4β7 binding by gp120 translates into an interaction 
by trimeric Env that influences virus infection and spread.  To address this question, we 
concentrated on virus infection assays rather than gp120 binding experiments. 
 In our attempts to define the role of α4β7 in HIV-1 transmission, we were able to replicate 
a previous key finding, namely that saturating levels of antibodies to α4β7 modestly suppressed 
infection and replication by the prototypic subtype B strain HIV-1/SF162 (9, 63).  The inhibitory 
effects of α4β7 antibodies on SF162 infection were both transitory and most evident when low 
levels of virus input were used, which is precisely what would be expected if α4β7 functioned as 
an attachment factor (63, 250).  Attachment of virus particles to the host cell surface is a 
significant rate-limiting step to virus infection in vitro, but can be overcome in part by spinoculation 
(256), the inclusion of polycations that enhance viral binding (57), or the expression of virus 
attachment factors such as CD209 or CD209R (279, 281).  In the case of attachment factors, 
their ability to enhance infection is most pronounced when low levels of virus are used.  Thus, our 
finding of a partial inhibition of SF162 replication in α4β7-positive T cells six days post infection at 
the lowest virus input is entirely consistent with previous reports and shows that our assays are 
sufficiently sensitive to measure the impact of α4β7 blockade on virus infection.  Despite this, we 
found no inhibition of any T/F or CC subtype B or C virus using cells from multiple donors and 
levels of virus empirically determined to be barely sufficient to establish a spreading infection.  
These findings are consistent with those of Pauls and colleagues, who found that a mAb to α4 
used for the treatment of multiple sclerosis and Crohn's disease did not impact infection of atRA-
treated CD4+ T cells by several HIV-1 strains, including two with the LDI/V tripeptide binding 
motif in the V2 region (272).  Since most of our T/F and CC viruses possessed the α4β7-binding 
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tripeptide motif as well as below average numbers of PNGs in the V1/V2 region, selection bias - 
i.e. the preferential inclusion of viruses that would be unlikely to interact with α4β7 - can also be 
excluded.  Thus, we favor the hypothesis that not all Envs that can bind α4β7 in the form of 
gp120 necessarily do so as unliganded trimers.  
 Our failure to detect enhancement of viral infection of human CD4+ T cells by primary 
subtype B or C viruses, including T/F viruses, due to α4β7 interaction is by no means definitive, 
but does suggest that extrapolating results from gp120 binding assays to more complex virion 
infectivity studies may be misleading.  It is possible that α4β7 interactions will be more important 
in other types of infection assays.  In addition, we have not tested the ability of gp120 proteins 
derived from our viruses to bind to α4β7, although the relevance of such findings remains 
uncertain unless the corresponding trimeric Env exhibits similar properties. Our results 
demonstrate the importance of using replication-competent viruses to study properties associated 
with mucosal transmission.   In contrast to single-round pseudovirus assays, experiments with 
IMCs are unbiased with respect to the genes that could influence fitness and enable detection of 
subtle differences following multiple rounds of replication. Thus, T/F and CC IMCs are ideal 
reagents for future studies of phenotypes that may influence HIV-1 transmission.  
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Materials and Methods 
Study subjects. This study was conducted according to the principles expressed in the 
Declaration of Helsinki. It was approved by the Institutional Review Boards of the University of 
Pennsylvania and Duke University. All subjects provided written informed consent for the 
collection of samples and subsequent analysis. Blood samples were obtained from 26 subjects 
infected with HIV-1 subtype C. A summary of their geographic origin and infection status is shown 
in Table 1. Blood specimens were collected in acid citrate dextrose, and plasma was separated 
and stored at −70°C.  
Generation of T/F and CC Envs and IMCs. The inference and cloning of T/F Envs and 
IMCs from SGA-derived viral sequences has been described (Figure S1) (3, 176, 204, 258, 313). 
To ensure efficient expression of cloned subtype C Envs for pseudotyping, the sense primer used 
for amplification of the corresponding rev1-vpu-env cassette lacked the rev initiation codon 
(underlined) (5’-CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3’) (191).  
Since chronic HIV-1 infections represent complex quasispecies of genetic variants, it is 
impossible to predict, based on sequence analysis alone, which members of this quasispecies 
are functional and which are defective or partially defective. To generate biologically relevant 
CCs, we thus targeted viral variants for both Env and IMC construction that exhibited evidence of 
a recent clonal expansion. Viral RNA was extracted from the plasma of chronically infected 
individuals and subjected to SGA and direct amplicon sequencing as described (3, 204), with the 
following modifications: 5′ half genome amplification: 1st round sense primer 2010ForRC 5′- 
GTCTCTCTAGGTRGACCAGAT -3′, 1st round antisense primer 2010Rev1C 5′- 
AAGCAGTTTTAGGYTGRCTTCCTGGATG -3′, 2nd round sense primer 2010R1C 5′- 
TAGGTRGACCAGATYWGAGCC -3′ and 2nd round antisense primer 2010Rev2C 5′- 
CTTCTTCCTGCCATAGGAAAT -3′; 3′ half genome: 1st round sense primer 07For7 5′- 
CAAATTAYAAAAATTCAAAATTTTCGGGTTTATTACAG -3′, 1st round antisense primer 
2.R3.B6R 5′- TGAAGCACTCAAGGCAAGCTTTATTGAGGC-3′, 2nd round sense primer VIF1 5′- 
GGGTTTATTACAGGGACAGCAGAG -3′ and 2nd round antisense primer Low2C 5′- 
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TGAGGCTTAAGCAGTGGGTTCC -3′. Thermal cycling conditions were identical to (204) except 
that 60°C was used for primer annealing. Sequences were then aligned using ClustalW (349) and 
subjected to phylogenetic analysis using PhyML (140).  Phylogenetic trees were inspected for 
clusters of closely related viruses, or “rakes”, which are indicative of a recent clonal expansion. 
(Figures 1, S2 and S3). In five subjects (Table 1), at least one env amplicon was identical in 
sequence to the inferred “rake” consensus and thus selected for cloning using the pcDNA3.1 
Directional Topo Expression kit (Invitrogen). In two subjects, observable “rakes” were limited to 
only two closely related sequences, which encoded Env proteins that differed by a single amino 
acid. In these cases, the amplicon that matched the within patient consensus at this ambiguous 
site was cloned.  In the remaining six subjects, the consensus sequences of the clonal expansion 
“rakes” were chemically synthesized and cloned (designated .synR1 in Table 3-1).  IMCs from 
chronically infected subjects (CH256, CH432, CH457, and CH534) were generated using the 
same approach. 3’ and 5’ half-genome SGA was performed using viral RNA from subjects with 
evidence of clonal expansion as determined by env sequencing. 3’ and 5’ half genome 
sequences were used to construct neighbor joining trees (Figure 3-4), and clusters of closely 
related sequences were selected for further analysis. A consensus sequence of the members of 
such “rakes” was generated using Consensus Maker (hiv.lanl.gov). 3’ and 5’ half genome 
sequences were confirmed to be identical in their 1,040 bp overlapping regions, chemically 
synthesized in fragments bordered by unique restriction enzymes, and ligated together to 
construct infectious proviral clones. 
Pseudovirus production. Virus pseudotypes were produced by co-transfecting 6 µg of 
pcDNA3.1+ containing the desired env clone with 10 µg of HIV-1 backbone (pNL43-ΔEnv-vpr+-
luc+ or pNL43-ΔEnv-vpr+-eGFP (catalog no. 11100 from the NIH Aids Research and Reference 
Reagent program (ARRRP) contributed by Haili Zhang, Yan Zhou, and Robert Siliciano (391)) 
into 293T cells using the calcium phosphate precipitation method. 72 h post-transfection, the 
pseudovirus-containing supernatant was filtered through a 22 µm filter, aliquoted, and stored at 
−80°C. Pseudovirus used to infect primary CD4+ T cells was concentrated by ultracentrifugation 
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through a 20% sucrose cushion. Pelleted pseudovirus was then resuspended in phosphate-
buffered saline (PBS) in 1/100th the initial volume. All luciferase-encoding pseudoviral stocks were 
serially two-fold diluted and used to infect NP2 cells to define the linear range of the assay. 
Coreceptor tropism testing and cell line infections. NP2 cells stably expressing CD4 
and either CCR5 (NP2/CD4/CCR5) or CXCR4 (NP2/CD4/CXCR4) were infected with luciferase-
encoding HIV-1 pseudoviruses by spinoculation in 96-well plates at 450 × g for 90 min at 25°C. 
Cells were lysed with Brite-Glo (Promega) at 2 h post-infection and analyzed on a Luminoskan 
Ascent luminometer. To assess sensitivity to coreceptor inhibitor maraviroc, NP2/CD4/CCR5 cells 
were preincubated for 30 min with saturating concentrations of the CCR5 inhibitor maraviroc (1 
µM; ARRRP catalog no. 11580; (103)) or the fusion inhibitor enfuvirtide (10 µg/ml) prior to 
infection. To assess sensitivity to broadly neutralizing mAbs (HIV-1 gp120 mAb IgG1 b12 
(ARRRP catalog no. 2640) from Dennis Burton and Carlos Barbas (47); HIV-1 gp120 mAb 
VRC01 (ARRRP catalog no. 12033) from Dr. John Mascola (379); HIV-1 mAbs PG9 and PG16 
(ARRP catalog no. 12149 and 12150) from IAVI (363)), viral pseudotypes were preincubated with 
10 µg/ml of antibody for 1 hour at 37°C. Virus and antibody mixes were then used to infect 
NP2/CD4/CCR5 cells. All NP2 cell line infections were done in at least triplicate in at least three 
independent experiments using R5-tropic JR-FL as a positive control and Env-deficient 
pseudotypes as a negative control.  
CD4 utilization efficiency. The ability of Env pseudoviruses to infect cells expressing 
low levels of CD4 was determined using affinofile cells, which are a modified 293T cell line that 
stably express CD4 and CCR5 under the control of independently inducible promoters (172).  
5x102 cells were plated in each well of a 96-well plate and allowed to grow for two days prior to 
infection. Cells were induced with 2 µM ponasterone, which induces supraphysiologic levels of 
CCR5 thus ensuring CD4 is the limiting factor in entry, and either 0.156 ng/ml (CD4-low) or 5 
ng/ml (CD4-high) minocycline 18 hours prior to infection.  Expression levels were monitored by 
quantitative FACS analysis (200). At the time of infection, media was exchanged and 25 µl of 
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luciferase-encoding pseudovirus was added. Cells were then spinoculated at 450g for 90 
minutes. Luciferase activity was measured three days post-infection. Each infection condition was 
done in at least triplicate in each of three independent experiments. Pseudovirus-containing 
vesicular stomatitis virus glycoprotein (VSV-G) which is CD4-independent and thus infects CD4-
high and CD4-low cells equally, HIV-1 JR-CSF Env which requires high levels of CD4, and HIV-1 
JR-FL Env which can utilize low levels of CD4 were included in all experiments as controls (322). 
To calculate CD4-use efficiency, mean relative light units in CD4-low cells were divided by the 
value obtained in CD4-high cells. The signal-to-noise ratio was higher in affinofile cells than 
NP2/CD4/CCR5 cells. Nine Envs (5 T/F, 4 CC) infected maximally-CD4-induced afffinofile cells 
less than 100-fold above background. For these Envs, we noted increased variability across 
independent assays. Additionally, the ratio of CD4-high to CD4-low infection was likely falsely 
elevated due to infection of CD4-low cells at background levels. These Envs are highlighted in 
Figure 2 and were excluded from subsequent analyses. 
Maraviroc IC50. Maraviroc IC50 values were determined by pretreating NP2/CD4/CCR5 
cells with 11 serial 3-fold dilutions of maraviroc, ranging from 5.9 µM to 0.1 nM, or no drug then 
spinoculating as above with luciferase-encoding pseudovirus and measuring luminescence 72h 
post-infection. NP2 cells were chosen for this experiment because in the absence of CCR5 
(NP2/CD4 only) these cells are highly restrictive to infection (339); thus entry through potential 
alternative coreceptors when CCR5 is blocked by maraviroc is negligible. IC50 was determined 
using Prism 4.0 to determine the best fitting non-linear curve. Reported IC50 values are the mean 
of four independent experiments, with each drug concentration/pseudovirus condition performed 
in duplicate. 
Primary human CD4+ T cell tropism assay. Primary human CD4+ T cells were purified 
by negative selection by the University of Pennsylvania's Human Immunology Core. Cells were 
stimulated with plate-bound anti-CD3 (clone OKT3) (eBiosciences) and anti-CD28 (clone 28.2) 
(BD Biosciences) and 20 U/ml recombinant interleukin-2 (IL-2) (aldesleukin, Prometheus 
Laboratories) in RPMI supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). Three 
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days after stimulation, cells were transferred to 96-well V-bottom plates. Five microliters of 
concentrated GFP-expressing pseudovirus was used to infect 6.7 × 105 cells in triplicate by 
spinoculating at 1,200 × g for 2 hours. Cells were then transferred to new 24-well plates, and new 
medium containing 20 U/ml IL-2 was added. Three days post-infection, cells were stained for flow 
cytometry (350, 372). 
Flow cytometry. A total of 1-2 × 106 cells from each condition were stained for flow 
cytometry. Incubations were done at room temperature in fluorescence-activated cell sorter 
(FACS) wash buffer (PBS, 2.5% FBS, 2 mM EDTA). Cells were first washed in PBS, then 
live/dead Aqua (Invitrogen) was added and incubated for 10 min. Next, anti-CCR7 IgM (BD) in 
FACS wash buffer was added and incubated for 30 min. Cells were then washed in FACS wash 
buffer before staining with anti-CD3–Qdot 655 (Invitrogen), anti-CD4–Alexa Fluor 700 (BD), anti-
CD45RO–phycoerythrin (PE)-Texas Red (Beckman Coulter), and anti-IgM–PE (Invitrogen) for 30 
min. Cells were then washed in FACS wash buffer and resuspended in 1% paraformaldehyde 
(PFA). Samples were run on an LSRII (BD) instrument and analyzed with FlowJo 8.8.6 
(Treestar). Cells were gated as follows: singlets (FSC-A by FSC-H), then live cells (SSC-A by 
live/dead), then lymphocytes (SSC-A by FSC-A), then CD3+ cells (SSC-A by CD3), then memory 
markers (CCR7 by CD45RO). 
To examine activation of cells treated with Act1, 2B4, isotype control murine IgG1, or no 
antibody, cells were pretreated with 33nm of the specified antibody for 1 hour, 2 days, or 5 days. 
At each time point, 1 × 106 cells were washed in PBS, then live/dead Aqua was added for 10 
minutes. Anti-CCR5-PE (BD), anti-CD4-PerCP-Cy5.5, anti-CD25-APC-Cy7, anti-HLA-DR-PE-
Cy7, anti-α4β7-Alexa Fluor 680 (clone Act1) and anti-CD45RO-TexasRed-PE were added in 
FACS wash buffer for 30 minutes. Cells were then washed in FACS wash buffer and treated with 
cytofix/cytoperm buffer (BD) for 17 minutes. Anti-CD3-V450, anti-CD69-APC, and anti-Ki67-FITC 
in perm/wash buffer were added and incubated for 1 hour at room temperature. Cells were 
washed in perm/wash buffer, fixed in 0.1% paraformaldehyde, run on an LSRII instrument and 
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data was analyzed with FlowJo. Live cells expressing CD3 and CD4 were analyzed for 
expression of activation markers.  
Production of HIV in primary CD4+ T cells. Replication competent viral stocks were 
generated by transfecting a 10cm dish 30% confluent with 293T cells with 6 µg of IMC DNA. 
Virus was harvested 72 hours post-transfection and filtered through a 45 micron low protein 
binding filter. 293T-derived HIV was then used to infect stimulated human CD4+ T cells. 18 hours 
after infection cells were washed twice to remove unbound 293T-derived virus.  CD4+ T cell 
derived HIV was then harvested 11 days post infection, filtered through a 45 micron filter, 
aliquoted and frozen at -80°C.  p24 antigen concentration of viral stocks was assessed by 
Alliance ELISA and high sensitivity alphaLISA (Perkin Elmer); these methods were in good 
agreement for all IMCs tested. 
Infection assay to assess effect of α4β7 blockade. Freshly isolated human CD4+ T 
cells purified by negative selection were stimulated with 1.5µg/ml anti-CD3 clone OKT3, 20 
units/ml IL-2, and 10 nM atRA.  atRA was resuspended in DMSO, filter sterilized, aliquoted in the 
dark, and immediately frozen at -80°C for no longer than one month. 24 hours after stimulation, 
media was removed, and new media with IL-2 and atRA was added.  Media was changed and 
new IL-2 and atRA were added every two to three days. Efforts were made to precisely follow 
previously reported methods (9, 63). Cells were infected six days post-stimulation for both 
pseudotype and replication competent HIV infection.  Cells were pre-treated for 1 hour with 33 nM 
Act1 (an α4β7 heterodimer specific mAb; ARRRP catalog no. 11718 from Dr. A. A. Ansari (198)) 
at 37°C prior to infection.  α4β7 expression and saturating mAb blockade was confirmed on the 
day of infection by flow cytometry.  α4β7 expression was determined with Alexa Fluor 680-
conjugated Act1 (Invitrogen). GFP-expressing pseudotype infections were performed as 
described above. SF162 and JR-FL pseudovirions were used as positive and negative controls, 
respectively (250). For infections with replication competent HIV, virus made in CD4+ T cells was 
used to limit potentially non-physiologic properties of 293T-derived HIV. 2x105 stimulated atRA-
treated CD4+ T cells were plated in 100 µl per well of a 96-well plate.  After incubation with Act1 
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or media only, 100 µl of CD4+ T cell-derived virus was added at a neat, 1:10, or 1:100 dilution.  
Cells were infected for five hours at 37°C without spinoculation and then cells were washed four 
times to remove unbound HIV. Three, six, and nine days post-infection, media was changed and 
p24 antigen concentration was assessed in the supernatant using an alphaLISA high sensitivity 
kit (Perkin Elmer) read on a Synergy H4 plate reader (BioTek instruments). Either four or six 
replicate wells were used per condition, and each alphaLISA measurement was performed 2-4 
times. AlphaLISA assays were performed in 25 µl volume in 384 well plates. Each plate 
contained an internal standard curve ranging four orders of magnitude with each standard 
concentration repeated in eight wells.  The lower limit of detection for most assays ranged 
between 3 and 10 pg p24 per mL. 
High-speed cell imaging. Purified CD4+ T cells were treated with atRA, anti-CD3, and 
IL-2, and infected as described for α4β7 blocking experiments. Nine days post infection, cells 
exposed to 10 µl of NL4-3-SF162, ZM249, CH162, CH256, and mock infected were pooled from 
six replicate wells, washed in PBS and then FACS wash buffer. Anti-CCR5-PE-Cy7, anti-CD54 
(ICAM-1)-PE-Cy5, anti-LFA-1-PE (clone MEM-148), and anti-α4β7-Alexa Fluor 680 (clone Act1) 
were added in FACS wash buffer and allowed to incubate for 30 minutes. Cells were then 
washed in FACS wash buffer and treated with cytofix/cytoperm buffer for 17 minutes. Anti-Gag-
FITC (clone KC-57) was added for 1 hour. Cells were fixed in 1% paraformaldehyde and DAPI 
was added 30 minutes prior to analysis. Samples were run on an ImageStream IS100 equipped 
with two cameras and 405, 488, and 658 nm excitation lasers. At least 20,000 images were 
collected per condition, and the upper limit of images classified as cells was set to 600 pixels to 
allow collection of cell-cell conjugates. Cells were gated as follows: singlets, doublets, and triplets 
(DAPI by brightfield area), then Gag+ (Gag intensity by Gag median pixel). Gag positivity was 
gated such that the percent of mock-infected Gag+ cells was equal in singlet, doublet, and triplet 
populations. A single Gag-expressing cell was sufficient for a doublet or triplet image to be 
considered Gag+, as confirmed by visual inspection of Gag+ images. LFA-1 and ICAM-1 
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expression were analyzed on nucleated (DAPI+), focused (brightfield gradient root mean square-
high), singlets (brightfield aspect ratio ~1) to ensure that all analyzed images were of high quality.  
Statistical analysis. To test the hypothesis that T/F Envs as a group were different from 
CC Envs in various functional measures, we used two-tailed Mann-Whitney tests. To test the 
hypothesis that Act1 treatment inhibited viral replication in CD4+ T cells, we again used two-tailed 
Mann-Whitney tests comparing the six biological replicates with and without Act1 treatment for 
each virus.  No attempts were made to correct for multiple testing, largely because Act1 treatment 
did not have the expected effect on T/F viruses.  Because six values from each group were 
compared, the minimum uncorrected p-value was 0.002.  Applying the conservative Bonferroni 
correction would render all comparisons insignificant (α level of 0.05 divided by 39 tests = 0.001).   
Thus, we conclude that Act1 inhibits or enhances only when multiple input levels of the same 
virus show a consistent effect.  To determine if cell-cell conjugates were infected more than 
expected by chance, the percent of Gag+ doublets was compared in a paired t-test to double the 
percent Gag+ singlets, and the percent of Gag+ triplets was compared to triple the percent Gag+ 
singlets.   
Nucleotide accession numbers. All newly obtained HIV-1 sequences have been 
submitted to GenBank and are available under accession numbers listed in Table 3-3. 
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Table 3-3. GenBank accession numbers of sequences generated for this study 
achemically synthesized sequences available in Table S1 of online version of this manuscript 
(doi:10.1371/journal.ppat.1002686). 
 
  
Infection 
stage Subject env clone accession numbers 
env SGA accession 
numbers 
5' half accession 
numbers 
3' half accession 
numbers 
Acute 20258279 HQ595763 and HQ595764 (env) JQ753730-JQ753770 n/a n/a 
 2833264 HQ595757 (env) JQ754177-JQ754189 n/a n/a 
 21197826 HQ595753 (env) JQ754190-JQ754202 n/a n/a 
 21283649 HQ595756 (env) JQ754203-JQ754229 n/a n/a 
 20927783 HQ595750 (env) JQ754230-JQ754240 n/a n/a 
 1245045 HQ595742 (env) JQ754241-JQ754250 n/a n/a 
 19157834 HQ595743 (env) JQ754251-JQ754286 n/a n/a 
 2935054 HQ595758 (env) JQ754287-JQ754304 n/a n/a 
Chronic 704010330 JQ777128 (env) JQ777111-JQ777136 n/a n/a 
 704010207 JQ777073 (env) JQ777061-JQ777086 n/a n/a 
 702010141 702010141.synR1a (env) JQ779286-JQ779324 n/a n/a 
 703010180 JQ777046 (env) JQ777046-JQ777060 n/a n/a 
 703010167 703010167.synR1a (env) JQ779884-JQ779913 n/a n/a 
 704010499 JQ777164 (env) JQ777144-JQ777164 n/a n/a 
 704010461 JQ777137 (env) JQ777137-JQ777143 n/a n/a 
 704010028 JQ777039 (env) JQ777026-JQ777045 n/a n/a 
 703010269 703010269.synR1a (env) JQ777165-JQ777194 n/a n/a 
 704010273 JQ777098 (env) JQ777087-JQ777110 n/a n/a 
 707010457 707010457.synR1a (env); CH457a (IMC) n/a JQ779148-JQ779169 JQ779128-JQ779147 
 705010534 705010534.synR1a (env); CH534a (IMC) n/a JQ779206-JQ779225 JQ779170-JQ779205 
 702010432 702010432.synR1a (env); CH432a (IMC) n/a JQ779256-JQ779285 JQ779226-JQ779255 
 703010256 CH256a (IMC) n/a JQ779098-JQ779127 JQ779074-JQ779097 
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Abstract 
The great majority of human immunodeficiency virus type 1 (HIV-1) strains enter CD4+ 
target cells by interacting with one of two coreceptors, CCR5 and CXCR4. Here we describe a 
transmitted/founder (T/F) virus (ZP6248) that was profoundly impaired in its ability to utilize CCR5 
and CXCR4 coreceptors on multiple CD4+ cell lines as well as primary human CD4+ T cells and 
macrophages in vitro, yet replicated to very high titers (>80 million RNA copies/ml) in an acutely 
infected individual. Interestingly, the envelope (Env) glycoprotein of this subtype B virus had a 
rare GPEK sequence in the crown of its third variable loop (V3) rather than the consensus GPGR 
sequence. Extensive sequencing of sequential plasma samples showed that the GPEK sequence 
was present in virtually all Envs, including those from the earliest time points after infection.  The 
molecularly cloned T/F virus was able to replicate, albeit poorly, in cells obtained from ccr5∆32 
homozygous donors. The ZP6248 T/F virus could also infect cell lines overexpressing the 
alternative coreceptors GPR15, APJ and FPRL-1. A single mutation in the V3 crown sequence 
(GPEK->GPGK) of ZP6248 restored its infectivity in CCR5+ cells but reduced its ability to 
replicate in GPR15+ cells, indicating that the V3 crown motif played an important role in usage of 
this alternative coreceptor. These results suggest that the ZP6248 T/F virus established acute 
infection in vivo by using coreceptor(s) other than CCR5 or CXCR4, or that the CCR5 coreceptor 
existed in an unusual conformation in this individual. 
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Introduction 
Human immunodeficiency virus type I (HIV-1) enters target cells by first binding to the 
primary receptor CD4 and then to a coreceptor, generally either the chemokine receptors CCR5 
or CXCR4 (28). CD4 binding induces structural changes in the envelope (Env) glycoprotein that 
form and expose the coreceptor binding site.  There are two main interactions between Env and 
coreceptor (77, 78, 164, 300, 301): the base of the third variable loop (V3) loop engages the N-
terminus of the coreceptor, while the crown of the V3 loop that includes the highly conserved 
GPGR/Q arch motif binds to the extracellular loops of the coreceptor, with the second 
extracellular loop of the coreceptor being particularly important (94, 164, 194, 291, 354). Although 
some HIV-1 strains are able to use a variety of different G protein-coupled receptors to gain entry 
into CD4+ cell lines, the great majority of these viruses use CCR5 and/or CXCR4 as coreceptors 
to infect primary cells (27, 28, 65, 128, 280, 381). CCR3, GPR15, APJ, and FPRL-1 are among 
the most frequently used alternative coreceptors when over-expressed on cell lines (66, 167, 251, 
280, 335).  Rare cases of HIV-1 strains that are able to use FPRL-1 and GPR1, but not CCR5 or 
CXCR4, have been reported (335).   
To characterize the biological processes underlying HIV/SIV transmission, we recently 
developed an experimental strategy that permits the identification, enumeration and molecular 
cloning of transmitted/founder (T/F) viruses (176, 312).  This strategy, which employs single 
genome amplification (SGA) and direct amplicon sequencing of HIV/SIV RNA or DNA from the 
plasma or infected cells, makes it possible to infer the nucleotide sequence of the viral strain(s) 
that initiated productive infection weeks earlier (3, 176, 177, 201, 312, 346, 384). An important 
prediction of this approach has been that inferred T/F viruses are fully functional and encode all 
proteins necessary to establish a new infection. Indeed, this prediction has been borne out in 
numerous studies, which have shown that T/F viral genes as well as full-length genomes are 
biologically active. Sets of T/F Envs have been shown to mediate efficient virus entry in single 
round infection assays, and they invariably use CCR5 as a coreceptor (176, 191). Similarly, T/F 
infectious molecular clones (IMCs) of HIV-1, SIVmac and SIVagm all produce replication 
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competent virus that grow to high titers in primary CD4+ T cells (125, 204, 313).  
To generate a comprehensive panel of T/F Env constructs for biological studies, we 
recently characterized more than 100 plasma samples from acute infection cases, including 
commercially available seroconversion panels of serial plasma donors (176).  Sequences 
spanning the rev-vpu-env region of the HIV-1 genome were amplified using the SGA method and 
used to infer the T/F env sequences (176, 313).  A subset of these were then cloned and 
subjected to functional studies. When a panel of subtype B env genes derived by this method 
was tested, all but one were highly functional in single round infection assays. The exception was 
an Env construct from an acutely infected plasma source donor with a highly unusual GPEK V3 
loop crown sequence that failed to utilize CCR5 or CXCR4 efficiently to infect cell lines or primary 
CD4+ cells, although function was restored when the V3 crown sequence was changed to GPER. 
The poor functionality of this unambiguously identified T/F Env was in stark contrast to the ability 
of the corresponding virus to replicate in vivo, as evidenced by high plasma viral load (>80 million 
RNA copies/ml) in the infected host. Here, we investigated the mechanisms underlying this highly 
unusual T/F virus phenotype. 
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Materials and Methods 
Amplification of the HIV-1 env gene. Serial plasma samples collected from an acutely 
infected plasma donor, ZP6248, were purchased from ZeptoMetrix. A total of seven plasma 
samples were collected between February 12 and March 9, 1997, and viral loads (VLs) were 
determined by the COBAS AMPLICOR HIV-1 MONITOR Test. Viral RNA was extracted from 
plasma collected on February 26, March 2 and March 9 using the PureLink viral RNA/DNA mini 
kit (Invitrogen, Carlsbad, CA) and used for cDNA synthesis using Superscript III (Invitrogen, 
Carlsbad, CA) and primer Env3’ex 5’-TTGCTACTTGTGATTGCTCCATGT-3’ (nt 8913-8936 in 
HXB2) in a 50 µl volume.  Single genome amplification (SGA) was used to obtain rev-vpu-env 
cassettes as previously described (176, 181). The first round PCR was carried out with primers 
Env5’ex 5′-TAGAGCCCTGGAAGCATCCAGGAAG-3′ (nt 5853-5877) and Env3’ex, and the 
second round PCR with primers Env1Atopo 5’-caccGGCTTAGGCATCTCCTATGG 
CAGGAAGAA-3’ (nt 5957-5983) and Env3’in 5’-GTCTCGAGATACTGCTCCCACCC-3’ (nt 8904-
8882). 
Sequence analysis. All SGA amplicons were sequenced directly by cycle sequencing 
and dye terminator methods using an ABI 3730xl genetic analyzer (Applied Biosystems, Foster 
City, CA).  Individual sequences were assembled and edited using the Sequencher program 4.7 
(Gene Codes, Ann Arbor, MI).  The env sequences were aligned using CLUSTAL W (349), and 
manual adjustment for optimal alignment was done using MASE (110).  The env sequence of the 
T/F virus was inferred as previously described (176).  A phylogenetic tree was constructed with 
complete env gene sequences using the Neighbor-joining method (311) and the Kimura two-
parameter model (179).  Highlighter analysis was performed through the LANL database website 
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html). The accession numbers 
are EU575573-EU575592.  
Generation of V3 mutants. Site-directed mutagenesis was carried out to introduce 
mutations into the V3 region of the env gene using the Quikchange Site-Directed Mutagenesis kit 
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(Stratagene, La Jolla, CA) as previously described (214).  A single mutation (E312G) was 
introduced into the ZP6248.wt env gene to make the ZP6248.E312G mutant. The mutagenesis 
reaction was transformed into XL1-Blue supercompetent cells and positive clones were confirmed 
by sequencing. 
Construction of YU2-ZP4248 chimeras. To conveniently insert a foreign env gene into 
the replication competent YU2 proviral clone, we first generated a modified YU2 clone (pYU2-
∆envMN), in which the partial vpu gene, complete env, and partial nef gene (nt 6186-8800) were 
replaced by a multiple cloning site fragment ACGCGTATCACAAGATTAGTGcGGCcgc (MluI-
14bp spacer-NotI).  The unique MluI and NotI sites (bold letters) that are rare among HIV-1 env 
genes were introduced.  The first 2 bp and the last 8 bp (underlined) are from the vpu and nef 
coding regions, respectively.  The small letters indicate those bases that are different from the 
original YU2 sequence. 
To clone the ZP6248.wt env gene into pYU2-∆envMN, both ZP6248.wt and 
ZP6248.E312G were amplified with Platinum Taq High Fidelity polymerase.   MluI and NotI 
restriction sites were introduced at the 5’ and 3’ ends of the amplified env genes, respectively, at 
the corresponding positions in the HIV-1 genome.  The PCR products were purified, digested with 
MluI and NotI, and ligated into the pre-treated pYU2-∆envMN vector.  The positive clones from 
transformed JM109 cells were identified and confirmed by sequencing. 
Single round infection assay. TZM-bl cells were infected with pseudovirions as 
previously described (180).  Infectivity was determined by measuring luciferase activity in the cell 
lysates using the Bright-Glo Luciferase Assay System (Promega Corp., Madison, WI) on a Victor 
2 luminometer (Perkin-Elmer Life Sciences, Shelton, CT). 
Determination of coreceptor usage. GHOST(3) indicator cell lines expressing CCR1, 
CCR2b, CCR3, CCR4, CCR8,  CXCR4, Hi5, X4R5, GPR15/BOB, STRL33/Bonzo, CX3CR1 were 
obtained from the NIH AIDS Research and Reference Reagent Program. Cells (3 x 105) were 
seeded in 12-well plates the day before infection. 100 ng p24 of each pseudovirion or infectious 
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virus prepared from transfected 293T cells was added to each well.  After absorption for six hours 
at 37oC, complete medium was added, and cell culture was maintained at 37oC with 5% CO2. 
Supernatant was collected daily, and virus replication was monitored by measuring the p24 
antigen content using the Alliance HIV-1 p24 ANTIGEN ELISA Kit (PerkinElmer, Boston, MA). 
Coreceptor usage was also determined on NP-2 cells expressing CD4 along with either CCR5, 
CXCR4, or other G protein-coupled receptors with Env pseudovirions as previously described 
(251, 335). 
Molecular cloning of the full-length ZP6248 T/F virus. To obtain an infectious 
molecular clone (IMC) of the ZP6248 T/F virus, SGA methods were used to amplify overlapping 
5' and 3' half genomes as well as the viral LTR from plasma viral RNA.  The full-length T/F 
sequence was inferred as described (125, 204, 313) and chemically synthesized as three 
subgenomic fragments.  These fragments were then cloned using unique restriction enzyme sites 
into a low copy number plasmid (modified pBR322 vector), which has been shown to prevent 
construct instability (313).  The integrity of the IMC was confirmed by nucleotide sequence 
analysis following large scale plasmid grow-up. 
Western blot. HIV-1 infectious clones were transfected into 293T cells in a T75 flask 
using FuGENE6 transfection reagent (Roche Diagnostics; Indianapolis, IN).  Briefly, 40 µg DNA 
was mixed with 120 µl of FuGENE6 in a total volume of 1.5 ml of serum-free DMEM, incubated 
for 30 minutes, and added to 293T cells (70% confluence) seeded one day earlier at 1.5 x107 
cells per flask. Forty-eight hours after transfection, the supernatants were harvested, and the 
viruses were pelleted through a 20% sucrose cushion at 27,000 rpm for 2 hours using an AH-629 
Swinging Bucket Aluminum Rotor. The pelleted virus particles and transfected 293T cells were 
lysed with 250 µl of lysis buffer (50mM Tris-HCl, 150mM NaCl, 20mM EDTA, 1% Triton-X100, 
0.1% SDS, pH 7.4). Western blot analysis was performed as previously described (180). The 
same amount of each virus (based on the p24 contents: 300 ng of the cell lysate and 10 ng of 
pelleted virus particles) was loaded on a NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen; 
Carlesbad, CA). After the samples were transferred to a nitrocellulose membrane, the membrane 
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was blocked in PBS containing 1% casein and 0.01% NaN3 for 1 hour.   The blot was reacted 
with purified HIVIG (Quality Biological, Gaithersburg, MD) and a mouse mAb 13D5 (1 µg/ml) to 
the HIV-1 Env protein.  Finally, the membrane was reacted with IRDye® 700DX  conjugated 
affinity purified anti-human IgG (Rockland Immunochemicals; Gilbertsville, PA) and Alexa-Fluor 
680-conjugated goat anti-mouse IgG (Invitrogen; Carlesbad, CA).  Fluorescence was detected on 
an Odyssey Infrared Imaging system (LiCor Biosciences; Lincoln, NE). 
Infection of CD4+ T cells and macrophages. Human CD4+ T cells were obtained from 
the Center for AIDS Research’s Immunology Core at the University of Pennsylvania.  All donors 
gave written informed consent.  Ccr5 wt and ccr5∆32 homozygous cells were stimulated with 
plate-bound anti-CD3 (eBiosciences, San Diego, CA) and anti-CD28 (BD Biosciences, San Jose, 
CA) for three days prior to infection.  Cells were maintained in RPMI with 10% FBS and IL-2 (20 
units/ml) throughout the experiment.  Cells were then infected with HIV-1 pseudovirions 
expressing GFP in the presence or absence of 50 µM AMD3100 as previously described (274).  
Prototype R5 (JRFL) and X4 (LAI) pseudovirions were used as controls. 
GFP pseudovirions were made by co-transfecting Env-pcDNA3.1 with pNL4-3deltaE-
EGFP in 293T cells.  Viruses were harvested 72 hours post-transfection and pelleted through a 
20% sucrose cushion.  Cells were then spinoculated with HIV-GFP pseudovirions for two hours at 
1200g.  Three days post-infection cells were analyzed by flow cytometry.  Experiments were 
repeated in two different ccr5∆32 homozygous donors, each time with a ccr5 wt control donor. 
Infections of matched donor CD4+ T cells and macrophages with the ZP6248 T/F and 
control IMCs were performed as previously described (313).  Briefly, virus stocks were prepared 
by transfecting a 10 cm dish 30% confluent with 293T cells with 6 µg of IMC DNA using FuGene 
(Roche, Indianapolis, IN).  CD4+ cells were positively selected and plated in polystyrene tissue 
culture dishes for two hours in HBSS with 10 mM Ca2+ and Mg2+ to remove adherent 
monocytes, then stimulated for 48 hours with 3 µg/ml Staphylococcal enterotoxin B. CD4+ T cells 
(5x105) were inoculated overnight with 50,000 IU of the control viruses (or 100ng p24 for 
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ZP6248.wt).  Monocyte-derived macrophages were derived by similarly plating peripheral blood 
mononuclear cells (PBMCs) in 24-well polystyrene plates to isolate monocytes, which were 
cultured with DMEM supplemented with 10% giant-cell conditioned media, 10% human AB 
serum, and 5 U/ml rhM-CSF (R&D systems, Minneapolis, MN).  After 6 days, macrophages were 
inoculated overnight with 100,000 IU of the control viruses (or 200 ng p24 for ZP6248.wt), then 
washed three times. Virus replication was monitored by measuring p24 antigen concentration in 
the supernatant. 
Flow cytometry analysis of HIV-1-infected CD4+ T cells. CD4+ T cells (1-2 x 106) per 
condition were stained with live/dead Aqua (Invitrogen, Carlsbad, CA), anti-CD3 Qdot655 
(Invitrogen, Carlsbad, CA), anti-CD4 Alexa 700 (BD Biosciences, San Jose, CA), anti-CD45RO 
PE Texas Red (Beckman Coulter, Miami, FL), anti-CCR7 IgM (BD Biosciences, San Jose, CA), 
and anti-IgM PE (Invitrogen, Carlsbad, CA).  Approximately 106 events were collected per 
condition.  The gating strategy was as follows: singlets (FSC-A by FSC-H), live cells (SSC-A by 
live/dead), lymphocytes (SSC-A by FSC-A), and T cells (SSC-A by CD3).  To assess viral 
tropism, infected cells, defined as GFP+, were back-gated on memory markers CCR7 and 
CD45RO.  Flow cytometry was performed on a BD LSR II and data was analyzed with FlowJo 
8.8.6 (TreeStar, Inc., Ashland, OR). 
CD4 and CCR5 dependent infection determined by Affinofile analysis. 293T cells 
expressing CD4 and CCR5 under independent inducible promoters, called affinofiles, were used 
to assess the CD4 and CCR5 utilization efficiency of ZP6248.wt and ZP6248.E312G as 
previously described (172).  Briefly, cells were plated in 96-well plates 48 hours prior to induction.  
An entire 96-well plate was used per virus representing 48 different CD4 and CCR5 conditions 
each in duplicate.  To induce cells two-fold serial dilutions of ponasterone A and minocycline 
(Invitrogen, Carlsbad, CA), starting at 2 uM and 5 ng/ml respectively, were added and cells were 
incubated for 18 hours prior to infection.  To infect cells, approximately 25 ng p24 of HIV-NL43-
luc+vpr+ pseudovirions were added to each well in the 96-well plate.  At 72 hours post-infection, 
luciferase activity was assessed using the Bright-Glo Luciferase Assay system and vector angles 
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and magnitude were quantified by VERSA (http://versa.biomath.ucla.edu/). Control viruses TA1 
(194) and maraviroc-resistant R3 (351) were included in all experiments  which were repeated in 
duplicate in each of at least three independent experiments. 
Detection of the minority variant by parallel allele-specific sequencing (PASS). The 
PASS assay was performed as previously described (49).  Briefly, 20 µl of 6% acrylamide gel 
mix, containing 1 µM acrydite-modified primer 1H1 5’Acr-
CAATAATTGTCTGGCCTGTACCGTCA-3’ (nt 7834-6859), cDNA template, 0.3% 
diallyltartramide, 5% rhinohide, 0.1% APS, 0.1% TEMED, 0.2% BSA and 17 µl cDNA were used 
to cast a gel on a bind-saline- (Amersham Biosciences, Piscataway, NJ) treated glass slide.  The 
in-gel PCR amplification was then performed in a PTC-200 Thermal Cycler with a mix of 1 µM 
primer 1C1 5’-GGATCAAAGCCTAAAGCCATGTGT-3’ (nt 6560-6583), 0.1% Tween-20, 0.2% 
BSA, 1x PCR buffer, 100uM dNTP mix, 3.3 units of Jumpstart Taq DNA polymerase (Sigma, St. 
Louis, MO), and H2O (up to 300 µl) under a sealed SecureSeal chamber (Grace Bio-Labs, Inc., 
Bend, OR).  PCR was carried out as follows: 94oC for 3 minutes; 65 cycles of 94oC for 30 
seconds, 56oC for 45 seconds, and 72oC for 1 minute; 72oC for 3 minutes. After PCR 
amplification, single-base extension (SBE) was performed with mutant and WT bases distinctively 
labeled with Cy3 and Cy5, respectively, using the sequencing primer 5’-
AACAACACAAGAAAAGGTGTACATATAGGACCAG-3’ (nt 7125-7164) that annealed just 
upstream of the mutation site (GAA->GGA).  The gel was scanned to obtain images with a 
GenePix 4000B Microarray Scanner (Molecular Devices, Sunnyvale, CA) and then analyzed with 
the Progenesis PG200 (Nonlinear Dynamics, Durham, NC) software.  Wild type and mutant 
viruses were determined by comparing their relative fluorescence intensities to normalized 
values. 
Coreceptor expression on PBMCs. A panel of antibodies was used to examine 
coreceptor surface expression on peripheral blood lymphocytes (PBLs), either PHA-stimulated or 
-unstimulated, using flow cytometry.   Four labeling steps were carried out: 1) 2.5 x 105 cells were 
incubated with 20 µg/ml of each of the following antibodies: anti-GPR15 (R&D Systems, 
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Minneapolis, MN), anti-FPRL-1 (R&D Systems, Minneapolis, MN), anti-APJ (R&D Systems, 
Minneapolis, MN), anti-CXCR4 (BD Pharmingen, San Diego, CA), or anti-CCR5 (BD Pharmingen, 
San Diego, CA); 2) cells were incubated with 10 µg/ml of FITC-labeled anti-mouse IgG (H+L) 
antibody (KPL, Gaithersburg, Maryland); 3) PE-Cy7-labled anti-CD4 antibody (BD Pharmingen, 
San Diego, CA) was incubated with the cells; and 4) the cells were finally incubated with Aqua 
Vital Dye (Invitrogen, Carlsbad, CA).  Each labeling step was carried out for 30 minutes at 4°C.  
Lymphocytes were washed with 3 ml of PBS containing 1% BSA between steps.  Lymphocytes 
fixed in PBS containing 1% paraformaldehyde were analyzed on a BD LSRII. 
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Results 
Viral kinetics during acute HIV-1 infection in subject ZP6248. Serial samples from an 
acutely infected male plasma source donor, ZP6248, infected with a subtype B HIV-1 were 
obtained before and after seroconversion, and virus load (VL), p24 and HIV-1 specific antibody 
levels were determined (Figure 4-1).  VLs were below detection limits (400 copies/ml) for the first 
four time points (between February 12 and 23, 1997) and then began to rise, reaching 87.7 
million copies/ml within the next 11 days (Figure 4-1). Subsequent samples were not available for 
analysis.  P24 antigen was detected at the last two time points, and HIV-1 specific antibodies 
(Abs) were detected by EIA, but not by Western blot analysis at the final time point.  According to 
the Fiebig staging system that is based on the sequential appearance of viral RNA, p24 antigen, 
and antibodies in plasma during acute infection (112), subject ZP6248 met the criteria for Fiebig 
stage I, Fiebig stage II and Fiebig stage III at the indicated time-points (Figure 4-1). The time 
course from Fiebig stage I to Fiebig stage III was similar to those observed in other acute HIV-1-
infections (201).  
Infection by a single T/F virus with an unusual V3 crown. Twenty full-length env gene 
sequences were obtained from the March 9 plasma sample using the SGA method.  Sequence 
analysis showed limited genetic diversity in the virus population, except for one env sequence 
which contained 13 G-to-A substitutions, characteristic of APOBEC-mediated hypermutation 
(Figure 4-2A).  A single T/F env gene sequence was inferred, which like most previously 
characterized T/F Envs was genotypically consistent with an R5 phenotype (176).  Examination of 
the deduced amino acid sequences of 20 SGA amplicons revealed a highly unusual V3 sequence 
that contained a GPEK rather than the subtype B consensus GPGR crown motif (Figure 4-2B). 
Only 13 of more than 90,000 HIV-1 V3 sequences in GenBank had this same GPEK V3 crown 
motif.  Six additional V3 sequences obtained from two earlier samples (February 26 and March 2) 
all had the identical GPEK crown sequences (Figure 4-2B). Thus, subject ZP6248 appears to 
have become productively infected with a single T/F virus that exhibited an unusual V3 crown.  
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Figure 4-1. Laboratory staging of acute HIV-1 infection in subject ZP6248. Plasma viral load 
(RNA copies/ml) was determined using the COBAS AMPLICOR HIV-1 MONITOR test (the 
threshold of the assay is 400 copies/ml). P24 antigen was detected using the Alliance HIV-1 p24 
ANTIGEN ELISA Kit (PerkinElmer, Boston, MA). HIV-1 specific antibodies were detected using 
the GS HIV-1/HIV-2 plus O EIA Kit and GS HIV-1 Western Blot Kit (Bio-Rad, Hercules, CA). The 
temporal appearance of HIV-1 specific markers according to the classification by Fiebig (112) is 
shown. 
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Figure 4-2. Identification of a rare GPEK V3 crown sequence in the ZP6248 envelope 
glycoprotein. (A) Single genome amplification (SGA) was used to infer the transmitted founder 
(T/F) env sequence. A Highlighter plot denotes the location of nucleotide substitutions in each 
SGA derived env sequence compared to the T/F virus.  The position of these substitutions is 
indicated on the bottom (p16 contains G-to-A changes characteristic of APOBEC-mediated 
hypermutation). Nucleotide substitutions and gaps are color-coded (all env sequences were 
derived from the March 9 time point). (B) Alignment of Env protein sequences in the V3 domain.  
Sequences from three time points (March 9, March 2 and February 26) are compared to the 
subtype B consensus sequence. The rare EK V3 crown motif found in all ZP6248 sequences is 
highlighted in red. Dashes in the alignment indicate sequence identity to the consensus; dots 
indicate deletions. 
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ZP6248 T/F Env fails to mediate virus entry into TZM-bl and GHOST cells. To 
examine its biological activity, the molecularly cloned ZP6248 T/F env gene was co-transfected 
with an env-minus HIV-1 backbone (SG3Δenv). Infectivity of the resulting pseudovirions was 
assessed in TZM-bl cells, which express CD4 as well as CCR5 and CXCR4. Unlike all previously 
analyzed T/F Envs (176, 191, 204), the ZP6248 T/F Env construct failed to mediate infection in 
both TZM-bl cells (Figure 4-3) as well as GHOST(3) cells expressing CD4 and either CCR5 or 
CXCR4 (data not shown). Thus, despite a very high virus load in the infected individual, the 
inferred T/F Env failed to mediate detectable virus infection in two commonly used reporter cell 
lines. 
Since it is known that V3 plays an important role in coreceptor binding (77, 78, 164, 300, 
301), we introduced a single nucleotide substitution (A->G) into the ZP6248.wt Env to generate a 
mutant, ZP6248.E312G with a consensus glycine (G) rather than the aspartic acid (E) at position 
312.  Pseudovirions generated with the ZP6248.E312G Env mutant were fully infectious in TZM-
bl cells expressing CCR5 and CXCR4 (Figure 4-3). This finding thus identified the rare GPEK 
crown motif as the reason for the inability of the ZP6248 Env to mediate infection of TZM-bl cells 
via either of the two major HIV coreceptors, and that a single mutation in the V3 crown sequence 
restored its infectivity to levels comparable to other primary R5 Envs. Given this, we used a 
parallel allele-specific sequencing method (49) to determine if viral genomes bearing subtype B 
consensus V3 loop sequences were present in this individual. We analyzed 1390 viral genomes 
from the March 9 plasma sample and found only two that contained the E312G sequence (Figure 
4-4).  Therefore, we conclude that the inferred T/F Env accurately reflects the dominant viral 
genotype in this individual, and that virions bearing the unusual GPEK motif were responsible for 
the primary infection. 
 
 
	  113 
 
Figure 4-3. Infectivity of pseudoviruses containing ZP6248 Env glycoproteins. Viral 
pseudotypes bearing the indicated Env glycoproteins were used to infect TZM-bl cells stably 
expressing CD4 and CCR5. Infectivity was determined by measuring relative light units (RLU) in 
cell lysates 48 hours after infection (y axis). ZP6248.wt represents the T/F Env, while 
ZP6248.E312G contained a single amino acid substitution in the V3 crown.  A subtype C Env 
(ZM53) was used as a positive control, while Env-negative pseudotypes (SG3∆env) were used as 
a negative control. 
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Figure 4-4. Detection of the rare ZP6248.E321G mutation during acute infection.  The 
presence of the ZP6248.E321G mutation (A to G) was examined by parallel allele-specific 
sequencing (PASS) analysis in plasma collected at the 9 March time point. In this assay, cDNA 
annealed to an acrydite-modified primer is immobilized in an acrylamide gel, after which in-gel 
PCR is performed, with the resulting products accumulating around the individual cDNA 
templates. Sequencing primers that anneal just upstream of the mutation site in V3 (GAA->GGA) 
can be used to distinguish wt and mutant bases at the same position by single-base extension 
using Cy3- and Cy5-labeled adenosine (wt) and guanosine (mutant), respectively. The gel was 
scanned to obtain images with a GenePix 4000B microarray scanner, and the spot number was 
counted using the Progenesis PG200 software. Green and red spots indicate wt and mutant 
bases, respectively, detected in individual viral genomes. Two mutants were identified by arrows. 
A partial image from one of the three experiments is shown. 
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ZP6248 T/F Env uses multiple alternative coreceptors for cell entry. The fact that the 
T/F Env clone failed to mediate efficient virus entry, coupled with our finding that a single amino 
acid substitution in the V3 loop rendered the ZP6248 Env functional in the TZM-bl assay, raised 
the possibility that the T/F virus from which it was derived had an altered in vivo coreceptor 
preference.  It was also possible that the ZP6248 T/F Env recognized CCR5 only when 
expressed in specific cell types, or that it did not pseudotype efficiently. To differentiate between 
these possibilities, we generated replication-competent YU2 chimeras containing either wild type 
(YU2-6248.wt) or mutant (YU2-6248.E312G) ZP6248 env genes and tested these constructs in a 
panel of GHOST(3) cells expressing CCR1, CCR2b, CCR3, CX3CR1, CCR4, CCR8, CXCR4, 
CCR5, CCR5/CXCR4, GPR15/BOB, and STRL33/Bonzo.  Consistent with the results obtained 
with pseudovirions, YU2-6248.wt did not infect CCR5+, CXCR4+, or CCR5/CXCR4+ cells, but 
replicated, albeit at very low titers, in GPR15+ cells (Figure 4-5).  Conversely, YU2-
ZP6248.E312G replicated well in CCR5+ and CCR5/CXCR4+ cells, but grew somewhat more 
poorly in GPR15+ cells.  
To further test the coreceptor preference of the ZP6248 envelope glycoprotein in a 
different cellular context, we infected NP-2 cells expressing CD4 along with either CCR5, CXCR4, 
or other G protein-coupled receptors with Env pseudovirions (335).  We found that ZP6248.wt 
mediated nearly equivalent levels of infection on cells expressing GPR15 or APJ, and weakly 
infected cells expressing FPRL-1 or CCR5 (Table 4-1). It was not unexpected that 
NP2/CD4/CCR5 cells were weakly infected but not TZM-bl cells by ZP6248 pseudovirus because 
the background of NP2 cells is 2-3 logs lower than TZM-bl cells (206).	  Once again, the virus with 
the E312G mutant exhibited greatly enhanced infectivity in cells expressing CD4 and CCR5. 
Finally, we compared the coreceptor usage of the ZP6248 Env to that of 24 subtype B T/F 
psudovirions using a panel of NP-2 cells expressing various G protein coupled receptors. In stark 
contrast to the other Envs in this panel which used CCR5 or CXCR4 most efficiently, ZP6248.wt 
predominantly used GPR15 and APJ, while the use of other coreceptors was negligible (Figure 4-
6). Additionally, we noted that ZP6248 used GPR15 much better than any other Envs in this 
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Figure 4-5. Coreceptor usage of ZP6248 Env. GHOST (3) cell lines expressing CD4 and the 
indicated coreceptors were infected with two replication-competent YU2/ZP6248 chimeras (YU2-
6248.wt and YU2-6248.E312G) as well as wild-type HIV-1 YU2.wt. Viruses normalized by p24 
content (100 ng) were used to infect cells, and virus replication was monitored by measuring p24 
antigen in culture supernatants 7 days after infection. The y axis shows the mean of p24 
concentrations from three independent experiments. Error bars represent one standard error of 
the mean. 
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a NP-2 cells expressing CD4 and the various potential coreceptors as noted were infected with 
NL4-3 luc+ pseudovirions. The ability to use the coreceptor was assessed by measuring relative 
light units (RLUs) in cell lysates and comparing the results to those for CXCR4- and CCR5-using 
control Envs. 
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panel (data not shown). The ZP6248.E312G mutant, on the other hand, showed a pattern of entry 
into NP-2 cells indistinguishable from many other T/F Envs (Figure 4-6). Thus, the ZP6248 T/F 
Env is clearly distinct from other T/F Envs we have analyzed, and failed to mediate efficient 
infection of cell lines expressing CD4 and CCR5 unless residue 312 in the V3 crown sequence 
was changed to consensus subtype B glycine. 
To determine if ZP6248.wt Env was expressed and incorporated into virions properly, we 
analyzed Env content in cell lysates and secreted virus particles from transfected 293T cells by 
Western blot. Compared to YU2, both YU2-6248.wt and YU2-6248.E312G contained lower 
amounts of Env though cleavage efficiency appeared normal (Figure 4-7). However, since the 
YU2-6248.E312G virus exhibited high levels of infection on cells expressing CD4 and CCR5, it is 
evident that the amount of Env on YU2-6248.wt was not limiting for virus infection. 
Full-length ZP6248 T/F virus infects GPR15+ but not CCR5+ GHOST cells. To 
determine whether the atypical function of the ZP6248 Env would be recapitulated in its regular 
genomic context, we inferred the sequence of the entire ZP6248 T/F provirus and generated a 
full-length IMC.  Overlapping genomic halves were amplified from plasma viral RNA from the 
March 9 sample using the SGA method as previously described (313).  As observed for the env 
gene, both half-genome sequences were homogenous and coalesced to an unambiguous 
consensus sequence representing the T/F virus (Figure 4-8A), which was then synthesized and 
cloned using three subgenomic fragments (Figure 4-8B).  When virus derived from the molecular 
clone was used to infect a GHOST cell panel, only GPR15 expressing cells became weakly 
infected, demonstrating that the full-length ZP6248 T/F virus exhibited the same coreceptor 
preferences as the viral pseudotypes and the YU2-ZP6248 chimera (data not shown).  
ZP6248 T/F virus infects CD4+ T cells from ccr5∆32 homozygous donors. We next 
sought to determine if ZP6248 Env could mediate efficient infection of primary human CD4+ T 
cells, and if so, to identify the receptors used for virus entry. Unfortunately, cells were not 
available from this donor, though we were able to determine that this individual had a wildtype 
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Figure 4-6. Comparison of the ZP6248 Env tropism to that of other subtype B T/F Envs. 
Entry of ZP6248.wt and ZP6248.E312G pseudotypes into 18 different NP-2 cell lines stably 
expressing CD4 and the indicated seven-transmembrane domain receptors was compared to that 
of 24 subtype B T/F Envs. The cell line that was infected most efficiently for each virus was 
normalized to one (dark red), while the entry into the other cell lines was expressed as a fraction 
of this value as indicated by the key within the figure. Dendrograms on the top and left of the heat 
map represent hierarchical clustering of the data that show coreceptors with similar patterns of 
usage by Envs (top) and Envs with similar coreceptor tropism (left). 
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Figure 4-7. Protein expression from transfected cells. 293T cells were transfected with the 
proviral clones indicated, and cell lysates and viral supernatants were harvested 48 h post-
transfection. Protein expression and processing was examined by Western blot analysis using an 
HIV-1-positive human serum sample and a mouse MAb (13D5) specific for the HIV-1 Env protein 
(31). The position of the Env precursor (gp160) and the extracellular domain (gp120) are 
indicated. Protein standards are indicated on the left. 
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Figure 4-8. Molecular cloning and biological characterization of the T/F virus of subject 
ZP6248. (A) 5’ (4377bp) and 3’ (4528bp) half-genomes overlapping by 66bp were amplified by 
SGA from plasma viral RNA (March 9 time point) and used to infer the sequence of the single T/F 
virus infecting subject ZP6248 as previously described (125, 204, 313). The Highlighter plots 
denote the location of nucleotide substitutions compared to the inferred T/F sequence, with their 
position indicated on the bottom. Nucleotide substitutions and gaps are color coded. (B) The full-
length ZP6248 genome was synthesized in three overlapping fragments and cloned into a 
modified pBR322 vector as described (347). (C) Viruses harvested from transfected 293T cells 
were examined for their ability to replicate in activated primary human CD4+ lymphocytes (left) 
and monocyte-derived macrophages (right) from the same donor. The x-axis indicates days post 
infection; the y-axis denotes p24 antigen concentration (ng/ml) in the culture supernatant. 
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ccr5 genotype (not shown). We obtained both ccr5 wt and ccr5∆32 homozygous human CD4+ T 
cells from several donors and performed infection assays using ZP6248.wt and ZP6248.E312G 
Env pseudovirions expressing a GFP reporter. One of two representative experiments using cells 
from different ccr5 wt and ccr5∆32 homozygous donors is shown in Figure 4-9A.  In the presence 
of the CXCR4 inhibitor AMD3100, ZP6248.wt pseudoviruses infected 0.17% of ccr5 wt cells and 
0.047% of ccr5∆32 homozygous cells compared to 1.53% and 0.009% for ZP6248.E312G 
pseudovirions, respectively. Similar results were obtained in the absence of AMD3100, and using 
cells from a second donor. In addition, the replication competent ZP6248 T/F virus replicated with 
severely delayed kinetics and to a much lower titer in CD4+ T cells, and failed to replicate in 
macrophages (Figure 4-8C).  Interestingly, prolonged culture of the ZP6248 T/F virus in CD4+ T 
cells resulted in the selection of a variant with a GPGK V3 crown motif that conferred efficient 
CCR5 use (data not shown).  Finally, the ZP6248 T/F virus replicated even more poorly in 
ccr5∆32 homozygous CD4+ T cells, and only at high inocula (data not shown).  Thus, Env 
pseudovirions and IMC-derived virus bearing an unusual V3 loop sequence could utilize one or 
more alternative coreceptors to mediate inefficient entry into ccr5∆32 homozygous cells although 
it also used CCR5 poorly.  
Tropism analysis of the ZP6248 T/F virus. The failure of the ZP6248 T/F Env to 
mediate efficient infection of primary CD4+ T cells raised the possibility that it was uniquely 
adapted to its host which in turn could have exhibited unusual features, such as unusual CCR5 
expression, post-translational processing, or conformation. While cells were not available from 
this donor, we reasoned that a more detailed analysis of viral tropism might shed light on this 
issue. Therefore, we employed a highly sensitive CD4+ T cell subset tropism assay to determine 
if virions bearing the ZP6248.wt or ZP6248.E312G Envs exhibited any unusual properties.  CD4+ 
T cells were obtained from several donors and infected with GFP-expressing pseudovirions. Cells 
from individual donors were stained with CCR7 and CD45RO to define naïve, central memory, 
effector memory, and effector memory RA cell subsets (TEMRA).  HIV-1-infected cells were then 
back-gated to evaluate tropism among different CD4+ T cell subsets.  5.2% of ZP6248.wt 
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pseudovirus-infected cells were naïve, 35.6% were central memory, 58.6% were effector 
memory, and 0.6% were TEMRA compared to 0.3%, 19.3%, 79.4%, and 1.0% for ZP6248.E312G, 
respectively (Figure 4-9B). This distribution of infected cells amongst the various CD4+ T cell 
subsets is similar to what we have observed for other subtype B viruses, indicating that the 
ZP6248.wt Env and ZP6248.E312G Envs did not exhibit unusual CD4+ T cell subset preference. 
However, once again, ZP6248.wt was poorly infectious compared to ZP6248.E312G. 
 We also took a second approach to examine the tropism of ZP6248 Env pseudovirions, 
performing infection assays on affinofile cells, which are a human 293T cell line that expresses 
CD4 and CCR5 under independent inducible promoters making it possible to modulate receptor 
levels across a broad physiologic range (172).  The affinofile cells were infected under various 
CD4 and CCR5 expression conditions with pseudoviruses bearing the ZP6248.wt or 
ZP6248.E312G Envs. We also performed infection assays with two control viruses: TA1 requires 
high levels of CCR5 for efficient virus infection, while MVC R3 can infect cells expressing very low 
levels of CCR5 (44). We found that ZP6248.wt Env required relatively high levels of both CCR5 
and CD4 for infectivity, while ZP6248.E312G Env could utilize very low levels of CCR5 at 
moderate CD4 expression levels (Figure 4-10A). In the affinofile cell system, the sensitivity to 
changes in CD4 and CCR5 use can be quantified by determining a vector angle (172).  A low 
vector angle is consistent with very efficient CCR5 use, while a high vector angle is associated 
with inefficient CCR5 use (194, 351).  The ZP6248.wt Env had a vector angle of 45°, consistent 
with its being equally dependent upon CCR5 and CD4 expression levels, while the 
ZP6248.E312G Env had a very low vector angle, consistent with very efficient CCR5 use at 
intermediate to high expression levels of CD4 (Figure 4-10B).  Of note, the infection level of 
ZP6248.wt pseudovirions was nearly one order of magnitude lower than that of ZP6248.E312G 
pseudovirions and TA1, and nearly two orders of magnitude lower than that of MVC R3 (Figure 4-
10B).  Taken together, these findings are consistent with previous cell line and primary cell data, 
which show that ZP6248.wt Env can utilize CCR5 for entry, but does so very inefficiently and only 
when CCR5 and CD4 expression levels are high. 
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Figure 4-9. Infection of human CD4+ T cells. Env pseudovirions expressing a GFP reporter 
were used to infect primary ccr5 Δ32/Δ32 or ccr5 wt CD4+ T cells in the presence of the CXCR4 
antagonist AMD3100. Viral infection was assessed by flow cytometry after gating on live, CD3+ 
cell singlets. (A) ccr5 Δ32/Δ32 or ccr5 wt CD4+ T cells were infected with ZP6248.wt and 
ZP6248.E312G in the presence of AMD3100. Mock-infected cells were used as a negative 
control while the X4 HIV-1 strain LAI was used as a positive control in the absence of AMD3100. 
(B) Infected cells were back-gated onto memory markers CCR7 and CD45R0 (CCR7+CD45RO-, 
naïve; CCR7+CD45RO+, central memory; CCR7-CD45RO+ effector memory; CCR7-CD45RO-, 
effector memory RA) to evaluate memory subset tropism of ZP6248.wt and ZP6248.E312G. The 
data is shown from one of two independent experiments from different donors.  
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Figure 4-10. ZP6248.wt uses CCR5 inefficiently. (A) ZP6248.wt and ZP6248.E312G 
pseudovirions were used to infect Affinofile cells which express CD4 and CCR5 with independent  
induction systems. ZP6248.wt requires high CCR5 expression for infection compared to 
ZP6248.E312G which can utilize very low levels of CCR5. Both Envs require moderate CD4 
expression for infection. (B) The sensitivity to changes in CD4 and CCR5 levels was quantified by 
Viral Entry Receptor Sensitivity Analysis (VERSA) which yields a single vector angle. Lower 
vector angles correspond to Envs that utilize CCR5 very efficiently as seen with the maraviroc-
resistant Env MVC R3 (1°), while higher vector angles are associated with inefficient CCR5 use 
as seen with the V3-loop truncated virus TA1 (71°). ZP6248.wt has a vector angle of 44° 
compared to 0° for ZP6248.E312G.  In addition, the vector magnitude can be quantified to assess 
overall infectivity.  ZP6248.wt is 5-fold less infectious than ZP6248.E312G and 40-fold less 
infectious than MVC R3, consistent with other cell lines and primary cell data. 
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Expression of coreceptors on the surface of CD4+ T cells. Since ZP6248 was able to 
infect CD4+ T cells without using CCR5 or CXCR4 coreceptors, albeit inefficiently, we asked 
whether alternative coreceptors, such as GPR15, APJ, and FPRL-1, were expressed on the 
surface of these target cells. We thus performed flow cytometry analysis of PBMCs from five 
normal healthy donors using antibodies specific for GPR15, APJ, and FPRL-1.  GPR15 was 
detected on 7.4% of CD4+ T cells, while APJ was present on 53.4% of CD4+ T cells (Figure 4-
11). FPRL-1 was also detected, but at a much lower frequency (1.1% of CD4+ T cells).  As 
expected, CXCR4 was found on nearly all CD4+ T cells, while CCR5 was expressed on 12.5% 
CD4+ T cells. Similar results were obtained for GPR15, APJ, and FPRL-1 on both unstimulated 
and PHA-treated PBMCs.  These results demonstrate that GPR15, APJ and FPRL-1 are all 
expressed on the surface of CD4+ T cells and could thus serve as alternative coreceptor for 
ZP6248 in vivo.  
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Discussion 
HIV-1 infection is primarily established by viruses that use CCR5 for entry (131, 176, 234, 
255, 313).  In this study, we identified and characterized a T/F virus, ZP6248, that replicated to a 
VL of 87.7 million copies/ml during acute infection in vivo, yet its Env glycoprotein failed to 
efficiently facilitate virus entry into CCR5 or CXCR4-bearing target cells in vitro. This finding was 
clearly at odds with previous results showing that T/F viruses are fully functional and invariably 
use CCR5 alone or, less commonly, in combination with CXCR4 to infect cells (176, 191). We 
sought to determine if the poor functionality of this T/F Env was due to methodological issues or 
whether this virus established infection in a naïve host by utilizing unusual viral and/or host 
factors that could provide insight into the mechanisms of HIV-1 transmission. 
A trivial explanation that could account for the poor functionality of the ZP6248 T/F Env is 
that its sequence does not reflect that of the virus that established infection in this host. Because 
the SGA and bioinformatics approaches we have taken to identify multiple T/F Envs have 
invariably yielded fully functional Env proteins that utilize CCR5 (and sometimes CXCR4 as well) 
to infect cells, this explanation is highly unlikely. As is common in recently infected individuals, 
extensive sequencing of env shortly after this individual became infected showed very limited 
genetic diversity and so our inference of the T/F env sequence is unambiguous. In addition, the 
ZP6248 T/F Env exhibited a highly unusual GPEK V3 crown sequence. All envs sequenced at 
three early time-points after infection contained this motif, as did all but two of 1390 genomes 
analyzed by PASS. lt is important to note that this frequency (0.15%) is well above the level of 
background in this assay (211); therefore a variant which was capable of using CCR5 efficiently 
in vitro was present, but was overshadowed in vivo by the variant with poorer in vitro CCR5 use. 
Overall, our data demonstrates that this individual was infected by a virus with a very unusual 
phenotype. 
Another technical issue that could account for poor viral infectivity would be if the ZP6248 
T/F Env is packaged into virions poorly. We think this possibility is unlikely, as we analyzed the 
ZP6248 T/F Env in four viral backgrounds: viral pseudotypes based on HIV-1 HxB2 and SG3 
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backbones, a replication competent HIV-1 YU2 chimera, and a replication competent, full-length 
molecular clone derived from subject ZP6248. In addition, immunoblots revealed levels of 
correctly processed ZP6248 Env in virus particles that were comparable to levels of the fully 
functional ZP6248.E312G mutant.  Therefore, we feel that the low infection levels cannot be 
explained by poor Env expression, processing, or virion incorporation. In addition, it is important 
to stress that the single E312G mutation in the V3 loop rendered the Env as functional in virus 
infection assays as most other primary R5 Envs, and it is difficult to envision how such a change 
could influence Env incorporation into virus particles. 
Despite adequate levels of expression and processing, the ZP6248 Env exhibited poor 
functionality on two different, commonly used cell lines as well as on primary human CD4+ T cells 
from 14 different donors. Detailed tropism studies revealed no unusual properties with regards to 
T cell subset infection, though relatively high levels of CCR5 and CD4 were needed to support 
infection. In addition, the sequence of the ZP6248 Env has no unusual genetic features save for 
the highly atypical V3 loop crown. Based on its sequence, this Env is predicted to use CCR5. 
Might this virus have used CCR5 to mediate efficient virus infection in vivo, even though it failed 
to do so in vitro? If so, we would predict that there was something unusual about the manner in 
which CCR5 was presented on the surface of cells in this individual - otherwise we should have 
observed robust infection in our in vitro assays. Unfortunately, we cannot rule-out this possibility 
as cells from this individual are not available for study, although we were able to obtain enough 
cellular debris from plasma to determine that both CCR5 alleles had wild-type sequences in the 
ORF. In addition, the unusual V3 loop sequence in this individual provides some clues: it is 
thought that the tip of the V3 loop interacts with the second extracellular loop of the viral 
coreceptors (164, 380), and this region of CCR5 (and CXCR4) can exhibit conformational 
heterogeneity (30, 199). In fact, CCR5 inhibitors such as maraviroc alter the conformation of the 
extracellular loops of CCR5 thus blocking interactions with Env (97, 185, 328). One mechanism 
by which HIV-1 can become resistant to these allosteric inhibitors is through mutations in the V3 
loop that enable it to interact with the altered receptor conformation (14, 32, 259, 274, 351, 355). 
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In addition, several studies have shown via the use of panels of conformation-specific monoclonal 
antibodies that CCR5 exhibits conformational heterogeniety on the surface of human CD4+ T 
cells, though the mechanisms that account for this as well as the implications of altered 
conformation on viral infectivity are not known (30, 199). Thus, it is possible that CCR5 in this 
individual exhibited an unusual conformation that was not recapitulated by the cells used in our in 
vitro assays, and that the ZP6248 T/F Env with its unusual V3 sequence was well-adapted to use 
this conformation. 
Another possibility is that virus in this patient used a coreceptor other than CCR5 to 
initiate infection. If so, this would be unprecedented for HIV-1, but not for SIV; SIVrcm from red-
capped mangabeys often uses CCR2 as a coreceptor as genetic absence of CCR5 is common in 
this species (54). In addition, SIVsmm from sooty mangabeys can also use a coreceptor other 
than CCR5 to mediate infection in vivo: genetic absence of CCR5 is relatively common in sooty 
mangabeys, but CCR5-negative animals are still infected with SIVsmm, though their virus loads 
are on average one-half log less than what is typically seen in CCR5+ animals (298). The 
coreceptor used by SIVsmm to replicate in sooty mangabeys has not yet been identified, though 
in vitro and genetic studies appear to rule-out the use of CXCR4. Therefore, in at least two non-
human primate species, robust in vivo replication by SIV can be achieved by utilization of 
coreceptors other than CCR5 or CXCR4.  
 Several HIV-1 strains have been shown to employ coreceptors other than CCR5 or 
CXCR4 to infect cells (27, 28, 65, 128, 280, 381), with CCR3, GPR15, APJ, and FPRL-1 being 
among those most frequently used (66, 167, 251, 280, 335).  However, these studies have 
typically employed cell lines that likely over-express these coreceptors, so it is difficult to assess 
whether utilization of these coreceptors can lead to infection of primary human cell types. In fact, 
with few exceptions, HIV-1 strains fail to infect human T cells from individuals who lack CCR5 in 
the presence of the CXCR4 inhibitor AMD3100, arguing that in this context alternative 
coreceptors typically cannot mediate infection (66, 330). However, ZP6248 was able to use three 
alternative coreceptors (GPR15, APJ and FPRL-1) to infect cell lines, using the former two much 
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more efficiently than CCR5. This pattern is strikingly different from that of all other subtype B T/F 
Envs recently analyzed in NP2 cells expressing various putative alternative coreceptors.  
Therefore it is reasonable to ask if these receptors are expressed in vivo on cell types relevant to 
transmission. Previous studies showed GPR15 mRNA in human colon tissue and CD4+ T 
lymphocytes as well as rhesus macaque peripheral blood mononuclear cells (67, 86, 109), FPRL-
1 in a large variety of cells and organs, including T and B lymphocytes (235), and APJ in the 
human brain (100) and also in activated PBMCs (58).  Using currently available antibodies, we 
have found that GPR15 and APJ are expressed on the surface of 7.7% and 56% of CD4+ T cells, 
respectively, while FPRL-1 can be found on only about 1% of CD4+ T cells.  The presence of 
these coreceptors on the surface of CD4+ T cells suggests that they may be used by ZP6248 in 
vivo. Since GPR15 is widely present in gut tissue, was the coreceptor used most efficiently by 
ZP6248, and is known to be used by some SIV and HIV-2 strains (86, 100, 357), it is the most 
likely candidate. 
Almost all T/F HIV-1 Envs use CCR5 efficiently in vitro and presumably in vivo as well, 
given the relative resistance of individuals who lack CCR5 to virus infection. However, this study 
reinforces the idea that the Env glycoprotein is incredibly plastic, and shows that our in vitro 
assays at times fail to recapitulate important virological properties that operate in vivo. Whether 
by exploiting an atypical CCR5 conformation or by using coreceptors not previously known to 
mediate transmission, the virus that infected subject ZP6248 did so without efficient use of CCR5 
in its standard form in multiple assays. In light of this, while attempting to block CCR5 use as an 
option for target cell entry (e.g., by maraviroc-containing microbicides) will likely be an effective 
prevention strategy, our report cautions that atypical presentations of CCR5 or alternative 
coreceptors may sometimes be used by HIV to result in establishment of primary infection.  
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Abstract 
Defining the virus-host interactions responsible for HIV-1 transmission, including the 
phenotypic requirements of viruses capable of establishing de novo infections, could be important 
for AIDS vaccine development. Previous analyses have failed to identify viral properties other 
than CCR5 and T cell tropism that are preferentially associated with transmission. However, most 
of these studies were limited to using viral pseudotypes to examine envelope (Env) function. 
Here, we generated full-length infectious molecular clones (IMCs) of mucosally transmitted 
founder (TF; n=27) and chronic control (CC; n=14) viruses of subtypes B (n=18) and C (n=23), 
and compared their phenotypic properties in assays specifically designed to probe the earliest 
stages of HIV-1 infection.  We found that TF virions were 1.7-fold more infectious (p=0.049) and 
contained 1.9-fold more Env per particle (p=0.048) compared with CC viruses.  TF viruses were 
also captured by monocyte-derived dendritic cells (moDCs) 1.7-fold more efficiently (p=0.035) 
and were more readily transferred to CD4+ T cells (p=0.025) than CC viruses. In primary CD4+ T 
cells, TF and CC viruses replicated with comparable kinetics; however, when propagated in the 
presence of interferon alpha (IFN-α), TF viruses replicated to significantly higher titers than did 
CC viruses (p=0.012). This difference was more pronounced for subtype B (62-fold) than subtype 
C (1.7-fold) viruses, possibly reflecting demographic differences of the respective patient cohorts. 
Together these data indicate that TF viruses are enriched for higher Env content, enhanced cell-
free infectivity, improved dendritic cell interaction and relative IFN-α resistance. These viral 
properties, which could act in concert, should be considered in the development and testing of 
future prevention strategies.  
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Introduction 
Understanding the host and viral factors that influence the ability of human 
immunodeficiency virus type 1 (HIV-1) to cross mucosal barriers may be critical for the 
development of an effective AIDS vaccine (331).  HIV-1 virions or infected cells are believed to 
cross the epithelium shortly after sexual exposure, although the mechanisms by which this occurs 
remain largely unknown.  Within the mucosa, viruses are believed to interact with dendritic cells 
(DCs), such as Langerhans cells, but do not productively infect these cells (159).  In the simian 
model of HIV-1, the first cells to become productively infected are resting intraepithelial CD4+ T 
cells, which represent the most abundant target cell type in the lamina propria (395).	  
Simultaneous with initial infection events, local innate immune responses are elicited, with 
plasmacytoid DCs accumulating rapidly at sites of virus entry.  These cells secrete cytokines and 
chemokines, such as MIP1-β and type I interferons, and orchestrate an early local innate immune 
response (209). After local infection in mucosal and submucosal tissues is established, HIV-1 
spreads to regional and distant lymphoid tissues including gut-associated lymphoid tissue (GALT) 
where virus expands exponentially, triggering a systemic cytokine storm preceding peak viremia 
(319, 343).  
Many host factors can influence whether virus exposure leads to productive infection, 
including the physical barrier of the mucosa and its associated mucous secretions (136, 248), 
target cell availability (212, 266, 398), immune activation (224), genital inflammation (195), and 
altered mucosal microbiota (12).  While HIV-1 is characterized by high genotypic and phenotypic 
diversity, the extent to which this variation influences the transmission process remains unclear.  
Transmission across intact mucosal barriers is inherently inefficient and invariably associated with 
a viral population bottleneck (159, 365). Indeed, in 60-80% of mucosal infections, a single 
transmitted founder (TF) virus is responsible for productive clinical infection (176).  This finding 
has raised the question whether the transmission process represents a stochastic event, in which 
every replication competent virus has a roughly equal chance of establishing a new infection, or 
whether the bottleneck selects for viruses that exhibit particular biological properties that 
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predispose them to cross the mucosa and replicate efficiently.  In support of the latter, transmitted 
viruses have generally been found to exhibit CCR5 tropism and share certain genetic features, 
including shorter variable loops, fewer potential N-linked glycosylation sites and amino acid 
signatures in their envelope glycoproteins (Envs) which may affect Env surface expression and/or 
other viral properties (59, 79, 88, 126, 203, 213, 309).  However, to date no consistent phenotypic 
correlate of these latter signatures with transmission biology has been identified.   
Initial phenotypic studies of viruses obtained in acute or early infection were generally 
limited to analyses of Env functions, which were almost exclusively conducted in the context of 
Env pseudoviruses. These analyses led to a number of hypotheses as to how transmitted viruses 
might differ from their chronic counterparts.  Such differences included more efficient engagement 
of receptor or coreceptor by transmitted Envs (5, 167), greater sensitivity to neutralizing 
antibodies resulting from a more open or accessible Env conformation (88, 390), or preferential 
interaction of Env with the integrin pair α4β7 (250).  A limitation of these studies, however, was 
that they employed viruses and/or Envs obtained weeks or months after the transmission event 
when substantial virus evolution and selection could have occurred.  Using single genome 
amplification (SGA) (312) and a model of random virus evolution (176), we generated Env 
sequences and molecular clones corresponding to actual TF viral genomes and showed for the 
first time that, at the moment of virus transmission and infection of the first cell, TF viruses  use 
CCR5 as the coreceptor for entry (171, 176, 270, 372).   We failed, however, to find corroborate 
previous evidence that TF Envs used CD4 and CCR5 more efficiently (270, 372), interacted 
specifically with α4β7 (270), or exhibited a preferential tropism for particular CD4+ T cell subsets 
(270, 372).  We also failed to identify an enhanced overall sensitivity TF Envs to neutralization, 
although subtype B TF Envs were slightly more sensitive to CD4 binding site neutralizing 
antibodies than subtype C TF Envs (372).  Most recently, we discovered that TF Envs are more 
completely inhibited by small molecule CCR5 antagonists than chronic control (CC) Envs 
consistent with altered CCR5 interactions, although the biological relevance of this finding 
remains to be determined (268).  Thus, except for preferential CCR5 coreceptor usage and T-cell 
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tropism, no other consistent phenotypic difference between TF and CC viruses has been 
identified. 
Env pseudotypes are generated by co-transfection of an env expression cassette with an 
env-minus proviral backbone. Since this backbone represents a standard (non-TF) HIV-1 
genome, the contribution of gene products other than Env to the TF phenotype cannot be 
assessed. Moreover, overexpression of Env, which is inherent in the co-transfection assay, 
precludes a meaningful assessment of virus-host cell interactions and particle composition. 
Reasoning that these shortcomings may have obscured phenotypic differences that could 
enhance mucosal transmission, we developed methods to clone full-length TF genomes and 
showed that these produced replication competent viruses that grew efficiently in CD4+ T cells 
but not macrophages (204, 257, 313). However, a systematic evaluation of the TF phenotype 
also required a sufficient number of chronic control (CC) viruses, also derived as full-length IMCs, 
for comparison. Here, we describe the generation and biological characterization of a 
comprehensive set of TF (n=27) and CC (n=14) IMCs, representing two major HIV-1 group M 
subtypes.  Using these novel reagents, we compared biological properties that would be 
expected to influence viral fitness during the earliest stages of the transmission process.  Our 
results reveal that TF viruses share common traits that likely enhance their fitness in crossing 
mucosal surfaces and in promoting the establishment of a productive local infection. 
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Results 
 
Infectious molecular clones of transmitted founder and chronic control viruses.  Although a 
limited number of TF and CC IMCs has previously been reported (204, 257, 270, 313), available 
clones were too few to conduct meaningful phenotypic comparisons. This has especially been 
true for viruses from chronically infected individuals, for which only four IMCs (all from subtype C 
infections) have been constructed (270).  To create a more balanced panel, both with respect to 
the number of TF and CC IMCs as well as their subtype representation, we cloned additional viral 
genomes from individuals enrolled in acute and chronic HIV-1 infection cohorts. Using previously 
reported methods (204, 257, 313), we inferred 12 additional TF genomes (Fig. 5-1) representing 
mucosally transmitted viruses from single (n=8) or multivariant (n=4) transmissions. Together with 
existing constructs, these comprised a panel of 27 TF IMCs, with equal representation of subtype 
B (n=13) and subtype C (n=14) viruses (Table 5-1).   
Chronically HIV-1 infected individuals harbor complex quasispecies of genetically diverse 
HIV-1 variants. Since it is impossible to predict based on sequence inspection alone which 
variants are biologically active and which are functionally impaired, we amplified between 20 and 
40 env genes or 3’ half genomes from chronic infection plasmas and searched for clusters of 
nearly identical sequences as indicators of recent clonal expansions (Fig. 5-2). We reasoned that 
the inferred common ancestors of these clusters must encode persistently replicating viruses and 
thus represented relevant controls for biological comparisons with TF viruses. Consistent with this 
interpretation, we found that all chronic IMCs generated from expansion rakes produced viruses 
that grew to high titers in CD4+ T cells. However, not all chronic infection samples were suitable 
for IMC construction. Analyzing over 60 plasmas, we identified only 14, including four reported 
previously (270), that exhibited clonal expansion rakes in both 3' and 5' halves of their viral 
genomes (Fig. 5-2). These were used to construct CC IMCs representing both subtype B (n=5) 
and subtype C (n=9) infections (Table 5-1).  
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Figure 5-1. Inference of TF genome sequences.  (A-V) Highlighter plots of SGA derived 5’ (left 
panel) and 3’ (right panel) half genome sequences are shown for two subjects acutely infected 
with subtype B (A-D) and nine subjects acutely infected with subtype C (E-V) viruses (Highlighter 
v2.1.1; hiv.lanl.gov); tick marks indicate differences compared to the top sequence (red, T; green, 
A; blue, C; orange, G; grey, gap), which is identical to the inferred TF sequence (A, B - CH607; C, 
D - CH470; E, F - CH200v1; G, H - CH228v1; I, J - CH131; K, L - CH164; M, N -  CH185; O, P - 
CH198; Q, R - CH042; S, T - CH067; U, V - CH162). Two TF viruses were inferred from subject 
703010200, with the second variant shown in bold below the sequences used to infer the first TF 
variant. 
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Table 5-1. Infectious molecular clones of mucosally transmitted founder and chronic 
control viruses. 
Subject IMC  Subtype Type Sex Risk factorb 
CD4 
count VL
c Sample 
date Stage
 Country of 
origin 
# 
TFs CoR
f Reference 
AD17 AD17 B TF M MSM n/a 47,600,000 6/14/99 IId USA 1 R5 204 
700010040 CH040 B TF M MSM n/a 2,197,248 7/25/06 IId USA 1 R5 258 
700010106 CH106 B TF M MSMW n/a 84,545,454 10/19/06 IId USA 1 R5 258 
700010470 CH470 B TF M MSM n/a 84,193 1/25/08 IVd USA 1 R5 this study 
700010607 CH607 B TF M MSM n/a 8,009 7/8/08 IVd USA 2 R5 this study 
REJO4541 REJO B TF M HSX n/a 722,349 9/28/01 Vd USA 1 R5 258 
RHPA4256 RHPA B TF F HSX n/a 1,458,354 12/5/00 Vd USA 1 R5 258 
SUMA0874 SUMA B TF M MSM n/a 939,260 5/13/91 IId USA 1 R5 258 
THRO4156 THRO B TF M MSM n/a 5,413,140 8/1/00 Vd USA 1 R5 258 
700010058 CH058 B TF M MSM n/a 3,565,728 9/8/06 IId USA 1 R5 258 
700010077 CH077 B TF M MSM n/a 394,649 8/31/06 II/IIId USA 1 R5/X4 258 
TRJO4551 TRJO B TF M MSM n/a 8,121,951 10/10/01 IId USA 1 R5 258 
WITO4160 WITO B TF M HSX n/a 325,064 8/4/00 IId USA 1 R5 258 
ZM247F ZM247Fv1 C TF F HSX n/a 10,823,500 10/28/03 IId Zambia 2 R5 312 
ZM247F ZM247Fv2 C TF F HSX n/a 10,823,500 10/28/03 IId Zambia 2 R5 312 
704010042 CH042 C TF M HSX n/a 181,000 1/29/07 IVd S. Africa 1 R5 this study 
705010067 CH067 C TF F HSX n/a 639,000 1/10/07 I/IId S. Africa 1 R5 this study 
703010131 CH131 C TF M MSMW n/a 411,873 3/8/07 I/IId Malawi 1 R5 this study 
705010162 CH162 C TF M HSX n/a 13,100,000 6/22/07 IIId S. Africa 1 R5 this study 
706010164 CH164 C TF M MSMW n/a 23,600 8/16/07 IVd S. Africa 1 R5 this study 
703010228 CH228v1 C TF M HSX n/a 47,549 6/1/07 IIId Malawi 2 R5 this study 
705010185 CH185 C TF F HSX n/a 14,800 7/13/07 I/IId S. Africa 1 R5 this study 
705010198 CH198 C TF M HSX n/a 14,950,000 7/13/07 I/IId S. Africa 1 R5 this study 
703010200 CH200v1 C TF M HSX n/a 165,501 5/11/07 I/IId Malawi 3 R5 this study 
703010200 CH200v2 C TF M HSX n/a 165,501 5/12/07 I/IId Malawi 3 R5 this study 
ZM246F ZM246F C TF F HSX n/a 10,013,800 1/14/03 IId Zambia 1 R5 312 
ZM249M ZM249M C TF M HSX n/a >2,000,000 8/5/03 IVd Zambia 1 R5 312 
STCO5453 STCOr1 B CC M MSM 796 67,964 2/15/05 2e USA n/a R5/X4 this study 
STCO5453 STCOr2 B CC M MSM 796 67,964 2/15/05 2e USA n/a R5/X4 this study 
WARO5662 WARO B CC F HSX 598 16,758 10/17/07 2.5e USA n/a R5 this study 
MCST4474 MCST B CC M MSM 634 29,500 7/2/07 9.5e USA n/a R5 this study 
RHGA1581 RHGA B CC M MSM 571 50,000 2/20/03 9.6e USA n/a R5 this study 
703010269 CH269 C CC F HSX 195 30,434 4/9/08 n/a Malawi n/a R5 this study 
702010293 CH293 C CC F HSX 339g 27,169 4/1/08 n/a Malawi n/a R5 this study 
702010432 CH432 C CC M HSX 261g 40,570 5/7/08 n/a Malawi n/a R5 270 
702010440 CH440 C CC F HSX 125g 25,583 5/12/08 n/a Malawi n/a R5 this study 
705010534 CH534 C CC F HSX 303g 63,300 8/26/08 n/a S. Africa n/a R5 270 
702010141 CH141 C CC F HSX 326h 151,282 11/13/07 n/a Malawi n/a R5 this study 
703010167 CH167 C CC F HSX 358g 73,505 5/24/07 n/a Malawi n/a R5 this study 
703010256 CH256y2 C CC F HSX 531 28,066 6/30/09 2e Malawi n/a R5 270 
707010457 CH457 C CC F HSX 450g 234,671 6/10/08 n/a Tanzania n/a R5 270 
a TF, transmitted founder; CC, chronic control. 
bMSM, men who have sex with men; HSX, heterosexual exposure; MSMW, men who have sex with men and women. 
c VL= viral load (RNA copies per ml of plasma). 
ddefined in (112).  
eduration of infection is given in years; n/a, data not available. 
fcoreceptor tropism as determined by AMD3100 and TAK779 inhibition: R5, CCR5 tropic; R5/X5 = CCR5/CXCR4 dual tropic. 
gaverage CD4 count from samples taken before and after IMC generation. 
ha single CD4 count is available for a sample taken 12 weeks prior to IMC generation. 
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Figure 5-2. Inference of CC genome sequences.  The phylogenetic relationships of SGA-
derived 5’ and 3’ half genome sequences from chronically infected subjects are shown.  Trees 
composed of 5’ (A, C, E, G, I, K, M, O, Q) and 3’ (B, D, F, H, J, L, N, P, R) half genome 
sequences were constructed using maximum likelihood methods.  Sequences highlighted in blue 
(subtype C) and red (subtype B) represent clonal viral expansions that were used to generate half 
genome consensus sequences for each subject (A, B - 702010141; C, D - 703010167; E, F - 
703010269; H, G 702010293; I, J - 702010440; K, L - MSCT4474; M, N - RHGA1581; O, P - 
STCO5453; Q, R - WARO5662). These consensus sequences, which were identical in a 1 kb 
region of overlap, were chemically synthesized and combined to generate full-length IMCs.  
Asterisks indicate bootstrap support of greater than 70% (the scale bar represents 0.001 or 0.01 
substitutions per site as indicated). 
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To determine the coreceptor usage of the 22 new IMCs, we infected CCR5 and CXCR4 
expressing reporter cells both in the presence and absence of their respective inhibitors (176). 
Consistent with previous analyses of Env pseudotypes (171, 176, 270, 372), the results indicated 
that all IMCs were CCR5 tropic, except for one TF and two CC viruses that were dual tropic for 
CCR and CXCR4 (Table 5-1).  
Phenotypic studies.  All biological experiments were performed using viral stocks that were 
CD4+ T cell derived, sucrose cushion purified and depleted of CD45+ microvesicles. Virus was 
quantified by measuring reverse transcriptase (RT) activity, viral RNA (vRNA) copy number and 
p24 antigen content. Comparing these values, we noticed that subtype C stocks appeared to 
contain about 5-fold less p24 antigen per unit of RT activity than subtype B stocks (Fig. 5-3A). 
This discrepancy was also seen when p24 antigen was normalized using RNA copy numbers 
(Fig. 5-3B). However, no such difference was observed when virion RT activity was compared to 
RNA copy number (Fig. 5-3C and D).  Similar results were obtained when viral stocks were tested 
in two additional p24 detection assays (Fig. 5-3E and F). Thus, three commonly used p24 capture 
assays recognized subtype C core proteins considerably less efficiently than subtype B core 
proteins, leading to a systematic underestimation of the number of viral particles in subtype C 
viral stocks. We therefore used RT activity to normalize virus input and measure virus replication 
in all subsequent experiments. 
To determine whether TF and CC viruses differed in their phenotypic properties, we used 
two complementary statistical approaches.  First, we used a conservative non-parametric 
permutation test (perm test) to address the central question of whether TF and CC viruses 
exhibited reproducible phenotypic differences. Second, we used a generalized linear model 
(GLM) to test for interactions between different parameters such as subtype and cell donors in 
replicate experiments, and to test for the independence of viruses from the same subjects. Since 
both virus status (TF or CC) and subtype (B or C) influenced the biological outcome, the GLM test 
allowed us to interpret the data with these variables taken into account. 
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Figure 5-3.  Virus quantification by p24 capture, RT activity and RNA content.  For each 
virus stock, p24 antigen content (measured in picogram), RT activity (measured in picograms), 
and viral RNA (vRNA) copy number were determined.  Individual panels compare these values 
for subtype B (solid circles) and subtype C (open circles) viruses, respectively. p24 antigen 
content was measured by alphaLISA (panels A and B; results are shown for four independent 
experiments), Alliance ELISA (panel E; results are shown for two independent experiments) and 
a method described by Grivel et al. (panel F; results are shown for two independent experiments). 
RT activity was measured using the colorimetric Roche Reverse Transcriptase Assay (results 
from three independent experiments are shown). Viral RNA copies were measured by the Roche 
COBAS AmpliPrep/COBAS Taqman HIV-1 v. 2.0 test at different viral dilutions (results from one 
experiment are shown). Values for subtype B and C viruses were compared using a Mann-
Whitney test (p-values are indicated). Panel D depicts the relationship between vRNA copies per 
ml (x-axis) and pg RT activity per ml (y-axis) for each virus stock, with Spearman’s correlation 
coefficient and p-value indicated. 
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Transmitted founder viruses exhibit enhanced infectivity. Plasma virus collected during 
ramp-up stages of acute SIVmac infection has been shown to be significantly more infectious 
than virus collected from later plasma samples (217).  To examine whether this was also true for 
HIV-1, we used a single round infection assay to determine whether TF virions were more 
infectious on a per-particle basis than CC virions. Serial dilutions of CD4+ T cell derived viral 
stocks were used to infect TZM-bl cells (which express luciferase under the control of an HIV-1 
promoter) and the resulting relative light units (RLUs) were expressed as a function of the input 
RT activity. The results showed that TF viruses as a group were 1.7-fold more infectious than CC 
viruses (Fig. 5-4A), although this difference was only marginally significant (p=0.049 by perm test; 
p=0.062 by GLM). Similar results were obtained when subtype B and C viruses were considered 
separately (there was no subtype dependence of infectivity by GLM, Fig. 5-4B).  To enhance 
virus infectivity, we repeated these experiments in the presence of diethylaminoethyl (DEAE) 
dextran, which is known to increase virion attachment to target cells (186, 278).  As expected, 
DEAE dextran increased the per particle infectivity of all viruses by up to three orders of 
magnitude (Fig. 5-4C), with a significantly greater effect on subtype C than subtype B virions 
(p=0.015 by GLM; Fig. 5-4D). However, in the presence of DEAE dextran the marginally 
significant difference between TF and CC viruses shifted to non-significance (p=0.068 by perm 
test; 0.083 by GLM). Taken together, these data indicate that TF viruses are on average twice as 
infectious as viruses that persist during chronic infection.  However, when normal barriers to cell-
free infection were mitigated by DEAE dextran, this difference was no longer significant, although 
a trend was still evident.  
Transmitted founder virions have a higher Env content.  Previous computational analyses of 
TF and CC env gene sequences revealed genetic signatures in TF viruses that increased Env 
expression and particle incorporation when tested in the context of pseudoviruses (10). We thus 
examined whether TF virions packaged more Env per particle than CC virions. To detect both 
subtype B and C Env proteins with comparable efficiency, we developed a new enzyme-linked 
immunosorbent assay (ELISA) that utilized antibodies previously shown to bind genetically highly 
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Figure 5-4.  Virion infectivity and Env content. (A-D) Infectivity values for TF and CC viruses 
(x-axis) are expressed as relative light units (RLU) per picogram (pg) of viral RT activity (y-axis). 
(A) Bars indicate the median infectivity of TF (filled) and CC (open) viruses, with interquartile 
ranges indicated. TF were 1.7-fold more infectious than CC viruses (p=0.049). (B) Infectivity 
values are shown for each virus. Subtype B and C viruses are shown in red and blue, with TF 
viruses indicated in dark red and CC viruses in light blue, respectively. Values indicate averages 
from four independent experiments. (C, D) Infectivity values are shown for TF and CC viruses as 
in panels A and B, except infections were performed in the presence of DEAE dextran. Values 
indicate averages from three independent experiments. (E, F) Env content of TF and CC virions 
(x-axis) is expressed as the mass ratio of Env and RT content (y-axis). (E) Bars indicate the 
median values of Env content for TF (filled) and CC (open) viruses, with interquartile ranges 
indicated. TF viruses contained 1.9 times more Env per unit of RT activity than CC viruses 
(p=0.048). (F) Env content is shown for each virus and color-coded as in B and D.  Values 
indicate averages from two independent experiments. 
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diverse envelope (gp120) proteins.  To capture Env, we used CD4-218.3-E51, a chimeric 
antibody that contains the first (D1) and second (D2) domains of human CD4 linked to the CD4-
induced (CD4i) monoclonal E51 (370).  To detect bound Env, we selected affinity-purified anti-
gp120-specific polyclonal antibodies that were isolated from human plasma (Advanced 
Bioscience Laboratories, Inc.). Using this ELISA, we found that TF viruses contained 1.9 times 
more Env per unit of RT activity than CC viruses (Fig. 5-4E), although these differences were only 
marginally significant (p=0.048 by perm test; p=0.057 by GLM). Subtype B viruses appeared to 
package 2.4-fold more Env per particle than subtype C viruses (Fig. 5-4F).  However, this was 
largely due to a binding preference of the capture antibody, which recognized subtype B Env 
glycoproteins twice more efficiently than subtype C Env glycoproteins.  Nonetheless, this subtype 
bias did not affect the differential between TF and CC viruses, which was seen for both subtypes 
B and C, and was controlled for in the statistical analyses (Fig. 5-4F). As expected, there also 
was a significant correlation between Env content and particle infectivity (r=0.33; p=0.036).   
Transmitted founder viruses bind dendritic cells more efficiently.  DCs have been proposed 
to play an important role in HIV-1 transmission, since they are located in the mucosa (105, 160, 
169), capture viruses using lectins (123, 356) and glycosphingolipid receptors (289), and 
efficiently transmit infectious particles to CD4+ T cells (19, 50, 106).  To examine whether TF and 
CC viruses differ in their ability to bind DCs, we pulsed immature monocyte-derived DCs 
(moDCs) with equal amounts of virus (normalized by RT activity), washed the cells extensively to 
remove cell-free virions, and then lysed the cells to quantify the amount of cell-associated virus. 
Using cells from three different donors (Fig. 5-5A), we found that moDCs captured TF viruses 1.6-
times more efficiently than CC viruses (p=0.040 by perm. test; p=0.060 by GLM). This increase 
was observed for both subtype B and C TF viruses (Fig. 5-5B), although subtype B viruses were 
captured 3.4-times more efficiently than subtype C viruses (p=4.6 x 10-6 by GLM; Fig. 5-5B).   
Because in the above experiment we had normalized virus input by RT activity, but had 
measured virion capture using the more sensitive p24 assay, we considered the possibility that 
the subtype-specific differences were an artifact of the p24 antigen capture assay. To explore 
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this, we repeated the binding experiment with cells from three additional donors, but this time 
normalizing virus input by p24 content (Fig. 5-5C and D). Despite adding an estimated 5-fold 
excess of subtype C virions, TF viruses were again captured 1.8-times more efficiently than CC 
viruses (p=0.030 by perm test; p=0.014 by GLM). Moreover, there was still a subtype specific 
difference, with subtype B viruses being captured 1.9-times more efficiently than subtype C 
viruses (p=0.0029 by GLM). As a control, we treated an aliquot of the pulsed moDCs with 0.25% 
trypsin-EDTA, and showed that this removed all detectable cell-associated virus, confirming that 
most of the DC-associated virus was surface-exposed (279).  We also cultured virus-exposed 
moDCs for nine days and showed that moDCs were not productively infected. Finally, we asked 
whether the percentage of captured virus for each strain correlated between different donors. 
This was indeed the case, regardless of whether virus input was normalized by RT activity or p24 
content, thus validating the DC binding assay (Fig. 5-6A). 
Although the combined data from all six donors indicated that DCs captured TF viruses 
1.7 fold more efficiently as CC viruses (p=0.035 by perm test; p=0.005 by GLM), there was 
considerable donor variability, with moDCs from donors A and F failing to yield significant binding 
differences (Fig. 5-5B and D).  To examine potential reasons, we compared surface expression 
levels of DC-SIGN (dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin) 
and macrophage mannose receptor by flow cytometry.  Interestingly, moDCs of donors A and F 
expressed lower levels of these molecules (Fig. 5-6B and C), suggesting that the number of Env-
specific binding sites on their cells was limited.  For the remaining four donors, moDC virus 
capture tended to correlate with particle Env content (Fig. 5-6D). These data suggest that virion 
Env content represents an important determinant in moDCs binding, although expression of 
lectins and other factors clearly also play a role (142).   
To examine the efficiency of virus transfer from moDC to CD4+ T cells, we pulsed 
moDCs with equivalent amounts of TF and CC viruses, co-cultured these cells with autologous 
CD4+ T cells, and then measured RT activity in culture supernatants as an indicator of virus 
replication. Analysis of cells from two different donors showed that TF viruses replicated to  
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Figure 5-5.  Monocyte derived dendritic cell binding.  The percent of captured TF and CC 
virus is plotted (y-axis) for moDC cell preparations from six different donors (A-F) (x-axis). (A, B) 
Virus input was normalized by RT activity. (C, D) Virus input was normalized by p24 content. (A, 
C) Bars indicate median values of moDC capture for TF (filled) and CC (open) viruses, with 
interquartile ranges indicated. TF viruses were captured 1.7 fold more efficiently than CC viruses 
(p=0.035). (B, D) Values are plotted for each virus individually (color coding for TF and CC 
viruses from subtypes B and C as in Fig. 5-4). Subtype B viruses were captured 3.4-times more 
efficiently than subtype C viruses (p=4.6 x 10-6 by GLM). 
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Figure 5-6.  Virus capture by moDCs is variable across donors and correlates only weakly 
with particle Env content. (A) The percent virus captured for each virus (y-axis) by cells from 
different donors (indicated) is shown in relation to the average percent virus captured of that virus 
in all donors (x-axis). Virus capture by cells from donors A and F were the least well correlated 
(Spearman correlation coefficient Rs = 0.72 and 0.40, respectively; other donors Rs > 0.8).  (B) 
The mean fluorescent intensity of DC-SIGN (dendritic cell-specific intracellular adhesion 
molecule-3-grapping non-integrin) and MMR (macrophage mannose receptor) staining (yellow 
and green bars, respectively), is shown for different donors (A-F) and virus input (RT activity or 
p24 content). Cells from donors A and F expressed less DC-SIGN and MMR than other moDC 
donors. (C) Images of representative moDCs expressing DC-SIGN (yellow) and MMR (green) for 
each donor. (D) The percent moDC capture of a given virus (y-axis) is shown in relation to its Env 
content (x-axis).  This relationship was significant for cells from donor B, with a trend observed for 
the other donors. (Rs and p-values are shown for each donor).  Subtype B TF and CC viruses are 
shown in dark and light red, respectively; subtype C TF and CC viruses are shown in dark and 
light blue, respectively.  Different moDC donors are shown by different symbols as indicated. 
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slightly higher titers than CC viruses (one representative donor is shown in Fig. 5-7).  Although 
these differences were not significant in the permutation test (p=0.104), significant differences in 
TF and CC virus titers were observed in the GLM analysis (p=0.025).  To explore the reason for 
this apparent discordance, we ran the permutation test on subtype B and C viruses separately 
(Fig. 5-7B), and found that subtype B TF viruses (p=0.004), but not subtype C TF viruses 
(p=0.23), grew to significantly higher titers than their respective chronic controls. Averaging 
across all days, this differences was 11.2-fold for subtype B, but only 1.4-fold for subtype C.  
Since subtype B virions bound moDCs 3.5-fold more efficiently than subtype C viruses (Fig. 5-5B 
and D), we interpret these findings to indicate that virions that bind moDCs more efficiently are 
also transferred to CD4+ T cells more efficiently.  
Transmitted founder viruses are relatively more resistant to IFN-α . CD4+ T cells represent 
the predominant target cells in gut-associated lymphoid tissues and the first cell type to become 
productively infected following transmission (227).  To determine the growth potential of TF and 
CC viruses in this cell type, we infected activated CD4+ T cells from three healthy donors with 
equivalent amounts of virus, and monitored viral growth by measuring RT activity in culture 
supernatants (Fig. 5-8A, C, E; grey lines).  Although TF viruses replicated to slightly higher titers, 
especially at the earliest time point post infection, this was not statistically significant (p=0.16 by 
perm test; p=0.186 by GLM). Thus, in activated CD4+ T cells, TF and CC viruses replicated with 
comparable efficiency.  
IFN-α is produced early in infection by plasmacytoid DCs (337), which are among the first 
cells to be recruited to the mucosal site of virus entry (209). This cytokine stimulates expression 
of hundreds of host genes (interferon stimulated genes; ISGs) (87), many of which have anti-HIV-
1 activity (324). IFN-α has also been shown to limit Env incorporation into virus particles that are 
released from infected CD4+ T cells (150).  To determine the sensitivity of TF and CC viruses to 
the antiviral activity of this cytokine, we analyzed their replication kinetics in CD4+ T cells in the 
presence of 500 U/ml of IFN-α.  Determining RT activity in culture supernatants as a measure of  
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Figure 5-7.  Dendritic cell mediated trans-infection. (A) Virus replication expressed as 
picograms (pg) of RT activity per ml of culture supernatant (y-axis) is shown after cocultivation of 
virus pulsed moDC with CD4+ T cells for one representative donor over time (x-axis). Bars 
indicate median values of viral replication for TF (filled) and CC (open) viruses, with interquartile 
ranges indicated (there were no significant differences between TF and CC viruses).  (B) Values 
are plotted for each virus individually (color coding for TF and CC viruses from subtypes B and C 
as in Fig. 5-4). Averaging across all days, subtype B TF viruses grew to 11.2-fold higher titers 
than subtype B CC viruses (p=0.004), while subtype C TF grew only 1.4-fold more efficiently than 
subtype C CC viruses (p=0.23).  
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Figure 5-8.  Virus replication in CD4+ T cells in the presence and absence of IFN-α .  (A, C, 
E) The replication kinetics of TF (solid lines) and CC (broken lines) viruses are shown in CD4+ T 
cells from three donors, in the absence (grey lines) and presence (black lines) of 500 U of IFN-α. 
RT activity indicated as picogram (pg) per ml of culture supernatant (y-axis) was measured every 
three days (x-axis). Data points indicate median values of virus production, with interquartile 
ranges indicated. In the presence of IFN-α, TF viruses grew to 24-fold higher titers than CC 
viruses (p=0.012). (B, D, F) The ratio of virus production in the presence and absence of IFN-α is 
plotted for each virus (y-axis) at different timepoints (days) post infection (x-axis) (color coding for 
TF and CC viruses from subtypes B and C as in Fig. 5-4).  Subtype B TF viruses grew to 62-fold 
higher titers than subtype B CC viruses (p=0.000013), while subtype C TF viruses grew only 1.7-
fold more efficiently than subtype C CC viruses (p=0.53). 
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viral replication, we found significant differences in the growth rate of TF and CC viruses (Fig. 5-
8A, C, E, black lines). However, this effect was highly subtype specific (Fig. 5-9). Estimating the 
magnitude of the IFN-α impact on TF versus CC virus replication, we found that subtype B TF 
viruses grew to 62-fold higher titers than subtype B CC viruses (p=0.000013 by GLM).  In 
contrast, subtype C TF viruses grew only 1.7-fold more efficiently than their respective CC 
viruses, which was not significant (p=0.53 by GLM).  Importantly, this difference was not due to a 
lack of IFN-α resistance of the subtype C TF viruses, but an increased IFN-α resistance of the 
respective chronic controls (Fig. 5-8B, D, F). Inclusion of gender and risk group information into 
the statistical analyses suggested that the observed subtype differences were not the result of an 
uneven representation of covariates, since neither gender nor risk group were statistically 
significantly associated with IFN-α resistance. However, due to the small number of viruses in 
each of these groups, the study was not sufficiently powered to examine the impact of gender 
and risk group, and a contribution of these factors can therefore not be excluded (Fig. 5-9). 
As a different way to analyze these data, we also calculated for each virus strain the ratio 
of virus production in the presence and absence of IFN-α (Fig. 5-8B, D, F). Comparing across all 
donors, we again found that TF viruses were significantly more resistant to inhibition by IFN-α 
than chronic viruses (p=0.027 by perm test). However, when considering the two clades 
separately, this was significant only for subtype B (p=0.0004 by one-sided Wilcoxon test), and not 
for subtype C (p=0.84). Viruses that were highly resistant in one donor were also highly resistant 
in the other donors (Fig. 5-10), indicating that their IFN-α phenotype was consistent between 
donors.  
To determine whether the higher titers of TF viruses were due to increased particle 
release or differences in viral spread, we used flow cytometry to measure the percent of infected 
cells in IFN-α-treated cultures from two donors (Fig. 5-11).  In the presence of IFN-α, TF viruses 
infected a larger number of cells than CC viruses, although the overall effect was only marginally 
significant (p=0.049 by perm test).  However, GLM analysis again detected a significant 
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Figure 5-9. Virus replication in CD4+ T cells in the absence and presence of IFN-α . 
Activated CD4+ T cells from three healthy donors (rows 1-3) were infected with equivalent 
amount of virus and cultured in the absence (left column) and in the presence (right column) of 
500 U of IFN-α. Virus replication was monitored by RT activity in culture supernatants (expressed 
as picogram per ml of culture supernatant) at four different time points (days) post infection (x-
axis). Values are shown for each virus. Subtype B and C viruses are shown in red and blue, with 
TF viruses indicated in dark red and CC viruses in light blue, respectively. Values indicate 
average RT activity from duplicate measurements. (A) open circles denote IMCs from female 
patients, filled circles from male patients. (B) open circles denote IMCs from heterosexual 
transmissions (HSX), filled circles from homosexual transmissions (MSM). Circles beneath the 
broken line indicate that no virus was detectable.  There was no significant interaction between 
subtype and gender (p=0.162 by GML), and gender was not a significant fixed effect when 
included as an independent variable (p=0.8), or when subtype was excluded from the model 
(p=0.4).  All MSM samples were from the B clade, so subtype-risk interactions could not be 
explored. 
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Figure 5-10.  IFN-α  resistance is consistent across donors and time-points.  The ratio of 
virus production in the presence and absence of IFN-α  for each virus (y-axis) is shown in relation 
to the average ratio of virus production in the presence and absence of IFN-α for the same virus 
(x-axis). Although there is donor-to-donor variability in the magnitude of the IFN-α effect, the 
observed levels of sensitivity or resistance are consistent across all donors. 
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interaction between subtype and TF/CC status (p=0.041), indicating that the differences were 
primarily due to subtype B viruses.  Since the ratio of virus production in the presence and 
absence of IFN-α correllated well with the percent of Gag positive cells (p<0.0001; Fig. 5-11B and 
C), it is likely that IFN-α resistance represents an enhanced ability to spread between CD4+ T 
cells.  Interestingly, this phenotype correlated only weakly with particle infectivity and Env content 
(not shown). Thus, Env content is not the main driver of the relative IFN-α resistance of TF 
viruses.  
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Figure 5-11. IFN-α  resistance affects cell-to-cell virus spread. (A) CD4+ T cells from two 
donors (A and B as shown in Fig. 4) were infected with TF (filled bars) and CC (open bars) 
viruses in the presence of 500 U of IFN-α and analyzed for Gag positive cells by flow cytometry 
12 days post infection. Bars indicate the median percent of Gag positive cells (y-axis), with 
interquartile ranges indicated. TF viruses infected a higher percentage of cells by day 12 than CC 
viruses (p=0.049). (B, C) The ratio of virus production in the presence and absence of IFN-α is 
shown for each virus at day 12 (x-axis) is shown in relation to the percent of Gag positive cells 
infected by this virus (y-axis). Viruses that are resistant to IFN-α infect a higher percentage of 
cells than viruses that are sensitive to IFN-α (Rs=0.80 and 0.63 for B and C, respectively; both 
p<0.0001).  
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Materials and Methods 
Study subjects 
Plasma samples were obtained from subjects enrolled in acute and established HIV-1 
infection cohorts (cohort 001).  A summary of available epidemiological data, clinical information, 
and infection status is shown in Table S1. Acutely infected individuals were staged as described 
(112). Whole blood was collected in acid citrate dextrose, and plasma was separated and stored 
at −70°C. All subjects provided written informed consent for the collection of samples and 
subsequent analysis.  The study was approved by the Institutional Review Boards of the 
University of Pennsylvania and Duke University. 
Single genome amplification (SGA) 
 SGA was performed as described previously (204, 270, 312, 313).  Briefly, plasma viral 
RNA was extracted, reverse transcribed using superscript III reverse transcriptase (Invitrogen), 
and the resulting cDNA was diluted in 96 well plates such that each well contained on average 
less than one cDNA template.  3’ and 5’ genome halves were amplified by nested PCR using 
primers and conditions as described (204, 270, 312, 313).  Amplicons were sequenced directly 
and any sequence containing double peaks in the chromatogram was excluded from further 
analysis.  The resulting sequences are thus representative of viral genomes present in the 
plasma, and devoid of PCR artifacts and cloning biases. 
IMC construction  
 Full-length TF and clonally expanded CC genome sequences were inferred as described 
(13, 204, 257, 270, 313). To clone TF genomes, overlapping half-genome and LTR fragments 
were amplified from PBMC genomic DNA, cloned into plasmid vectors, and combined within a 
plasmid vector (pBR322, pUC`9, or pCR-XL-TOPO) as a complete proviral genome (313).  To 
clone CC genomes, consensus sequences of viral expansion rakes were chemically synthesized 
(Blue Heron Biotech or GenScript) as 3 to 4 fragments and used to construct a complete provirus 
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(270).  This approach was also used for TF viruses derived from patients who were infected by 
multiple viruses, except for ZM247Fv1 and ZM247Fv2 that have been described elsewhere (313). 
Virus stock preparation 
 Virus stocks were generated by transfecting 30% confluent 293T cells (in a 10 cm dish) 
with 6 µg of IMC DNA. Virus was harvested 72 hours post-transfection and passed through a 
0.45 micron polyvinylidene fluoride filter.  Viral infectious units for each stock were determined 
using TZM-bl cells as described previously (366).  To generate physiologically relevant viral 
stocks, CD4+ T cells were positively selected (Miltenyi Biotec) from buffy coats of nine healthy 
donors (Research Blood Components), and cryopreserved using CS10 freezing media 
(CryoStor).  Cell aliquots were thawed quickly in a 37°C water bath, resuspended at a density of 
1x106 cells per ml, allowed to recover overnight in RPMI 1640 media containing 10% FBS and 30 
IU/ml IL-2 (CD4+ T cell media) in a 37°C incubator with 5% CO2, and then stimulated by adding 
Staphylococcal Enterotoxin B at a concentration of 50 ng/ml for 48 hours.  Cells were then pooled 
and 1x107 cells were inoculated with 1x105 infectious units of each 293T derived virus stock 
overnight in 1 ml of CD4+ T cell media.  Cells were washed and resuspended at 1x106 cells per 
ml in CD4+ T cell media.  An additional 10 ml of media was added at day three after infection.  
On day five after infection, all media was exchanged and cells were resuspended in 30 ml of 
CD4+ T cell media.  At day 11 post infection, microvesicles were depleted as described 
elsewhere (264) with the following modifications: biotinylated anti-CD45 antibody (clone 2D1, 
R&D systems) was added to streptavidin-coated magnetic beads (M-270 beads, Invitrogen) for 
one hour at room temperature at a concentration of 10 µg mAb per mg bead, washed three times 
in PBS then stored at 4°C. Beads were added to clarified supernatant to a final concentration of 
100 µg/ml for one hour at room temperature and then magnetically captured using a 50 ml 
conical tube magnet (StemCell Technology) at 4°C for 20 minutes.  Supernatant was passed 
through a 0.45 micron polyvinylidene fluoride filter and virus was pelleted through a 20% sucrose 
cushion at 100,000 g, resuspended in PBS, and stored in aliquots at -80°C. 
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 The p24 antigen content in virus stocks was quantified using commercially available 
PerkinElmer high sensitivity alphaLISA and Alliance ELISA p24 assays as well as an assay 
developed by Grivel and colleagues (33).  Viral RNA was quantified using the Roche COBAS 
AmpliPrep/COBAS Taqman HIV-1 v. 2.0 test.  Reverse transcriptase activity was determined 
using the Roche colorimetric reverse transcriptase assay.  
Since the alphaLISA p24 assay was approximately two orders of magnitude more 
sensitive than the RT activity assay, we sought to convert p24 antigen concentrations measured 
by this assay to RT activity in order to use this assay when RT determinations were below the 
limits of detection.  Thus, we calculated the ratio of p24 to RT activity for each virus in four 
independently prepared high-titer virus stocks.  Since these ratios were highly consistent, we 
used the average ratio for each virus strain to convert p24 to RT activity.  
Coreceptor tropism  
Coreceptor tropism was assessed by pre-incubating TZM-bl cells with 1.2 µM AMD3100 
and/or 10µM TAK779 before infection with 1x103 infectious units of 293T cell supernatant.  
Viruses were considered dual-tropic if inhibited at least 5% by AMD3100 and no more than 95% 
by TAK779. 
Analysis of per-particle infectivity 
 1x104 TZM-bl cells were seeded per well in a 96 well plate in 100 µl DMEM containing 
10% FBS.  After 24 hours, media was removed from each well, and cells were infected with 50 µl 
of virus serially diluted in DMEM containing 1% FBS with or without 10 µg/ml DEAE-Dextran.  
Two hours later, 50 µl of DMEM containing 20% FBS was added.  36 hours after infection, 
luciferase production was assayed using Brite-Glo luciferase substrate (Promega) and a Biotek 
H4 reader.  As a control, a third-generation fusion inhibitor (T2635) was added at a saturating 
concentration (1 µg/ml) 12 hours after virus addition to one of the duplicate wells (102).  Relative 
light units (RLUs) generated per volume of each virus stock were calculated using all virus 
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dilutions in the linear range of the assay (2x103-6x105 RLUs).  The infectivity per particle was then 
calculated as the RLU generated per pg of RT activity present in each virus stock. 
Particle Env content  
A sandwich ELISA was developed to measure virion Env content.  200 pg of the 
monoclonal E51-218.3-CD4 was added in 100 µl of 0.2 M sodium carbonate/bicarbonate (pH 10) 
solution to each well of 96 well ELISA plates (Nunc MaxiSorp) and incubated overnight. E51-
218.3-CD4 is a chimeric antibody that contains the first (D1) and second (D2) domains of human 
CD4 linked to the CD4-induced (CD4i) monoclonal E51.  Its architecture is similar to that of other 
chimeric antibodies (370), except that the peptide that links the CD4 and E51 moieties was 
modified for stability.  Wells were washed twice with 200 µl of PBS with magnesium and calcium 
containing 0.2% Tween 20 (PBS-T), blocked with 200 µl of 5% non-fat milk in PBS-T for 2 hours 
at room temperature, and washed three times with 200 µl of PBS-T.  Plates were stored at 4°C 
for up to one month.  Virus was diluted in PBS-T with 1% Triton X-100 detergent to disrupt 
virions, added to wells in three 10-fold serial dilutions (100 µl) and incubated at 37°C for two 
hours.  Commercially available gp120 standards were similarly diluted and added to wells in 
serial 2-fold dilutions starting at 100 ng/ml.  Wells were washed 5x with PBS-T and then 
incubated with 100 µl of horseradish peroxidase-conjugated, affinity-purified human anti-gp120 
(Advanced Bioscience Laboratories) for one hour at 37oC.  Wells were washed five times with 
PBS-T, incubated with o-phenylenediamine dihydrochloride substrate followed by 2 N sulfuric 
acid, and absorbance was read at 490 nm with a 630 nm reference.  After 15 minutes of 
development, the assay had a dynamic range from approximately 100 pg gp120/ml to 50 ng/ml. 
Multiple dilutions were used to determine the Env content for each virus stock, which was then 
normalized by the RT activity. 
Dendritic cell capture and trans-infection assays 
 Monocyte derived dendritic cells (moDCs) were differentiated from peripheral blood 
monocytes purified by CD14 immunomagnetic selection of PBMC isolated from buffy coats of 
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healthy donors.  Monocytes were further enriched by removing cells that did not adhere to 
polystyrene after 1 hour incubation at 37°C in RMPI 1640 with 5% NHS, and 1% HEPES buffer.  
Adherent cells were cultured in the same media supplemented with 100 IU/ml GM-CSF and 200 
IU/ml IL-4 (refreshed every two days) for seven days after which they became non-adherent.  On 
day six, cells were analyzed by flow cytometry.  1.0x106 cells were treated with Fc-receptor 
blocking reagent (Miltenyi Biotec) according to manufacturer’s instructions, stained with lineage 
cocktail 1 [which contains antibodies to CD3, CD14, CD16, CD19, CD20 and CD56) (FITC), 
CD11b (PE), CD11c (PE/Cy5) and CD14 (Pacific Blue)] or separately with CD209 (FITC), CD206 
(PE), CCR5 (PE-CF594) and DAPI, and analyzed using an Amnis ImageStream machine.  The 
phenotype of moDCs was lin1-, CD206+, CD209+, and CD11c+.  CD14 staining was less intense 
on fresh monocytes, but remained detectable on day six.  On day seven, 1x105 moDCs were 
seeded into a deepwell 96 well plate at a concentration of 1x106 cells per ml then pulsed with 30 
pg RT activity of each virus stock (diluted in 5 µl of RPMI) for 3 hours.  To calculate the amount of 
p24 added to each well, 15 µl of well-mixed cells and media were removed, and p24 was 
measured.  Next, cells were washed three times with 1 ml of pre-warmed Hank’s balanced salt 
solution with calcium and magnesium to remove cell-free virus.  Cells were then lysed in PBS 
containing 0.5% Triton X-100 and the percent capture was calculated as the cell-associated p24 
divided by p24 present prior to wash.  For one TF virus (CH040), 300 pg and 3 pg RT activity was 
also added to determine the linear range of the assay.  In both cases, the percent capture was 
not statistically different than when 30 pg were added.  As an additional control, 30 pg of CH040 
was added to wells with no moDCs to determine possible background due to incomplete removal 
of media between washes.  No p24 was detectable in these wells.  For a small number of viruses 
(3-5), no p24 was detectable after washing.  Thus, we used the limit of p24 detection to calculate 
the percent capture.  Because we observed that adding as much as 10 times more virus in this 
assay did not affect the percent capture, we repeated this assay in three additional donors adding 
600 pg of viral p24 antigen of each virus. When input was normalized by p24, only one virus in 
one donor was captured at a level below the assay’s limit of detection. 
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 To test for productive infection of moDCs, 3.3x104 moDCs were cultured in 200 µl of 
RMPI 1640 with 5% normal human serum, and 1% HEPES buffer with 100 IU/ml GM-CSF and 
200 IU/ml IL-4 for nine days in 96 well plates.  Media was replaced at day six.  To test if bound 
virus was accessible to trypsin, 3.3x104 moDCs were incubated in 0.25% trypsin-EDTA for 15 
minutes at 37°C prior to the final wash in HBSS, then lysed as above. 
 To measure moDC transfer to CD4+ T cells, buffy coats were split, with half of the cells 
processed to isolate monocytes as above and the other half depleted of non CD4+ T cells 
(RosetteSep, StemCell Technologies).  MoDCs were generated as above and CD4+ T cells were 
stimulated for 48 hours with 50 ng/ml SEB then cultured at 1x106 cells per ml in CD4+ T cell 
media.  On day seven, 1x105 DCs were pulsed for three hours with 50 pg RT of each virus then 
washed as above and co-cultured with 5x105 CD4+ T cells in 1 ml of CD4+ T cell media in 48 well 
plates.  To measure virus replication, 200 µl of media were sampled with replacement every two 
days. At day 6, 800 µl of media was exchanged. 
Virus replication in the presence and absence of IFN-α   
 CD4+ T cells were isolated from buffy coats by depleting non-CD4+ T cells and then 
stimulated with 50 ng/ml SEB for 48 hours in CD4+ T cell media at a concentration of 1x106 cells 
per ml.  The cocktail used for depletion contains anti-CD123 antibodies, and thus also depletes 
plasmacytoid dendritic cells.  Cells were washed, resuspended at 1x107 cells per ml, with 2x106 
cells incubated overnight with an equivalent amount of each virus (30 pg RT activity).  Next, cells 
were washed twice with 1 ml of PBS and split into two equal parts, one of which was cultured in 
CD4+ T cell media alone and the other supplemented with 500 U/ml IFN-α (A2; PBL 
Laboratories) in 1 ml in 48 well plates.  200 µl of media were sampled with replacement every 
three days. At day six, 800 µl was exchanged with fresh media containing 500 U/ml IFN-α. 
 On day 12, cells were analyzed by flow cytometry.  Cells were washed 1x in PBS then 
incubated with 1 µl of a 1:1000 dilution of live/dead green stain (Invitrogen) in DMSO.  Cells were 
incubated for 30 minutes at 4°C with anti-CD4 antibody (OKT4 APC/Cy7, BioLegend), washed 
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and permeabilized using Cytofix/Cytoperm kit (BD) according to manufacturer’s instructions, and 
then incubated with anti-Gag antibody (KC-57 RD-1, Beckman-Coulter) for one hour at 4°C.  
Cells were fixed in 1% paraformaldehyde and analyzed on an Amnis ImageStream instrument.  
Gag positive cells were expressed as a percentage of all living cells.  All samples were collected 
and analyzed under code, and four mock-infected cultures were used to define baseline anti-Gag 
staining. Cell viability at day 12 in mock-infected cultures was comparable in the presence and 
absence of IFN-α.    
Statistical analyses 
We used two statistical strategies to determine whether TF and CC viruses have distinct 
phenotypic characteristics. A non-parametric rank-based permutation test was used to determine 
whether values from TF viruses were significantly different from those derived from CC viruses. 
This test was designed to account for clade and donor differences, and the p-value reflected the 
likelihood of observing differences between TF and CC viruses by chance alone. The test took 
into account that (i) viruses were derived from two clades (B and C), (ii) repeat experiments were 
performed using different donor cells; and (iii) in some experiments responses were evaluated at 
different times.  Specifically, the TF ranking for each experiment was determined, and if an 
experiment was repeated, its ranks were summed across the replicate experiments (for example, 
if 3 repeat experiments were done in 3 different donor cells, and a TF IMC scored the highest in 
two experiments, second in the third, the sum of the ranks for that IMC was 1+1+2 = 4). TF and 
CC labels were then randomly reassigned 10,000 times, and the sum of the various ranks from 
the randomized data tallied. The fraction of occurrences of a given rank-sum value observed in 
10,000 randomized data sets provides an estimate for the probability of observing that rank-sum 
value in the actual data by chance alone. Thus, the fraction of occurrences in the randomized 
data of rank-sum values equal to or less than that observed rank-sum in the actual data provides 
a p-value that the observed rank-sum is statistically significant.  Each IMC was randomized 
independently, including cases in which multiple IMCs were derived from the same subject, 
because these IMCs were genetically and phenotypically distinctive. The independence of the 
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IMCs was supported by subsequent GLM analyses (see below). The code for this permutation 
test was written in-house for this project using perl. 
The general linearized model (GLM) consisted of fitting a log-normal generalized mixed-
effect model to the data; all analyses related to the model were performed using R (http://www.r-
project.org/). The advantage of using this model was that it allowed us to estimate the impact of, 
and assess the relationships between, different parameters. Using this approach, we modeled the 
response variables in each experiment versus subtype (B or C) and transmitted (TF) or chronic 
(CC) status, considering the cell donor and the IMC as random effects to account for the different 
levels of donor and IMC responses. We compared nested models, simplifying from more complex 
models to simpler ones (with less variables) in a step-wise manner using the Akaike Information 
Criterion (AIC), and we only kept variables that reached a significance level of 0.05 or lower. This 
allowed us to test for possible interactions between variables, for example, when the response 
variable had a different TF vs. CC effect between clades.  To test whether the various IMCs were 
independent when derived from the same subject, we also introduced a variable “patient”. The 
patient variable was never statistically supported in our models, suggesting the IMC were 
behaving independently, even when derived from the same individual. The GLM was 
implemented using the glmer function (http://lme4.r-forge.r-project.org/), and the anova function 
(52) was used to compare models using the AIC. We used a Shapiro-Wilcoxon test (306) to show 
that the data were consistent with a log-normal distribution.   
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Discussion 
A primary goal of AIDS vaccine development is to prevent acquisition of HIV-1 at 
mucosal surfaces.  In this context, it is critical to determine whether newly transmitted HIV-1 
strains share properties that provide novel targets for effective immunization.  For this purpose, 
the analysis of full-length TF genomes is ideal, since their corresponding IMCs contain the 
complete genetic information of viruses that successfully transmit infection. Moreover, genetic 
linkage is maintained to preserve potentially important regulatory and structural protein 
interactions (176, 204, 257, 313). Characterizing a large set of TF and CC IMCs from two major 
HIV-1 group M subtypes B and C, we found that TF viruses were slightly more infectious on a per 
particle basis, packaged slightly more Env and bound to moDCs more efficiently than chronic 
control viruses.  We also found that TF viruses were more resistant to the antiviral effects of IFN-
α, although this was statistically significant only for subtype B TF viruses. These biological 
differences could act in concert to enhance cell-free infection and virus replication in the face of 
an early innate immune response.  
Analyzing particle composition and infectivity, we found that TF virions were on average 
twice as infectious and contained twice as much Env as CC virions.  These phenotypic 
differences are consistent with data from a recent genetic study (126), which identified sequence 
signatures in the signal peptide of TF Env sequences.  When tested in the context of 
pseudoviruses, these signatures increased steady state Env expression and particle 
incorporation (10). Assuming 35 enzymatically-active RT dimers per virion, we estimate that the 
median TF virion contains 18 Env trimer spikes, while the median CC virion contains seven– a 
value essentially identical to previous estimates (55).  Since only one or a few functional Env 
trimers are believed to be necessary for cell fusion and infection (218, 382), it would appear that 
TF viruses carry an “excess” of envelope glycoprotein. However, such “excess” may be of 
advantage during the earliest stages of HIV-1 infection, since viruses with a higher Env content 
can be expected to also contain more functional trimers. Particle-associated Env may also play a 
role beyond the mere fusion and cell entry function (15).  For example, excess Env could ensure 
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more stable attachment of virions to target cells and/or could be involved in receptor and/or co-
receptor mediated signaling (15).  In addition, excess Env may compensate for shedding or 
inactivation by semen (221) and cervicovaginal mucous (262). Thus, it seems likely that the 
increased Env content and associated enhanced infectivity of TF viruses serve to increase their 
transmission fitness.  Conversely, the lower Env content of CC viruses may be more 
advantageous once infection is established and may even be selected for by Env-specific 
neutralizing antibodies. 
We also found that TF viruses bind more efficiently to moDCs than their chronic 
counterparts.  Although moDCs are only a proxy for classical mucosal DC subsets, previous 
studies have shown that tissue- and in vitro- derived DCs have similar virus capture capabilities 
(134, 144, 168). Thus, it is likely that the improved interaction of TF viruses with tissue culture 
derived moDCs is also a reflection of their in vivo biological properties. The differential binding of 
TF viruses was statistically significant across different donors and across both clades, and thus 
seems to represent a general feature of TF viruses. There are at least two steps in the 
transmission process where this phenotype may confer an advantage. First, more efficient 
binding to tissue resident DCs may increase the likelihood of a successful transfer to CD4+ T 
cells. Second, more efficient binding to emigrating DCs may promote the seeding of regional 
lymph nodes (341). In this context, it is of interest that adaptive changes that conferred mucosal 
transmissibility to a commonly used SHIV strain (SF162P3) increased the binding capacity of its 
Env glycoprotein to DC-SIGN (162). Our data are thus consistent with the view that DCs are 
among the first cells to interact with HIV-1 after exposure and that this interaction is important for 
transmission, although DCs themselves are not productively infected. 
One unexpected finding was that TF viruses replicated and spread in CD4+ T cells in the 
presence of IFN-α more efficiently than did CC viruses. Although this effect was most pronounced 
for subtype B TF viruses, a trend was also observed for subtype C TF viruses. This finding raises 
the question whether IFN-α responses in the mucosa are protective against HIV-1 infection. On 
first glance, the answer to this question seems to be no.  Previous studies in macaques 
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concluded that the initial innate immune response is ineffective at containing SIVmac infection 
and may even enhance early viral replication (209). Moreover, mucosal pre-treatment with toll-like 
receptor (TLR) agonists induced IFN-α, but did not protect animals from SIVmac challenge (77). 
However, these studies were not only assessing the effects of IFN-α, but were also causing 
immune activation by inducing pro-inflammatory cytokines and chemokines.  In fact, it has been 
shown more recently that systemic administration of pegylated IFN-α alone delayed SIVmac 
infection in treated compared to untreated macaques following a high-dose vaginal challenge 
(Danny Douek, personal communication). It thus appears that early interferon responses can be 
protective against HIV-1 infection. The fact that IFN-α levels (157) as well as interferon regulatory 
factor polymorphisms (18) have been associated with protection in highly exposed but uninfected 
individuals is consistent with this hypothesis. Thus, the induction of an effective early “anti-viral 
state” appears to contribute to the population bottleneck associated with mucosal HIV-1 
transmission.  
We hypothesized that virions containing more Env would be more resistant to IFN-α, 
because in vitro experiments had shown that this cytokine can decrease cell-free virus 
transmission (361), particle release (383) and particle infectivity (150, 392).  However, we failed 
to see a significant correlation between IFN-α resistance and Env content or virion infectivity.  
Thus, higher baseline Env incorporation cannot explain the IFN-α resistant phenotype of TF 
viruses. Nonetheless, the ability of TF viruses to replicate in the presence of IFN-α indicates that 
resistance conferring determinants must exist. There are several candidates, such as the 
accessory proteins Vpu and Vif, which are known to counteract the interferon stimulated genes 
tetherin and APOBEC3G, respectively (252, 333), as well as the Tat protein, which has been 
reported to modulate the IFN-induced RNAse L antiviral pathway (325) and to down-regulate the 
ISG protein kinase R (304). Structural proteins, such as Gag, may also contribute to IFN-α 
resistance by exhibiting differential sensitivity to the tripartite motif (TRIM) family of proteins (24, 
296, 385). Finally, IFN-α resistance may not only be protein-mediated, since variation the number 
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of transcription factor binding sites in the LTR could also influence IFN-α sensitivity (16, 170). 
Notably, there is a relationship between IFN-α resistance and efficiency of transmission in other 
viruses, including Venezuelan Equine Encephalitis virus (342) and Bovine Viral Diarrhea Virus 
(53, 233), suggesting that increased IFN-α resistance may be a common property of transmitted 
founder viruses. 
If IFN-α resistance is a pre-requisite for efficient HIV-1 transmission, one would expect 
this viral property to be conserved across all clades. The lack of significance between subtype C 
TF and CC viruses seems to argue against this; however, Figure 4 shows that this is not due to a 
loss of IFN-α resistance of subtype C TF viruses.  Instead, the 62-fold difference observed for 
subtype B viruses reflects a much greater IFN-α sensitivity of the respective chronic viruses. 
Although our panel of TF and CC IMCs is larger than any previously tested set, there are 
epidemiological differences between the patient cohorts from which they were derived. For 
example, all but one of the chronic subtype B IMCs were derived from men who had sex with 
men, while seven of eight chronic subtype C IMCs were derived from women (Table S1).  This 
gender bias, although not statistically significant, may have contributed to the increased IFN-α 
resistance of chronic subtype C viruses, since pDCs of women have been reported to generate 
more IFN-α in response to HIV-1 than pDCs of men (230).  In addition, all subtype C viruses were 
derived from individuals living in Africa, while all subtype B viruses were derived from patients 
residing the US (Table S1).  Thus, environmental factors, such as concurrent infections that 
increase general inflammation levels, may have contributed to the much higher IFN-α resistance 
of the African CC viruses.  Moreover, all subtype C infected subjects with established infection 
had lower CD4 counts (Table S1) and thus possibly more advanced disease, which could have 
also influenced the level of IFN-α resistance of their viruses (101, 192). Finally, if loss of IFN-α 
resistance is the result of pressure from host adaptive responses, then duration of infection, 
which was unknown for all subtype C infected subjects, may have been an important variable. 
Borrow and colleagues have recently demonstrated that subtype B viruses isolated from subjects 
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later in infection are more sensitive to IFN-α than the viruses isolated shortly after transmission 
(Fenton-May et al, manuscript in preparation). Thus, it seems clear that to decipher the 
differences in IFN-α resistance observed here, future studies will need to consider patient 
demographics, subtype, route of transmission and duration of infection in addition to TF and CC 
virus status. 
One of the motivations to characterize the phenotypic properties of TF viruses is the 
possibility that virus traits might be uncovered that could represent useful vaccine targets. In this 
context, the increased Env content of TF viruses may increase their sensitivity to neutralization by 
allowing antibodies to bind bivalently and crosslink more densely-packed Env spikes (184). 
Similarly, the identification of key ISGs that contribute significantly to viral control during the most 
vulnerable stages of HIV-1 infection may provide a new vaccination strategy, either by vaccine 
vector mediated type I IFN production and/or by the induction of T cells that express the critical 
antiviral ISGs. 
The molecular identification and biological analysis of TF viral genomes is a powerful 
enabling tool for characterizing the transmission requirements and subsequent evolution of HIV-1, 
SIV and other viruses (176, 204, 205, 257, 297, 313).  In the present study, we used TF analyses 
to characterize the biological properties of full-length HIV-1 genomes captured at the moment of 
transmission.  Although we identified significant phenotypic differences, none of these completely 
differentiated TF from CC viruses and the magnitude of the differences in these properties was 
generally modest. This is not surprising since TF viruses, by necessity, represent a subset of a 
much larger and more diverse set of viruses that replicates persistently throughout chronic 
infection. We speculate that the viral population bottleneck associated with mucosal transmission 
is mediated largely by physical barriers associated with the genitourinary and gastrointestinal 
tracts but also by specific virus-host cell interactions necessary for virus infection and replication.  
Each of which may pose hurdles to virus acquisition.  Thus, even slight advantages of TF viruses 
at one or more of these biophysical checkpoints could result in a transmission fitness advantage. 
Defining the viral determinants that underlie this fitness may provide further insights into the 
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biology of mucosal HIV-1 transmission that can enhance vaccine immunogen design. 
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Introduction 
 Transmitted/founder (T/F) human immunodeficiency viruses have all the biological 
properties required for transmission.  Therefore, targeting the key properties of these viruses 
should be a high priority when designing interventions to prevent transmission.  Chapters two and 
three describe the intrinsic envelope glycoprotein (Env) function of T/F and chronic control (CC) 
viruses from subtypes B and C, with a focus on receptor and coreceptor interactions.  Chapter 
four reports a virus that established primary infection despite extremely inefficient use of CCR5 
when tested in vitro.  Chapter five characterizes T/F and CC viruses biochemically and in binding 
and replication experiments using primary cells.  Together this work builds a foundation for future 
studies of T/F virus biology.  Three differences between T/F and CC viruses deserve focused 
follow-up studies: a poorly understood feature of many CC Envs typified by low-level resistance to 
maraviroc, the high Env content of T/F viruses, and the relative resistance of T/F viruses to 
interferon alpha (IFN-α).  Here I propose a number of experiments that could be used as starting 
points for such follow-up.  
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Future Directions 
Intrinsic Env entry functions.  Chapters two and three described experiments using, for 
the most part, Env complementation assays to determine the entry functions of subtype B and C 
T/F and CC viruses.  While the most obvious difference between these two studies is the subtype 
of virus investigated, several other important differences should be noted.  First, the approach 
used to generate control Envs was different between the two; subtype B control envs were 
chosen at random from the many envs detected after single-genome amplification (SGA) from the 
plasma of chronically infected individuals.  The only selective criterion was that the Env mediated 
entry into TZM-bl reporter cells; some 30% of envs sequenced from the plasma by SGA do not 
encode Envs capable of this basic function (180).  In contrast, we required that all subtype C 
control envs have evidence of in vivo clonal amplification, arguing strongly for their in vivo 
functionality.  Although we do not yet know the precise mechanisms responsible for clonal 
amplification (362), this provides the highest level of assurance available that the control Envs 
tested are functional and relevant to ongoing chronic infection, rather than evolutionary dead-
ends integrated and thereby archived in long-lived CD4+ T cells.  Thus the control Envs used for 
subtype C represent a more stringent comparison than the control Envs used for subtype B.  In 
contrast, all 24 of the T/F Envs for subtype B came from infections initiated by a single T/F 
variant, whereas six of 20 subtype C T/F viruses were from multiple-variant transmissions.  This 
is despite the majority of subtype B Envs being transmitted to men who have sex with men, which 
has higher risk of multiple-variant transmission (204) than heterosexual contact, the known risk 
factor for the subjects infected with the subtype C T/F variants we tested.  Multiple-variant 
transmission is also associated with intravenous drug use (21) and inflammatory genital diseases 
(145), which are associated with a substantially increased epidemiological risk of transmission 
(305).  Thus it is possible that for some of the subtype C T/F Envs the barriers to mucosal 
transmission were less intact than those for subtype B.  
The most apparent biological difference between the panels of subtype B and C T/F and 
CC Envs was in their sensitivity to CD4 binding site (CD4bs) antibodies and pooled polyclonal 
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antibodies from human immunodeficiency virus type 1 (HIV-1) infected individuals (HIVIG) 
(Figures 2-6 and 3-7).  T/F Envs from subtype B Envs were significantly more sensitive to VRC01 
and b12 than CC Envs, whereas a non-significant trend in this direction was seen for subtype C.  
The reagents used to address this hypothesis were arguably more appropriate for subtype B than 
for subtype C; b12 poorly neutralized all subtype C Envs relative to VRC01 and the HIVIG 
preparation used for subtype C was selected from a small number of subjects containing very 
broadly neutralizing antibodies.  Thus at this point we are unable to definitively address the 
following possibilities to account for this difference: 1) there is a subtype-specific biological 
difference in this property, with subtype B T/F and CC Envs having different neutralization 
sensitivity, 2) there is a real difference that would be observed if a larger or more representative 
(e.g. more T/F Envs from single-variant transmissions) panel of subtype C Envs was used 3) 
There would be no difference in this property, even for subtype B, if clonally-expanded, in vivo 
functional subtype B Envs were used as controls.  Fortunately, this ambiguity does not influence 
the important message of our finding for vaccine design: CD4bs antibodies potently inhibit T/F 
Envs (perhaps even more so than chronic Envs), and virus resistance to these antibodies may be 
associated with a functional “cost” in terms of CD4 use efficiency (Figure 3-8).  Thus this class of 
antibodies would be ideal to elicit by vaccination, which is less cleaar for the PGT class of 
antibodies, reported to be less potent against T/F Envs than CC Envs (246). 
Similarities between the phenotype of T/F Envs from subtypes B and C allow us to 
generalize several conclusions about T/F Env entry function relative to control Envs.  First, 
neither subtype C or subtype B T/F Envs efficiently mediate entry into cells that express low 
levels of CD4.  Examples of such cells include macrophages (73) and dendritic cells (271).  
Tropism for these cell types is dependent on efficient entry (322), thus our data suggests that T/F 
viruses are not macrophage or dendritic cell tropic, consistent with reports by others (204, 257, 
313).  In contrast, T/F Envs do mediate efficient entry into primary CD4+ T cells, especially 
effector memory CD4+ T cells.  The CD4+ T cell subset was preferentially infected by T/F Env 
pseudoviruses from subtypes B and C, potentially due to higher expression of the coreceptor 
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CCR5 (316).  While all T/F Envs tested to date are capable of using CCR5 as a coreceptor and 
there are no examples of T/F Envs that use CXCR4 exclusively, T/F Envs appear to have a 
similar efficiency of CCR5 use as CC Envs.  This was determined by measuring the inhibitory 
effect of blocking CCR5 with the small molecule maraviroc (MVC); similar concentrations of MVC 
were required to inhibit 50 percent of infection (IC50) by both T/F and CC Env pseudoviruses on 
NP2/CD4/CCR5 cells.  However, if the maximal inhibition (MI) by saturating MVC is examined 
rather than the IC50, MVC showed a trend towards more complete inhibition of entry by T/F than 
CC Envs in both subtypes B and C (268).  When data from both B and C panels was combined, 
this difference was statistically significant.  Indeed, when both panels were tested again on a cell 
line expressing higher levels of CCR5 (affinofile cells), the difference in MI by MVC between T/F 
and CC Envs became readily apparent (268).  Thus T/F Envs are more completely inhibited by 
MVC than CC Envs, though the mechanisms underlying this phenotypic difference are not yet 
clear; it is unlikely that any of these viruses have ever been exposed to MVC, thus the low-level 
MVC resistance of many CC Envs is an epiphenomenon. 
One focus of chapter three is the hypothesis that the integrin pair α4β7 promotes entry 
and infection by subtype C T/F Envs more than for CC Envs.  This hypothesis is consistent with 
known genetic signatures pertaining to glycosylation of the variable loops and seems to provide a 
mechanism by which viruses could specifically target highly permissive CD4+ T cells in the gut 
(62, 250).  However, we found no evidence that blocking the Env/α4β7 interaction decreased 
infection of primary T/F or CC viruses although it did have some effect on the lab strain SF162.  
Unpublished structural data suggests that the gp120 residues thought to be critical for binding 
α4β7 mediate protomer-protomer interactions and are thereby internally sequestered and 
prevented from binding α4β7 (Joe Sodroski, personal communication).  It is therefore very 
unlikely that α4β7 interacts with Env prior to CD4 engagement as originally conceived (63).  
Practically speaking, unless compelling data using physiologically relevant viruses is presented to 
support that claim that α4β7 is an important host protein for HIV-1 transmission, future 
experiments are unnecessary.  However, if there is a role for α4β7 after CD4 engagement, 
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investigators might develop tools that allow this interaction to be studied in experimental systems 
that are more easily manipulated and permit testing of many viruses.  For example, 
pseudoviruses could be generated in cells (e.g. 293S GnTI-) lacking N-
acetylglucosaminyltransferase I activity to generate a glyocosylation pattern more reflective of 
primary cells (38) and monoclonal antibodies that induce an “active” conformation of α4β7 with 
high affinity for its ligands (48) could be used to study the Env/α4β7 interaction using cell lines.   
Future work is needed to define the differences in intrinsic entry functions of T/F Envs in 
comparison to those of CC Envs more generally and in higher resolution.  First, only subtype B 
and C have been examined in detail.  Ongoing work suggests that while subtype A T/F viruses 
are CD4+ T cell-tropic and not macrophage tropic, subtype D T/F viruses are often macrophage 
tropic (13).  Future investigators aiming to identify general phenotypic properties of T/F Envs 
should endeavor to compile panels of T/F Envs of multiple subtypes using the same stringent 
selection criteria.  Based on our experience, differences in intrinsic Env function are likely to be 
subtle.  Thus panels of at least 50 T/F and 50 CC Envs should be tested simultaneously.  This 
problem is well illustrated by the following: in the subtype B panels there was a significant 
difference in T/F and CC Env sensitivity to VRC01 and HIVIG, in subtype C there was a trend in 
the same direction, and pooling all data revealed a significant difference between T/F and CC.  
However, given the differences in selection criteria between these two panels and post hoc 
statistical analysis, this difference is difficult to interpret. 
Future studies should focus on the mechanism of the difference in MVC inhibition by T/F 
and CC Envs, specifically that T/F viruses are less completely inhibited by MVC than CC Envs 
(269).  Some biologically plausible hypotheses include: 1) T/F Envs have a conserved, 
constrained means of interacting with CCR5 that is more sensitive to inhibition by MVC because 
the Env/CCR5 interaction must mediate cellular signaling (369) in order for a virus to be efficiently 
transmitted, but this signaling is not required during chronic infection.  This could be tested by 
calcium flux experiments or other experiments to probe differences in intracellular signaling of T/F 
and CC gp120 and viruses. 2) The MVC sensitivity of T/F Envs is a surrogate of resistance or 
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sensitivity to inhibition by one or more of the various CCR5-interacting beta-chemokines that 
could be present at high levels during primary infection, including CCL3, CCL4, CCL5, or 
CCL3L1.  This would be straightforward to test, although purchasing enough of these 
recombinant proteins from commercial sources for a comprehensive analysis might be cost-
prohibitive. 3) CCR5 is known to exist in different antigenic conformations, which are expressed 
at different levels on different cell types (31, 199).  Perhaps the initial target cells during mucosal 
transmission are more constrained in their expression of CCR5 isoforms.  Exclusive use of the 
isoforms expressed by these cells for entry could be associated with complete inhibition by MVC.  
Characterizing CCR5 expression on primary cells from mucosal tissues and cell lines using well-
defined monoclonal antibodies with known CCR5 isoform recognition preferences would thus 
refine this hypothesis and help define the CCR5 isoforms/epitopes involved in this phenomenon.  
One clue regarding this phenomenon comes from the observation that Envs incompletely 
inhibited by MVC also tend to require more of the fusion inhibitor T20 to reach 50% inhibition 
(Rs=0.59, p=0.00007).  However, these data are available only for only subtype B panel at this 
time, so the generality of this correlation should be examined.  This might suggest a general 
explanation for the observed MVC resistance of CC Envs relating to the kinetics of Env 
conformational change.  
The use of CCR5 in a constrained, MVC-sensitive manner is a key generalizable feature 
of T/F Envs.  Indeed, it was observed for the virus described in chapter four (ZP6248) which used 
CCR5 in vitro very inefficiently.  ZP6248 is informative despite being an extreme outlier because it 
helps delineate the properties necessary and sufficient for transmission.  Pseudoviruses 
expressing the Env of this virus entered NP2 cells expressing CCR5 approximately two orders of 
magnitude less than the next lowest T/F pseudovirus (Figure 4-6), and only 5-fold more efficiently 
than the X4-using Env NL4-3 (Table 4-1).  In contrast, this Env mediated entry into NP2 cells 
expressing the alternative coreceptor GPR15 more efficiently than any other T/F or CC Env 
tested.  Thus efficient use of CCR5, at least as tested in vitro, is not an absolute requirement for 
transmission although it is observed in the vast majority of T/F viruses.  One speculation is that 
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ZP6248 actually did use CCR5 in vivo, although in a form that is not recapitulated in vitro or 
present at high levels in peripheral CD4+ T cells.  Thus the coreceptor use of ZP6248 should be 
revisited once there is a better understanding of the MVC-inhibition phenomenon, as the two may 
be related.  Another possibility is that this virus used GPR15 to establish primary infection.  In any 
case, this observation highlights the phenotypic diversity of T/F HIV-1 and should motivate future 
studies with the goal of quantifying the selective advantage R5-use confers for HIV-1 
transmission (51, 299).  However, all current data suggests that MVC-containing microbicides 
should be very effective against the population of viruses most relevant to mucosal transmission, 
ignoring concerns about pharmacokinetics or adherence.  Furthermore, structurally defining the 
Env domains involved in the constrained, MVC-sensitive CCR5 use of T/F viruses could guide 
immunogen design. 
Function of infectious molecular clones (IMCs).  The atypical coreceptor use of the 
Env described in chapter four prompted us to generate an IMC representing the entire genome of 
the T/F virus.  This was done to ensure that the phenotype of the Env pseudovirus was 
representative of the complete T/F virus, which was indeed the case for this virus.  Previously, we 
characterized two T/F env expression cassettes that did not functionally complement an env-
deficient HIV-1 provirus backbone (191).  Because the inference of the T/F env sequence was 
unambiguous, the Envs encoded by these cassettes must have mediated entry sufficient for 
transmission.  Indeed, complete IMCs of the viruses in question were fully functional in a variety 
of experimental systems.  We then defined the source of the pseudovirus assay artifact: a post-
transcriptional block in steady-state Env production in the pseudovirus system that was specific to 
env cassettes with a certain reading frame configuration upstream of env (191).  Thus due to 
differences in Env protein production, and therefore incorporation into particles, pseudoviruses 
generated using these env cassettes were not representative of the complete T/F virus from 
which the envs were derived.  Such a phenomenon may explain the seeming discordance of 
Figure 2-4 and Figures 5-5 and 5-7, although differences in virus input normalization likely also 
play a role. 
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The entry function of T/F Envs described in chapters two through four was determined 
primarily using trans-complementation assays and thus does not address whether viral genes 
other than env or differences in Env requiring production and incorporation in its native context 
play a role in transmission.  Therefore we characterized subtype B and C T/F and CC IMCs as 
reported in chapter five.  The first hypothesis we tested was based on the most significant 
genotypic difference between T/F and chronic env sequences – conservation of a histidine at 
residue 12 of the signal peptide in T/F viruses (126).  This residue was shown to lead to 
increased Env expression and incorporation (11).  Furthermore, a number of other T/F signatures 
were found in the signal peptide or cytoplasmic tail of gp41, locations considered more likely to 
influence Env content than Env receptor binding functions (although the cytoplasmic tail of gp41 
is important for both (60)).  Thus we hypothesized that increased Env incorporation represented a 
biological difference between T/F and CC viruses that could be accomplished thorough a number 
of individually weak genotypic signatures.  Our data support this hypothesis, with T/F viruses on 
average containing about twice as much Env as CC viruses.   
Future studies of the consequences of increased Env content on virus neutralization and 
sensitivity of virus-producing cells to antibody (Ab) dependent cell-mediated cytotoxicity (ADCC) 
are warranted.  For example, it has been hypothesized that HIV-1 avoids Ab neutralization by 
containing relatively few Env spikes, such that a single Ab can only interact with one spike at a 
time (184).  Thus if Env density is increased on T/F viruses to a level that allows bivalent Ab 
binding, there may be a paradoxical increase in neutralization sensitivity to Abs that are capable 
of cross-linking spikes.  This could be tested either by engineering an epitope tag into the fourth 
variable region of gp120 of a panel of viruses with different Env content (295) or generating 
pseudovirus with a spectrum of Env content by changing the ratio of transfected env to backbone 
DNA.  If this theory is borne out, targeting regions of Env structurally positioned to allow cross-
spike binding by Ab might be ideal.  It is also of interest to determine if cells infected by viruses 
with high Env content are more readily targeted for ADCC than cells infected by viruses with low 
Env content.  Since virus assembly takes place at the plasma membrane (173), Env must be 
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present here, at least momentarily, prior to virus budding; in many cases viruses with high Env 
content have been shown to have high cell surface Env expression (219, 320, 386, 387).  Thus 
there may be more target molecules for Env-binding antibodies present on the surface of cells 
producing viruses with high Env content.  Cell surface IgG binding correlates directly with ADCC 
(338), thus increased cell surface Env binding would likely lead to increased killing of infected 
cells.  This would also provide a biologically plausible mechanism for differences in Env content 
between the acute and chronic phases of infection, as ADCC-mediating antibodies gradually 
increase during early chronic infection and then generally remain at high levels (11, 132, 261). 
Functional Env content can likely be modulated in a number of ways, including matrix-
gp41 interaction (60), endocytosis mediated by the gp41 cytoplasmic tail (317), CD4 
downregulation efficiency (8), and Env stability (4), but which of these are employed by T/F 
viruses to achieve high Env content is not known.  If there were to be a conserved interaction 
important for high Env incorporation, it could make an attractive drug target.  There are many 
potential starting points:  Previous investigators have concluded that Env incorporation is the 
major determinant of Env content (56), but this could be confirmed using relevant T/F and CC 
viral strains.  The influence of all of the signature genotypes identified by Korber and colleagues 
(126) on Env content could be determined in the context of IMCs.  Furthermore, the role of Env 
potential asparagine-linked glycan (PNLG) count, consistently observed to be slightly lower in T/F 
viruses, on Env processing, retention in the Golgi complex, steady state expression, or content in 
virions should be explored and the impact of T/F env codon usage on inhibition by the restriction 
factor schlafen 11 examined (206).   
Characterizing the downstream biological consequences of increased Env content might 
help build a more complete model of the cell-host interactions important for mucosal 
transmission.  We show that infectivity and dendritic cell binding correlated weakly with Env 
content, but more experiments would be needed to determine if Env content directly affects these 
properties.  Cells infected by HIV-1 with high Env content activated NFkB, increased proviral 
transcription, and higher virus production (15).  This suggests that increased Env may play a role 
	  194 
in signaling.  Furthermore, the stability of viruses with high Env content at physiological 
temperatures and pH, as well as in complex biological solutions such as semen or cervicovaginal 
mucous, should be determined. 
The relative resistance of T/F viruses to interferon alpha (IFN-α) is another area for future 
focus.  Our interpretation that T/F viruses are selected on the basis of their ability to overcome 
innate immune responses during mucosal transmission challenges the concept that these earliest 
responses to HIV-1 infection are ineffective or even harmful.  The most direct support for the 
notion of a harmful innate response comes from the observation that mucosal administration of 
toll-like receptor agonists did not prevent transmission after high-dose SIV challenge despite 
inducing IFN-α (364).  The challenge dose used in these experiments was sufficient to infect 
15/16 animals after two mucosal exposures, in contrast to the 100-1000 mucosal exposures often 
occurring prior to HIV-1 infection.  Thus these experiments should be repeated with a lower 
challenge dose.  Indeed, direct administration of IFN-α prior to repeated low-dose challenge was 
protective, and a lower number of T/F variant were observed in animals that were eventually 
infected (Daniel C. Douek, personal communication).  The dynamics of IFN-α in different stages 
of HIV-1 infection should also be re-examined because increased infectiousness has been 
observed during late-stage disease (161), which may relate to the elevated IFN-α and 
correspondingly IFN-α resistant viruses present at this stage  (101, 192). 
   The mechanism of IFN-α resistance by T/F viruses should be defined in order to 
translate this finding into a useful intervention.  Some but not much of the IFN-α resistance of T/F 
viruses may be related to their increased Env content.  The existence of an IFN-α-induced activity 
that specifically limits Env incorporation can be inferred from early work (89, 150).  One molecule 
with such an activity is the secretory glycoprotein 90K, encoded by LGALS3BP (127), thus its 
influence on T/F and CC virus production should be explored.  One candidate for a viral protein 
mediating IFN-α resistance is the viral protein U (Vpu).  Vpu has been shown to deplete interferon 
regulatory factor 3 (92), which otherwise activates transcription of IFN-a and interferon stimulated 
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genes in the context of virus infection (91).  In addition to hypothesis-based approaches to 
identify viral proteins involved in IFN-α resistance, knockouts of all accessory genes in 
representative T/F and CC IMCs should be tested for IFN-α resistance and the step in the viral 
life cycle that IFN-α has disparate effects on T/F and CC viruses should be defined.  If viral 
proteins necessary for IFN-α resistance are identified, the functional motifs involved should be 
targeted by vaccination.  Our data suggests that high IFN-α resistance is less critical in chronic 
infection.  Thus immunizing chronically infected individuals against these proteins might lead to 
virus mutation at motifs important for IFN-α resistance.  Evolutionarily, this can be thought of as 
applying a selective pressure that can be readily escaped from with little within-host fitness cost, 
yet escape bears a large cost in terms of inter-host fitness, i.e. transmission (202).  However, 
IFN-α resistance is not necessarily a protein-mediated effect; the influence of nucleotide 
sequence variation in the long-terminal repeat (LTR), including variants with more or fewer 
functional NFkB binding sites (16, 170, 229), on IFN-α resistance should be explored.  Finally, we 
tested the replication of T/F and CC IMCs in very highly stimulated CD4+ T cells.  The ability of 
T/F and CC viruses to infect minimally activated CD4+ T cells should also be tested (340), 
especially considering the evidence that these are the initial target cells in SIV-infected animals.   
Our favored interpretation of the phenotypic differences between T/F and CC viruses 
described here is that they are due to selective transmission of viruses with certain biological 
properties.  Formally, there are several other interpretations, including phenotypic 
compartmentalization of viruses with T/F-like properties in genital secretions or biased selection 
of T/F lineages that have experienced less pressure from host adaptive immune systems than CC 
lineages due to acute-to-acute transmission chains.  Perhaps only a subset of chronically infected 
individuals harbor virus that is competent for ongoing transmission, and while mucosal barriers 
only allow transmission of viruses from such patients, all variants present in an inoculum from 
such individuals have an equal likelihood of being transmitted.  These possibilities might best be 
definitively addressed by performing studies similar to those here using viruses from transmission 
pairs and from subjects sampled longitudinally from acute infection.  This should become 
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exponentially more facile with advances in DNA sequencing, chemical synthesis, and in vitro 
manipulation (232).  Additionally, experimental infection of humanized mice with T/F and CC HIV-
1 variants could directly determine if T/F viruses are more readily transmitted.  Repeat low-dose 
challenge of macaques with SIV variants with known phenotypes (e.g. high vs low Env content or 
IFN-α resistance) could be used to challenge macaques to determine if transmission is selective 
on the basis of these phenotypes. 
Developing new mathematical models of viral population dynamics incorporating these 
results may be helpful to understand mucosal HIV-1 transmission.  For example, serial bottleneck 
events present a risk of fitness loss due to genetic drift and irreversible accumulation of 
deleterious mutations known as “Muller’s ratchet” (111).  While generally applicable only to 
organisms that do not recombine, Muller’s ratchet may apply to HIV-1 in the case of serial single-
variant transmissions.  Such an effect has been demonstrated for other RNA viruses with high 
mutation rates (98).  Passage of HIV-1 in vitro has been associated with severe fitness loss after 
as few as seven passages (388).  Selective transmission of “fit” viruses may prevent such an 
effect, even if only one variant is transmitted.  Models that could estimate the impact of 
intermittent multiple-variant transmissions or superinfection on the fitness of a viral lineage might 
be especially informative.  Finally, it would be helpful to understand the effect of interventions that 
decrease the number of transmitted variants in the absence of sterilizing protection, as this may 
be the most tractable goal in the high-risk populations in which HIV-1 incidence continues to 
increase (5). 
In summary, our results provide a foundation to understand the biology of T/F viruses.  
Due to the fact that T/F viruses are drawn from the larger population of CC viruses, there is no 
“black and white” dichotomy in the traits of T/F and CC viruses.  However, T/F viruses are a non-
random subset of CC viruses, quantitatively different in a number of phenotypes including 
coreceptor tropism, Env content, and IFN-α resistance.  Future work is needed because our 
current knowledge of these differences is phenomenological rather than mechanistic.  While the 
results described here can be used to refine conceptual models of mucosal HIV-1 transmission, 
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higher resolution information about the phenotypic differences between T/F and CC viruses is 
needed to translate this knowledge into useful interventions. 
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